
<html lang="en"     class="pb-page"  data-request-id="2c481897-b712-4c25-a6fd-570e454a8947"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b01413;issue:issue:10.1021/jmcmar.2017.60.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor" /></meta><meta name="dc.Creator" content="Xiaofei  Liang" /></meta><meta name="dc.Creator" content="Fengchao  Lv" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Hong  Wu" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Zongru  Jiang" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Weili  Miao" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Zhenquan  Hu" /></meta><meta name="dc.Creator" content="Juan  Liu" /></meta><meta name="dc.Creator" content="Xiaochuan  Liu" /></meta><meta name="dc.Creator" content="Zheng  Zhao" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Shanchuan  Zhang" /></meta><meta name="dc.Creator" content="Zi  Ye" /></meta><meta name="dc.Creator" content="Chu  Wang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Yinsheng  Wang" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Description" content="BMX is a member of TEC family nonreceptor tyrosine kinase and is involved in a variety of critical physiological and pathological processes. Through combination of irreversible inhibitor design and..." /></meta><meta name="Description" content="BMX is a member of TEC family nonreceptor tyrosine kinase and is involved in a variety of critical physiological and pathological processes. Through combination of irreversible inhibitor design and..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 14, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01413" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01413" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01413" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01413" /></link>
        
    
    

<title>Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01413" /></meta><meta property="og:title" content="Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0015.jpeg" /></meta><meta property="og:description" content="BMX is a member of TEC family nonreceptor tyrosine kinase and is involved in a variety of critical physiological and pathological processes. Through combination of irreversible inhibitor design and type II inhibitor design approaches, we have discovered a highly selective and potent type II irreversible BMX kinase inhibitor compound 41 (CHMFL-BMX-078), which exhibited an IC50 of 11 nM by formation of a covalent bond with cysteine 496 residue in the DFG-out inactive conformation of BMX. It displayed a high selectivity profile (S score(1) = 0.01) against the 468 kinases/mutants in the KINOMEscan evaluation and achieved at least 40-fold selectivity over BTK kinase. Given the fact that BMX mediated signaling pathway is still not fully understood, compound 41 would serve as a useful pharmacological tool to elucidate the detailed mechanism of BMX mediated signaling pathways." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01413"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01413">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01413&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01413&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01413&amp;href=/doi/10.1021/acs.jmedchem.6b01413" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1793-1816</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01392" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01507" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaofei++Liang">Xiaofei Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengchao++Lv">Fengchao Lv</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Wu">Hong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zongru++Jiang">Zongru Jiang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weili++Miao">Weili Miao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenquan++Hu">Zhenquan Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Liu">Juan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaochuan++Liu">Xiaochuan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Zhao">Zheng Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shanchuan++Zhang">Shanchuan Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zi++Ye">Zi Ye</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chu++Wang">Chu Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yinsheng++Wang">Yinsheng Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CHMFL−HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Chemistry, University of California—Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Hefei Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, P. R. China</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">∇</span> <span class="aff-text">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div><div class="corresp-info"><strong>*</strong>For J.L.: phone, 86-551-65593186; E-mail, <a href="/cdn-cgi/l/email-protection#52383b3c353e3b27123a3f343e7c33317c313c"><span class="__cf_email__" data-cfemail="d0bab9beb7bcb9a590b8bdb6bcfeb1b3feb3be">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For Q.S.L.: phone, 86-551-65595161; E-mail, <a href="/cdn-cgi/l/email-protection#e392908f8a96dad4a38b8e858fcd8280cd808d"><span class="__cf_email__" data-cfemail="fb8a8897928ec2ccbb93969d97d59a98d59895">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01413&amp;href=/doi/10.1021%2Facs.jmedchem.6b01413" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1793–1816</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 31, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 September 2016</li><li><span class="item_label"><b>Published</b> online</span>14 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 March 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01413</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1793%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaofei%2BLiang%252C%2BFengchao%2BLv%252C%2BBeilei%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D5%26contentID%3Dacs.jmedchem.6b01413%26title%3DDiscovery%2Bof%2B2-%2528%25283-Acrylamido-4-methylphenyl%2529amino%2529-N-%25282-methyl-5-%25283%252C4%252C5-trimethoxybenzamido%2529phenyl%2529-4-%2528methylamino%2529pyrimidine-5-carboxamide%2B%2528CHMFL-BMX-078%2529%2Bas%2Ba%2BHighly%2BPotent%2Band%2BSelective%2BType%2BII%2BIrreversible%2BBone%2BMarrow%2BKinase%2Bin%2Bthe%2BX%2BChromosome%2B%2528BMX%2529%2BKinase%2BInhibitor%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1816%26publicationDate%3DMarch%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01413"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1914</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01413" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaofei&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Fengchao&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Zongru&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Weili&quot;,&quot;last_name&quot;:&quot;Miao&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhenquan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xiaochuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shanchuan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zi&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Chu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Yinsheng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1793-1816&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01413&quot;},&quot;abstract&quot;:&quot;BMX is a member of TEC family nonreceptor tyrosine kinase and is involved in a variety of critical physiological and pathological processes. Through combination of irreversible inhibitor design and type II inhibitor design approaches, we have discovered a highly selective and potent type II irreversible BMX kinase inhibitor compound 41 (CHMFL-BMX-078), which exhibited an IC50 of 11 nM by formation of a covalent bond with cysteine 496 residue in the DFG-out inactive conformation of BMX. It displayed a high selectivity profile (S score(1) = 0.01) against the 468 kinases/mutants in the KINOMEscan evaluation and achieved at least 40-fold selectivity over BTK kinase. Given the fact that BMX mediated signaling pathway is still not fully understood, compound 41 would serve as a useful pharmacological tool to elucidate the detailed mechanism of BMX mediated signaling pathways.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01413&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01413" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01413&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01413" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01413&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01413" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01413&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01413&amp;href=/doi/10.1021/acs.jmedchem.6b01413" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01413" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01413" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01413%26sid%3Dliteratum%253Aachs%26pmid%3D28140585%26genre%3Darticle%26aulast%3DLiang%26date%3D2017%26atitle%3DDiscovery%2Bof%2B2-%2528%25283-Acrylamido-4-methylphenyl%2529amino%2529-N-%25282-methyl-5-%25283%252C4%252C5-trimethoxybenzamido%2529phenyl%2529-4-%2528methylamino%2529pyrimidine-5-carboxamide%2B%2528CHMFL-BMX-078%2529%2Bas%2Ba%2BHighly%2BPotent%2Band%2BSelective%2BType%2BII%2BIrreversible%2BBone%2BMarrow%2BKinase%2Bin%2Bthe%2BX%2BChromosome%2B%2528BMX%2529%2BKinase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D5%26spage%3D1793%26epage%3D1816%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/jmcmar.2017.60.issue-5/20170309/jmcmar.2017.60.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">BMX is a member of TEC family nonreceptor tyrosine kinase and is involved in a variety of critical physiological and pathological processes. Through combination of irreversible inhibitor design and type II inhibitor design approaches, we have discovered a highly selective and potent type II irreversible BMX kinase inhibitor compound <b>41</b> (CHMFL-BMX-078), which exhibited an IC<sub>50</sub> of 11 nM by formation of a covalent bond with cysteine 496 residue in the DFG-out inactive conformation of BMX. It displayed a high selectivity profile (S score(1) = 0.01) against the 468 kinases/mutants in the KINOMEscan evaluation and achieved at least 40-fold selectivity over BTK kinase. Given the fact that BMX mediated signaling pathway is still not fully understood, compound <b>41</b> would serve as a useful pharmacological tool to elucidate the detailed mechanism of BMX mediated signaling pathways.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bone marrow kinase in the X chromosome (BMX, also called ETK) is a nonreceptor tyrosine kinase belonging to the TEC family which also includes BTK, ITK, TEC, and TXK kinases.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Varieties of biological evidence demonstrate that BMX is involved in tumorigenicity, cell motility, adhesion, angiogenesis, proliferation, and differentiation. BMX is expressed primarily in bone marrow but also wildly found in granulo/monocytic cells, epithelial and endothelial cells, as well as brain, prostate, heart, and lung.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8">(2-8)</a> BMX kinase contains a pleckstrin homology domain (PH) that mediates membrane association, a Tec homology domain (TH) that consists of a proline rich region, a SRC homology 3 domain (SH3) that is involved in inter- and intramolecular interactions, and a SRC homology 2 domain (SH2) that recognizes phosphotyrosine containing peptides and proteins from the amino terminus, as well as the kinase domain in the carboxyl terminus.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> BMX participates in signal transduction in response to virtually all types of extracellular stimuli which are transmitted by growth factor receptors, G-protein coupled receptors, cytokine receptors, antigen receptors, and integrins.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> BMX is regulated by a variety of nonreceptor tyrosine kinases like SRC, JAK, SYK, and FAK family kinases and lipid kinase such as PI3K. In turn, BMX may be involved in regulation of several signaling pathways including AKT, STAT3, PKC, PLCγ, and p21-activated kinases under certain conditions.<a onclick="showRef(event, 'ref3 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref9">(3, 9)</a></div><div class="NLM_p">Because of the potential pathological roles of BMX in malignant disorders, several small molecule or peptide inhibitors of BMX were developed.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, most of these inhibitors are multiple target compounds. Besides BMX kinase, they usually also potently inhibit other TEC family kinases or other protein kinases.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> For example, compound <b>1</b> (BMX-IN-1, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which covalently modified Cys 496, displayed high selectivity profile against other protein kinases but also strongly inhibited BTK kinase (IC<sub>50</sub> = 10.4 nM).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Compounds <b>2</b> (CI-1033),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><b>3</b> (PD168393),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><b>4</b> (LFM-A13),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and <b>5</b> (PCI-32765)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> have also been reported to bear BMX kinase activity although their primary targets are other structurally related kinases such as EGFR and BTK, etc. Given the fact that BMX mediated signaling pathway in the physiological and pathological context is still not fully understood yet, selective BMX kinase inhibitors are highly desired for mechanistic investigation and proof-of-concept efficacy validation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative inhibitors that bear BMX kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Accumulated evidence have shown that irreversible kinase inhibitors, which possess a number of potential advantages including high potency, prolonged pharmacodynamics, suitability for rational design, and ability to validate pharmacological specificity, sometimes may exhibit distinct selectivity profile from conventional reversible inhibitors.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> However, although BMX kinase bears a cysteine 496 residue which is feasible for design of irreversible inhibitors, similar cysteine residues located at the identical position were also found in 11 other kinases such as TEC kinase family (BMX, ITK, RLK, TEC), EGFR family (EGFR, HER2, HER4), as well as BLK, JAK3, and MAP2K7 kinases.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Therefore, in order to achieve a high selectivity, other selectivity trimming factors need to be introduced. Type II kinase inhibitors, which are featured by binding to the inactive conformation of kinase and occupying the nonhighly conserved allosteric pocket generated by “DFG-out” motif flip,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> sometimes can provide better selectivity compared to type I inhibitors and have attracted extensive attention in the kinase targeted drug discovery.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Therefore, we postulated that combining the irreversible inhibitor design and type II inhibitor design approaches might provide better selectivity. Here, we described our medicinal effort that led to the discovery of a highly selective type II irreversible BMX kinase inhibitor compound <b>41</b> (CHMFL-BMX-078), which bound to the “DFG-out” inactive conformation of BMX kinase, meanwhile took advantage of the cysteine 496 residue to form a covalent bond.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structure–Activity Relation (SAR) Exploration</h3><div class="NLM_p">During search of BMX inhibitor with type II binding mode, we found that the dihydropyrimidopyrimidine compound <b>6</b> (GNF-7),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> which has been reported as a type II inhibitor that was capable to inhibit the T315I “gatekeeper” point mutant of BCR-ABL, could potently inhibit BMX kinase at 10 μM (98% inhibition). However, it also potently inhibited other kinases such as JAK1, -2, and -3, FGFR3, FLT3, PDGFR, TRKC, c-RAF, CSK, JNK, MKK, etc. After docking compound <b>6</b> to the X-ray crystal structure of BMX (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>), we found that it adopted a canonical type II binding mode (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). The 2-amine pyrimidine moiety (“hinge binding” part in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) formed hydrogen bond in the hinge region. The trifluoromethylbenzene moiety (“tail” part in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) occupied the allosteric hydrophobic pocket generated by DFG-out shifting. The amide moiety formed two hydrogen bonds with Glu 460 and Asp 554, respectively (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). The methylpyridine moiety (“head” part in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) oriented to the adjacent area of the hinge-binding region. Interestingly, the distance between the N atom of pyridine and the cysteine 496 residue was about 5.3 Å, which was feasible for irreversible inhibitor design (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Virtually attaching an acrylamide to the N position in the head moiety of compound <b>6</b> (compound <b>7</b>) did show a covalent bond formation, meanwhile still kept type II binding in the modeling (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C–D). Thus, we proposed that by installing a suitable electrophile at the methylpyridine N position, meanwhile exploring other key binding elements of compound <b>6</b> and taking advantage of the nonhighly conserved DFG-out hydrophobic pocket might provide a new highly selective type II irreversible BMX kinase inhibitor, and these efforts finally resulted in the discovery of compound <b>41</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeling of interactions of dihydropyrimidopyrimidine compounds <b>6</b> and <b>7</b> with BMX kinase (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>). (A) The Cys 496 is 5.3 Å from the N atom in the head moiety of compound <b>6</b>. (B) The covalent bond formed between the acrylamide moiety of compound <b>7</b> and Cys 496. (C) Demonstration of canonical hydrogen bonds in the type II binding mode between compound <b>6</b> and DFG-out inactive conformation of BMX kinase. (D) Demonstration of canonical hydrogen bonds in the type II binding mode between compound <b>7</b> and DFG-out inactive conformation of BMX kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of the discovery of compound <b>41</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For SAR exploration, we used the recombinant BMX kinase protein to test compounds’ enzymatic inhibition capability (IC<sub>50</sub>). In addition, to avoid the problems of different ATP concentrations used in the enzymatic assay (μM ranges) and cellular assay (mM ranges), which usually makes the compounds displaying potent activity in vitro lose the activity in cell, we also used BaF3 cells transformed with TEL fused BMX kinase whose proliferation depend on BMX kinase to monitor the compound’s cellular activity (GI<sub>50</sub>). Parental BaF3 cells were used to monitor the compound’s general selectivity. Ideally, in this assay, the highly selective and potent compound would show strong antiproliferative efficacy against BaF3-TEL-BMX cell but not parental BaF3 cell. To test our design, we first prepared compound <b>7</b> and found that compared to compound <b>6</b>, it retained high potency against BaF3-TEL-BMX cell (GI<sub>50</sub> < 0.0005 μM; IC<sub>50</sub> = 8 nM) and meanwhile showed potent inhibitory activity against parental BaF3 cell (GI<sub>50</sub> = 0.74 μM) like <b>6</b>, which indicated that its selectivity still needed to be improved (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Because compound <b>7</b> still potently inhibited parental BaF3 cells, to detect its real activity against BMX kinase, we then examined <b>7</b>’s activity against BMX total tyrosine phosphorylation with purified BMX wt kinase and the C496S mutant. Interestingly, compound <b>7</b> exhibited an EC<sub>50</sub> of 18 nM against BMX wt and an EC<sub>50</sub> of 477 nM against C496S mutant (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). This indicated that <b>7</b> might inhibit BMX kinase through irreversible binding mode. Encouraged by this finding, we decided to keep the head moiety as the acrylamide substituted methyl aniline like <b>7</b> and further modify the linker and tail parts in order to achieve better selectivity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the R1 Moiety<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>7</b>’s effects against the total tyrosine phosphorylation of purified BMX wt and C496S mutant proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first fixed the linker part and varied the tail moiety which occupied the hydrophobic pocket generated by the “DFG” motif shift in the inactive conformation. Switching the trifluoromethyl substituent (<b>7</b>) to the <i>o</i>-methoxy (<b>8</b>) or <i>p</i>-methoxy group (<b>9</b>) resulted in significant activity loss against BMX (IC<sub>50</sub> = 591 and 1535 nM; GI<sub>50</sub> = 3.01 and 1.07 μM, respectively) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Similarly, introduction of one or two more methyloxy groups to the benzene ring in the tail part (<b>10</b>–<b>14</b>) all led to activity loss compared to <b>7</b>. Interestingly, cyclization of a 3,4-dimethoxy group to form a five-membered ring (<b>15</b>) started to gain back the BMX activity (IC<sub>50</sub> = 382 nM; GI<sub>50</sub> = 0.23 μM). Although it was still about 500-fold less active than compound <b>7</b> in terms of GI<sub>50</sub>, it started to show the selectivity against parental BaF3 cell (GI<sub>50</sub> > 10 μM). However, cyclization of 3,4-dimethyl group to form six-membered ring (<b>16</b>) caused complete activity loss to BMX (IC<sub>50</sub> = 1263 nM; GI<sub>50</sub> > 10 μM). While 5,6,7,8-tetrahydronaphthalene (<b>17</b>) in the tail part gained back a moderate activity (IC<sub>50</sub> = 813 nM; GI<sub>50</sub> = 0.86 μM), introduction of another methyl group (<b>18</b>) or trifluoromethyl group (<b>19</b>) to compound <b>7</b> generated moderate activities against BMX (IC<sub>50</sub> = 2468 and 1544 nM; GI<sub>50</sub> = 1.24 and 0.78 μM). Replacement of 4-methoxy substituent (<b>9</b>) with <i>N</i>,<i>N</i>-dimethylamine (<b>20</b>) did not affect the potency too much. Interestingly, although 2-fluoro-6-methylbenzene (<b>21</b>) only displayed moderate activity against BMX (IC<sub>50</sub> = 480 nM; GI<sub>50</sub> = 2.78 μM), shifting the methyl group from the 6- to the 5-position (<b>22</b>) dramatically increased its growth inhibition activity against BaF3-TEL-BMX (IC<sub>50</sub> = 120 nM; GI<sub>50</sub> = 0.031 μM) meanwhile displayed a good selectivity to the parental BaF3 cell (GI<sub>50</sub> > 10 μM). Replacement of the 3-(trifluoromethyl)benzoic acid group in the tail moiety of <b>7</b> with more bulky amino acids, i.e., phenylanaline (<b>23</b>) and tryptophan (<b>24</b>), both completely abolished the activity to BMX. A more flexible leucine moiety (<b>25</b>) exhibited slightly better activity against BMX (IC<sub>50</sub> = 33 nM; GI<sub>50</sub> = 0.13 μM) meanwhile kept a good selectivity against parental BaF3 cells (GI<sub>50</sub> > 10 μM). However, the more bulky Boc-protected glutamic acid moiety (<b>26</b>) decreased the activity again (IC<sub>50</sub> = 4620 nM; GI<sub>50</sub> = 8.35 μM). Further replacement in the tail moiety of <b>7</b> with different para-substituted cyclohexane derivatives (<b>27</b>–<b>31</b>) did not show increased activity against BMX.</div><div class="NLM_p">We then turned our attention to the linker part for further SAR study (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Considering that the cyclic urea ring was rigid, we thought that opening the ring would presumably generate more flexibility of the scaffold. Replacement of the cyclic urea to amide moiety (<b>32</b>) exhibited moderate biochemical inhibition (IC<sub>50</sub> = 37 nM), great antiproliferative efficacy against BaF3-TEL-BMX cell (GI<sub>50</sub> = 0.013 μM) as well as good selectivity over parental BaF3 cell (GI<sub>50</sub> > 10 μM). Interestingly, saturation of the acrylamide to propinamide (<b>33</b>) displayed about 6-fold selectivity against BaF3-TEL-BMX cell (IC<sub>50</sub> = 102 nM; GI<sub>50</sub> = 0.085 μM) compared to <b>32</b>, meanwhile kept the selectivity window to parental BaF3 cells (GI<sub>50</sub> > 10 μM). Encouraged by these results, we decided to keep this core linker scaffold and explore more on the tail moiety. Replacement of the 3-trifluoromethyl group with 3-methoxy group on the benzene ring (<b>34</b>) dramatically decreased the potency against BMX kinase (IC<sub>50</sub> = 2380 nM) and BaF3-TEL-BMX cell (GI<sub>50</sub>, 6 μM). Neither shifting the 3-methoxy group to the 2-position (<b>35</b>), 4-position (<b>36</b>), nor the 3,4-dimethyoxy (<b>37</b>) or the [1,3]dioxo (<b>38</b>) substituents on the tail benzene ring retained the activity against BaF3-TEL-BMX cell. The 2,4-dimethoxy group (<b>39</b>) and [1,4] dioxine (<b>40</b>) substituents on the tail benzene ring displayed about 7-fold enzymatic inhibition loss (IC<sub>50</sub>, 225 and 279 nM) and 10-fold growth inhibition loss against BaF3-TEL-BMX cell (GI<sub>50</sub> = 0.119 and 0.155 μM) compared to <b>32</b>. Interestingly, the 3,4,5-trimethoxy substituted benzene ring (<b>41</b>) retained the antiproliferation efficacy against BMX (IC<sub>50</sub> = 11 nM; GI<sub>50</sub> = 0.016 μM). Saturation of the acrylamide to propinamide (<b>42</b>) resulted in about 20-fold (IC<sub>50</sub>) and 40-fold (GI<sub>50</sub>) activity loss against BMX, indicating an irreversible binding. The 2-fluoro-5-methyl substituted benzene ring (<b>43</b>) also kept the inhibitory activity against BaF3-TEL-BMX (GI<sub>50</sub> = 0.044 μM) in the similar range to <b>32</b>. Reverting the amide linkage in compound <b>32</b> (<b>44</b>) caused increased potency against BMX (IC<sub>50</sub> = 86 nM; GI<sub>50</sub> = 0.008 μM) meanwhile gained activity to parental BaF3 cell (GI<sub>50</sub> = 4.9 μM), which indicated off-target activities. Reverting the amide linkage in compound <b>41</b> (<b>45</b>) led to about 6-fold growth inhibition activity loss against BaF3-TEL-BMX cell (GI<sub>50</sub> = 0.098 versus 0.016 μM) and 50-fold enzymatic inhibition activity loss (IC<sub>50</sub> = 540 versus 11 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the R3/R4 Moieties<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">Because compounds <b>32</b> and <b>41</b> exhibited the best potencies against BaF3-TEL-BMX cells and best selectivity over parental BaF3 cells, we then examined them together with their reversible version compounds <b>33</b> and <b>42</b> in a panel of TEL transfused isogenic BaF3 cells to further explore their selectivity profiles (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The results demonstrated that compound <b>32</b> displayed relatively strong potency against PDGFRα (GI<sub>50</sub> = 0.099 μM) and moderate activity to PDGFRβ (GI<sub>50</sub> = 0.13 μM), ABL (GI<sub>50</sub> = 0.118 μM), cKIT (GI<sub>50</sub> = 0.38 μM) but no apparent activity against FLT3 kinase (GI<sub>50</sub> > 10 μM). By comparison, compound <b>41</b> displayed better selectivity than <b>32</b>. It only moderately inhibited PDGFRα/β (GI<sub>50</sub> = 0.67, 0.91 μM) but not other kinases. Interestingly, both compounds <b>32</b> and <b>41</b> had no apparent activities against EGFR, JAK3, or BLK kinases, which bear similar cysteine residue at the identical position. In addition, the potent inhibitory activity against BMX kinase of both compounds <b>32</b> and <b>41</b> could be rescued by IL-3, which is the natural growth stimulator of isogenic BaF3 cells, indicating that their antiproliferative activity against BaF3-TEL-BMX cells mainly came from the BMX activity inhibition. Because compound <b>41</b> exhibited better selectivity among these structurally similar kinases, we decided to further characterize its biological profiles.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Effects of Compounds <b>32</b>–<b>33</b> and <b>41</b>–<b>42</b> against a Panel of Isogenic BaF3 Cell Lines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">compd <b>32</b> (GI<sub>50</sub>, μM)</th><th class="colsep0 rowsep0" align="center">compd <b>33</b> (GI<sub>50</sub>, μM)</th><th class="colsep0 rowsep0" align="center">compd <b>41</b> (GI<sub>50</sub>, μM)</th><th class="colsep0 rowsep0" align="center">compd <b>42</b> (GI<sub>50</sub>, μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">parental BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-ABL</td><td class="colsep0 rowsep0" align="center">0.118 ± 0.056</td><td class="colsep0 rowsep0" align="center">0.044 ± 0.001</td><td class="colsep0 rowsep0" align="center">2.56 ± 0.07</td><td class="colsep0 rowsep0" align="center">2.51 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT</td><td class="colsep0 rowsep0" align="center">0.38 ± 0.03</td><td class="colsep0 rowsep0" align="center">0.17 ± 0.02</td><td class="colsep0 rowsep0" align="center">2.01 ± 0.05</td><td class="colsep0 rowsep0" align="center">2.80 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-PDGFRa</td><td class="colsep0 rowsep0" align="center">0.099 ± 0.014</td><td class="colsep0 rowsep0" align="center">0.045 ± 0.005</td><td class="colsep0 rowsep0" align="center">0.67 ± 0.06</td><td class="colsep0 rowsep0" align="center">0.37 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-PDGFRb</td><td class="colsep0 rowsep0" align="center">0.13 ± 0.07</td><td class="colsep0 rowsep0" align="center">0.059 ± 0.006</td><td class="colsep0 rowsep0" align="center">0.91 ± 0.05</td><td class="colsep0 rowsep0" align="center">0.79 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-FLT3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">8.6 ± 0.24</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-EGFR</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-JAK3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">8.3 ± 0.16</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-BLK</td><td class="colsep0 rowsep0" align="center">5.9 ± 0.7</td><td class="colsep0 rowsep0" align="center">6.5 ± 0.9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-BMX</td><td class="colsep0 rowsep0" align="center">0.013 ± 0.004</td><td class="colsep0 rowsep0" align="center">0.085 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.016 ± 0.003</td><td class="colsep0 rowsep0" align="center">0.61 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-BMX+IL3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Compound <b>41</b>’s Selectivity Profiling</h3><div class="NLM_p">We next examined compound <b>41</b> against a panel of 468 kinases/mutants in the DiscoverRx’s KINOMEscan profiling platform. At the concentration of 1 μM, compound <b>41</b> demonstrated high selectivity with a S score(1) = 0.01 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf" class="ext-link">Table 1</a>). The data indicated that compound <b>41</b> had strong binding (with a percent control number less than 1) against DDR1, p38α, and ABL1 kinases. Interestingly, <b>41</b> did not show strong binding to BMX in KINOMEscan assay (percent control number 14). This might due to the reason that BMX kinase did not prefer the DFG-out inactive conformation under this assay condition. This phenomenon was also observed for ABL1 kinase, e.g., compound <b>41</b> displayed a binding factor of 0.7 against ABL1-nonphosphorylated (inactive conformation) but 6.5 against ABL1-phosphorylated (active conformation). To further confirm this hypothesis, we then used the recombinant inactive (unphosphorylated) and active (phosphorylated) BMX kinase proteins respectively to test compound <b>41</b>’s binding <i>K</i><sub>d</sub> values with MST (microscale thermophoresis) technology (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). The results demonstrated that for the inactive state of BMX kinase, compound <b>41</b> displayed a binding <i>K</i><sub>d</sub> of 81 nM, while for the active state of BMX kinase that was generated by preincubation of the kinase with 1 μM ATP overnight, <b>41</b> exhibited a binding <i>K</i><sub>d</sub> of 10200 nM. The over 120-fold difference of these <i>K</i><sub>d</sub> values further suggested that <b>41</b> preferred to bind to the inactive conformation of the kinase with a type II binding mode. Given the fact that KINOMEscan is a binding assay and cannot fully reflect the compound’s inhibitory activity, we then further confirmed these potential targets with the Invitrogen SelectScreen biochemical assay (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D). Compound <b>41</b> exhibited an IC<sub>50</sub> of 11 nM against BMX, while the reversible version compound <b>42</b> (IC<sub>50</sub> = 230 nM) was about 21-fold less active, indicating an irreversible binding mode. For the structurally very similar BTK kinase, compound <b>41</b> displayed an IC<sub>50</sub> of 437 nM, which was about 40-fold less active compared to BMX. In addition, compound <b>41</b> also displayed about 10-fold selectivity against p38α kinase (IC<sub>50</sub> = 106 nM) and 24-fold selectivity against DDR1 kinase (IC<sub>50</sub> = 265 nM) compared to BMX.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity profiling of compound <b>41</b> with DiscoverRx KINOMEscan technology and biochemical IC<sub>50</sub> values of compounds <b>41</b> and <b>42</b> measured with Invitrogen SelectScreen Technology. (A) Treespot demonstration of <b>41</b>’s selectivity in 468 kinase targets. Measurements were performed at a concentration of 1 μM of the compound. The affinity was defined with respect to DMSO control. (B) Other targets that demonstrated strong binding to <b>41</b> with a percent control number less than 1. (C) Binding <i>K</i><sub>d</sub> values of compounds <b>41</b> and <b>42</b> with purified recombinant inactive and active BMX kinase proteins measured by MST (microscale thermophoresis) technology. (D) Biochemical IC<sub>50</sub> values of compounds <b>41</b> and <b>42</b> measured with Invitrogen SelectScreen Technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Compound <b>41</b>’s Binding Mode Exploration</h3><div class="NLM_p">To better understand the binding mode of compound <b>41</b>, we then docked it into the BMX X-ray crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). The modeling result demonstrated that compound <b>41</b> did prefer to adopt a type II binding mode and form a covalent bond with Cys 496 as expected. The aminopyrimidine moiety formed two hydrogen bonds with Met 492 in the hinge area. The −OH side chain of “gatekeeper” residue Thr 489 formed a hydrogen bond with the oxygen atom of amide group. The Glu 460 residue in the c-helix and Asp 554 residue in the DFG motif formed two typical hydrogen bonds with the amide group near the tail moiety. The backbone of Leu 423 and Cys 496 residues also formed two hydrogen bonds with the amide group in the acrylamide moiety. In addition, the 3,4,5-trimethoxylbenzene in the tail moiety occupied the hydrophobic pocket formed by “DFG” motif through van der Waals interactions. The side chain of Phe 555 interacted with the aminomethyl group in the linker moiety through p−π van der Waals.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode illustration of compound <b>41</b> with BMX kinase. (A) Putative binding model of <b>41</b> with BMX inactive conformation (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>). (B) Effects of compounds <b>41</b> and <b>42</b> on BMX wt and C496S mutant’s total-tyrosine phosphorylation. Purified His-tag labeled recombinant full length of the inactive state of BMX wt and C496S mutant were first treated with the inhibitors and then incubated with 40 μM ATP before the total protein phosphorylation was detected with Western blot. (C,D) LC-MS/MS in the MRM mode revealed the compound <b>41</b>-conjugated Cys 496-containing tryptic peptide derived from recombinant BMX after reaction with <b>41</b>. Shown in (C) are the selected-ion chromatograms (SICs) for monitoring the indicated transitions arising from the fragmentations of the [M + 3H]<sup>3+</sup> ions of the unmodified (top) and compound <b>41</b>-modified (bottom) Cys 496-containing peptides. Displayed in (D) are the MS/MS for the [M + 3H]<sup>3+</sup> ions of the unmodified (top) and compound <b>41</b>-modified (bottom) cysteine-containing peptides averaged from the peak at around 69.6 min. From the peak areas found in the SICs, it can be estimated that approximately 23% of Cys 496 was modified.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We also performed the in vitro kinase assay with BMX wt and C496S mutant in order to further confirm the irreversible binding mode of compound <b>41</b>. The results showed that compound <b>41</b> was about 80-fold more potent against BMX wt (EC<sub>50</sub> = 5.8 nM) than C496S mutant (EC<sub>50</sub> = 459 nM) for the inhibition of BMX total tyrosine phosphorylation (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). Meanwhile, the reversible version compound <b>42</b> inhibited the wild-type BMX total tyrosine phosphorylation with an EC<sub>50</sub> of 197 nM, which was about 34-fold less active than compound <b>41</b>. To further confirm the covalent binding, we then performed the mass spectrometry experiments and the results demonstrated that upon incubation, C496 in the BMX kinase was indeed modified by compound <b>41</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C,D and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf" class="ext-link">Figure 1</a>). These data, together with the antiproliferation results observed from BaF3-TEL-BMX cells, suggested that compound <b>41</b> indeed adopted an irreversible binding mode through forming a covalent bond with Cys 496 of BMX protein.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Compound <b>41</b>’s Effect in Cells</h3><div class="NLM_p">Because BMX’s role in pathology has not been fully validated yet and currently there is no BMX dependent disease model, we chose a panel of established cancer cell lines including prostate cancer, bladder cancer, and renal cancer, which had been reported to express BMX kinases to test the antiproliferative effects of compound <b>41</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Not surprisingly, compound <b>41</b> only exhibited moderated growth inhibition efficacies against most of these cell lines (submicomolar GI<sub>50</sub>). However, it did not show apparent inhibitory activities against normal mouse cells CHO and CHL (GI<sub>50</sub> > 10 μM), which suggested no general toxicity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compound <b>41</b> against a Panel of Cancer Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">cell origin</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RV-1</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="center">3.45 ± 1.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU-145</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="center">7.89 ± 1.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="center">3.45 ± 0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EJ</td><td class="colsep0 rowsep0" align="left">bladder cancer</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hb-c</td><td class="colsep0 rowsep0" align="left">bladder cancer</td><td class="colsep0 rowsep0" align="center">8.87 ± 0.87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">J82</td><td class="colsep0 rowsep0" align="left">bladder cancer</td><td class="colsep0 rowsep0" align="center">5.78 ± 0.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T24</td><td class="colsep0 rowsep0" align="left">bladder cancer</td><td class="colsep0 rowsep0" align="center">8.98 ± 2.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5637</td><td class="colsep0 rowsep0" align="left">bladder cancer</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">769-P</td><td class="colsep0 rowsep0" align="left">renal cancer</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">786-O</td><td class="colsep0 rowsep0" align="left">renal cancer</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A-498</td><td class="colsep0 rowsep0" align="left">renal cancer</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ACHN</td><td class="colsep0 rowsep0" align="left">renal cancer</td><td class="colsep0 rowsep0" align="center">4.93 ± 0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHL</td><td class="colsep0 rowsep0" align="left">normal lung of mouse</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHO</td><td class="colsep0 rowsep0" align="left">normal ovary of mouse</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">We then chose a prostate cancer cell line DU145 that overexpressed FLAG labeled BMX kinase to confirm compound <b>41</b>’s effect on cells (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Given the fact that currently there is no workable specific phosphorylated BMX antibody, we decide to examine the overall tyrosine phosphorylation with general <i>p</i>-tyrosine antibodies. The results showed that <b>41</b> did potently inhibit overall BMX kinase tyrosine phosphorylation starting from the concentration of 1 μM.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>41</b> on inhibition of total tyrosine phosphorylation in DU-145 cells with overexpressed FLAG labeled full length BMX kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Compound <b>41</b>’s In Vivo Pharmacokinetic Property Evaluation</h3><div class="NLM_p">Next, we evaluated the pharmacokinetic property of compound <b>41</b> in rats (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The data showed that <b>41</b> exhibited a short half-life (<i>T</i><sub>1/2</sub> = 0.80 ± 0.34 h) in iv injection. It is noteworthy that for irreversible inhibitors, a short half-life is actually preferred to avoid potential off-target toxicities and drug–drug interactions, which can lead to increased therapeutic margins.<a onclick="showRef(event, 'ref17 ref25'); return false;" href="javascript:void(0);" class="ref ref17 ref25">(17, 25)</a> Compound <b>41</b> also displayed an acceptable <i>C</i><sub>max</sub> (13565.23 ng/mL) and AUC<sub>(0–<i>t</i>)</sub> (1386.41 ng/mL·h) in iv injection. However, <b>41</b> was not absorbed by oral administration, indicating that this compound could be administrated through iv or ip injection when used as a research tool.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Property Evaluation of Compound <b>41</b> on Sprague–Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd <b>41</b></th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>(0–<i>t</i>)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>(0–∞)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center" char="±">MRT<sub>(0–<i>t</i>)</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv (1 mg/kg) mean ± SD</td><td class="colsep0 rowsep0" align="char" char="±">1386.41 ± 133.93</td><td class="colsep0 rowsep0" align="char" char="±">1388.25 ± 132.98</td><td class="colsep0 rowsep0" align="char" char="±">0.224 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.80 ± 0.34</td><td class="colsep0 rowsep0" align="center">0.017</td><td class="colsep0 rowsep0" align="char" char="±">13565.23 ± 1627.96</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po (10 mg/kg) mean ± SD</td><td class="colsep0 rowsep0" align="char" char="±">13.39 ± 4.72</td><td class="colsep0 rowsep0" align="char" char="±">27.63 ± 2.50</td><td class="colsep0 rowsep0" align="char" char="±">2.76 ± 0.82</td><td class="colsep0 rowsep0" align="char" char="±">6.11 ± 2.35</td><td class="colsep0 rowsep0" align="center">0.19 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">5.58 ± 1.8</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthetic procedure was depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The intermediate <b>49</b> was prepared following the previously reported route.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, substitution of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (<b>46</b>) with methylamine afforded methylamine pyrimidine <b>47</b>, then LAH reduction of the ethyl ester to alcohol (<b>48</b>) followed by oxidation reaction furnished the aldehyde <b>49</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Reductive amination of <b>49</b> with <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate provided the intermediate <b>50</b>, which was then converted to the cyclic urea <b>51</b> with triphosgene. Exposure of the methyl sulfide <b>51</b> to m-CPBA generated the corresponding sulfoxide <b>52</b>, which was transformed into the Boc protected aniline <b>53</b>. Removal of the Boc protection group (<b>54</b>) followed by amide coupling reaction provided the amide product <b>55</b>,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> which was then acylated with acryloyl chloride to gave target compounds <b>7</b>–<b>31</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7</b>–<b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>Me·HCl, TEA, THF, 0 °C to rt; (b) LiAlH<sub>4</sub>, THF, 0 °C to rt; (c) MnO<sub>2</sub>, DCM, rt; (d) <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate, MeOH/AcOH, reflux, then NaBH<sub>3</sub>CN, rt; (e) triphosgene, DIPEA, dioxane, 0 °C to rt; (f) m-CPBA, DCM, 0 °C to rt; (g) <i>tert</i>-butyl 5-amino-2-methylphenylcarbamate, LHMDS, THF, −78 °C to rt; (h) 4 M HCl in MeOH, rt; (i) R-COOH, HATU, DIPEA, DMF. (j) For the synthesis of <b>7</b>–<b>22</b> and <b>27</b>–<b>31</b>: acryloyl chloride, THF, DIPEA, rt. For the synthesis of <b>23</b>–<b>26</b>: acryloyl chloride, THF, DIPEA, rt; then HCl in MeOH, rt.</p></p></figure><div class="NLM_p">Compounds <b>32</b>–<b>43</b> were prepared following the procedure shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compound <b>47</b> was hydrolyzed to the corresponding carboxylic acid <b>56</b>, which was coupled with <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate to afford the amide intermediate <b>57</b>. Deprotection of the Boc group (<b>58</b>) followed by acylation with substituted acyl chloride derivatives furnished the sulfide intermediate <b>59</b>, which was then subjected to oxidation, amination, reduction, and acryloylation or propionylation to furnish the desired compounds <b>32</b>–<b>43</b>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>32</b>–<b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, EtOH, H<sub>2</sub>O, rt; (b) <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate, HATU, DIPEA, DMF; (c) 4 M HCl in MeOH, rt; (d) R′COCl, THF, DIPEA, 0 °C; (e) m-CPBA, DCM, 0 °C; (f) 4-methyl-3-nitroaniline, dioxane, TFA, 120 °C; (g) SnCl<sub>2</sub>, MeOH, reflux. (h) For the synthesis of <b>32</b>, <b>34</b>–<b>41</b>, and <b>43</b>: acryloyl chloride, THF, DIPEA, rt. For the synthesis of <b>33</b> and <b>42</b>: propionyl chloride, THF, DIPEA, rt.</p></p></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, compounds <b>44</b>–<b>45</b> were prepared starting from carboxylic acid <b>46</b>. Amide coupling reaction with methyl 3-amino-4-methylbenzoate afforded methyl ester <b>63</b>, which was then hydrolyzed to carboxylic acid <b>64</b>. Another amide coupling with corresponding aniline derivatives generated the sulfide intermediate <b>65</b>, which was then subjected to oxidation, amination, reduction, and acryloylation to offer the final compounds <b>44</b> and <b>45</b>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>44</b>–<b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 3-amino-4-methylbenzoate, HATU, DIPEA, DMF, rt; (b) NaOH, MeOH, H<sub>2</sub>O, rt; (c) R-NH<sub>2</sub>, HATU, DIPEA, DMF, rt; (d) m-CPBA, DCM, 0 °C to rt; (e) 4-methyl-3-nitroaniline, LiHMDS, THF, −78 °C to rt; (f) SnCl<sub>2</sub>, MeOH, reflux; (g) acryloyl chloride, THF, DIPEA, rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from a dihydropyrimidopyrimidine scaffold based multitarget compound <b>6</b> bearing high BMX potency, through combination of irreversible inhibitor design and type II inhibitor design approaches, we discovered a highly selective type II irreversible BMX inhibitor <b>41</b> via eight steps of chemical synthesis (over 9% overall yield). Compound <b>41</b> exhibited great selectivity over kinases such as BTK, JAK3, EGFR, and MAP2K7 that bore a structurally identical cysteine residue in BMX kinase. Molecule docking results of <b>41</b> and BMX suggested a type II irreversible binding mode, which was proved to be biologically relevant. Compound <b>41</b> potently inhibited BMX total tyrosine phosphorylation but only displayed moderate antiproliferative efficacies against prostate cancer cells, bladder cancer cells, and renal cancer cells that overexpressed BMX kinase, which further suggested that BMX kinase did not play key roles for the growth of these cancer cells. In addition, compound <b>41</b> displayed a pharmacokinetic profile that was acceptable for iv or ip injection, although its bioavailability was poor, which prevented it from oral administration and required further medicinal exploration. The highly selective profile of compound <b>41</b> among all of the known BMX inhibitors made it a useful pharmacological tool to further elucidate the BMX kinase mediated signaling pathways in both the pathological and physiological context.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">All reagents and solvents were purchased from commercial sources and used as obtained unless specified otherwise. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterium chloroform (CDCl<sub>3</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent XDB-C18 column (4.6 mm × 50 mm, 1.8 μm) using a water/acetonitrile (each with 0.2% (v/v) formic acid) gradient at a flow rate at 0.4 mL/min. Flash column chromatography was conducted using silica gel (Silicycle 40–64 μm). The purities of all compounds were determined to be above 95% by HPLC.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3(trifluoromethyl)benzamide (<b>7</b>)</h4><div class="NLM_p">To a solution of <b>55a</b> (40 mg, 0.063 mmol) in anhydrous THF (5 mL) were added DIPEA (74 μL, 0.37 mmol) and acyloylchroride (5.2 μL, 0.066 mmol) at 0 °C under argon. The reaction mixture was stirred at 0 °C for 1 h, then allowed to warm to room temperature for 2 h. The resulting mixture was concentrated to give the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–1%) to give the product <b>7</b> as white solid (20 mg, yield 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.57 (s, 1H), 9.56 (s, 1H), 9.54 (d, <i>J</i> = 17.3 Hz, 1H), 8.33 (d, <i>J</i> = 4.5 Hz, 1H), 8.29 (d, <i>J</i> = 7.6 Hz, 1H), 8.15 (s, 1H), 7.98 (d, <i>J</i> = 5.5 Hz, 2H), 7.85–7.78 (m, 2H), 7.67 (d, <i>J</i> = 8.3 Hz, 1H), 7.49 (d, <i>J</i> = 8.2 Hz, 1H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 7.13 (d, <i>J</i> = 8.3 Hz, 1H), 6.55 (s, 1H), 6.25 (d, <i>J</i> = 17.0 Hz, 1H), 5.75 (d, <i>J</i> = 10.0 Hz, 1H), 4.71 (d, <i>J</i> = 13.9 Hz, 1H), 4.53 (d, <i>J</i> = 13.9 Hz, 1H), 2.51 (s, 3H), 2.16 (s, 3H), 2.15 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.36, 163.71, 159.49, 157.49, 153.72, 152.66, 141.74, 139.04, 138.18, 136.42, 136.06, 132.31, 131.41, 131.21, 130.48, 130.25, 129.13, 128.69, 126.83, 124.71, 124.64, 123.10, 120.26, 119.83, 116.71, 116.25, 102.94, 53.98, 28.81, 18.57, 17.09. LC-MS (ESI, <i>m</i>/<i>z</i>): 616.6061 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>8</b>–<b>45</b> were prepared following the synthetic procedure of <b>7</b>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-methoxybenzamide (<b>8</b>)</h4><div class="NLM_p last">Yield 69%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H), 10.05 (s, 1H), 8.76 (s, 1H), 8.07 (s, 2H), 7.72 (s, 1H), 7.64 (d, <i>J</i> = 7.3 Hz, 1H), 7.51 (d, <i>J</i> = 7.3 Hz, 2H), 7.41 (d, <i>J</i> = 7.2 Hz, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 2H), 7.07 (t, <i>J</i> = 7.3 Hz, 1H), 6.45 (dd, <i>J</i> = 16.6, 10.1 Hz, 1H), 6.27 (d, <i>J</i> = 16.7 Hz, 1H), 5.77 (d, <i>J</i> = 9.8 Hz, 1H), 4.67 (d, <i>J</i> = 13.9 Hz, 1H), 4.48 (d, <i>J</i> = 14.0 Hz, 1H), 3.91 (s, 3H), 3.28 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.67, 163.56, 160.49, 157.46, 156.93, 153.81, 152.72, 141.81, 138.48, 138.30, 137.46, 132.38, 132.26, 131.30, 130.81, 130.48, 130.13, 127.48, 127.33, 125.54, 120.97, 119.04, 118.61, 116.70, 116.24, 112.47, 102.59, 56.36, 47.11, 28.42, 18.13, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 578.2465 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methoxybenzamide (<b>9</b>)</h4><div class="NLM_p last">Yield 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 10.02 (s, 1H), 8.74 (s, 1H), 8.07 (s, 2H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.73 (s, 1H), 7.49 (dd, <i>J</i> = 16.3, 8.2 Hz, 2H), 7.26 (d, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 8.1 Hz, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 2H), 6.46 (dd, <i>J</i> = 16.9, 10.1 Hz, 1H), 6.27 (d, <i>J</i> = 16.8 Hz, 1H), 5.76 (d, <i>J</i> = 9.9 Hz, 1H), 4.66 (d, <i>J</i> = 13.7 Hz, 1H), 4.47 (d, <i>J</i> = 13.9 Hz, 1H), 3.84 (s, 3H), 3.27 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.16, 163.56, 162.27, 160.55, 157.47, 153.78, 152.73, 141.80, 138.35, 137.74, 132.27, 131.29, 130.80, 130.36, 129.99, 127.59, 127.47, 127.32, 119.03, 118.61, 117.45, 116.90, 114.03, 102.55, 55.87, 47.10, 28.42, 18.12, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 578.2452 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,4-dimethoxybenzamide (<b>10</b>)</h4><div class="NLM_p last">Yield 80%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.28 (s, 1H), 10.03 (s, 1H), 8.70 (s, 1H), 8.06 (s, 2H), 7.56 (dd, <i>J</i> = 70.3, 33.9 Hz, 5H), 7.23 (d, <i>J</i> = 32.2 Hz, 2H), 7.08 (s, 1H), 6.41 (d, <i>J</i> = 10.7 Hz, 1H), 6.26 (d, <i>J</i> = 16.4 Hz, 1H), 5.77 (d, <i>J</i> = 9.0 Hz, 1H), 4.64 (d, <i>J</i> = 13.7 Hz, 1H), 4.46 (d, <i>J</i> = 13.5 Hz, 1H), 3.84 (s, 6H), 3.26 (s, 3H), 2.22 (s, 3H), 2.10 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.36, 163.74, 160.46, 157.45, 153.79, 152.80, 152.00, 148.72, 144.34, 141.71, 138.29, 138.16, 137.52, 132.05, 131.35, 130.97, 130.44, 127.59, 127.49, 121.48, 118.67, 118.57, 117.59, 117.17, 111.37, 102.56, 56.10, 56.05, 47.06, 28.40, 18.04, 17.15. LC-MS (ESI, <i>m</i>/<i>z</i>): 608.2568 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,5-dimethoxybenzamide (<b>11</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 10.12 (s, 1H), 8.76 (s, 1H), 8.07 (s, 2H), 7.73 (s, 1H), 7.56–7.45 (m, 2H), 7.32–7.09 (m, 4H), 6.72 (s, 1H), 6.46 (dd, <i>J</i> = 16.0, 10.3 Hz, 1H), 6.27 (d, <i>J</i> = 16.8 Hz, 1H), 5.77 (d, <i>J</i> = 9.8 Hz, 1H), 4.67 (d, <i>J</i> = 13.7 Hz, 1H), 4.48 (d, <i>J</i> = 13.6 Hz, 1H), 3.83 (s, 6H), 3.28 (s, 3H), 2.24 (s, 3H), 2.12 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 608.2534 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,4-dimethoxybenzamide (<b>12</b>)</h4><div class="NLM_p last">Yield 73%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (d, <i>J</i> = 19.9 Hz, 2H), 8.76 (s, 1H), 8.08 (s, 2H), 7.72 (s, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 7.21 (dd, <i>J</i> = 45.9, 15.7 Hz, 5H), 6.53–6.37 (m, 1H), 6.27 (d, <i>J</i> = 16.8 Hz, 1H), 5.77 (d, <i>J</i> = 8.7 Hz, 1H), 4.67 (d, <i>J</i> = 13.2 Hz, 1H), 4.48 (d, <i>J</i> = 12.7 Hz, 1H), 3.84 (d, <i>J</i> = 19.6 Hz, 6H), 3.28 (s, 3H), 2.24 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.98, 163.56, 160.48, 157.47, 153.81, 153.02, 152.72, 146.38, 141.82, 138.49, 138.30, 137.49, 132.28, 131.93, 131.29, 130.81, 130.50, 127.46, 127.29, 124.64, 120.59, 119.07, 118.64, 116.57, 116.13, 115.11, 102.62, 61.52, 56.47, 47.12, 28.42, 18.12, 17.23. LC-MS (ESI, <i>m</i>/<i>z</i>): 608.2578 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,5-dimethoxybenzamide (<b>13</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H), 10.08 (s, 1H), 8.75 (s, 1H), 8.06 (d, <i>J</i> = 8.2 Hz, 2H), 7.73 (s, 1H), 7.52 (d, <i>J</i> = 7.7 Hz, 1H), 7.41 (d, <i>J</i> = 7.5 Hz, 1H), 7.32–7.22 (m, 2H), 7.20–7.03 (m, 3H), 6.47 (dd, <i>J</i> = 16.9, 10.2 Hz, 1H), 6.27 (d, <i>J</i> = 16.9 Hz, 1H), 5.76 (d, <i>J</i> = 10.2 Hz, 1H), 4.66 (d, <i>J</i> = 13.9 Hz, 1H), 4.48 (d, <i>J</i> = 13.9 Hz, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 3.28 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.11, 163.57, 160.48, 157.47, 153.81, 153.52, 152.71, 151.10, 141.79, 138.50, 138.34, 137.33, 132.30, 131.28, 130.78, 130.51, 127.56, 127.27, 125.80, 119.05, 118.60, 117.72, 116.73, 116.27, 115.11, 114.02, 102.61, 56.95, 56.05, 47.11, 28.41, 18.13, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 608.2512 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,4,5-trimethoxybenzamide (<b>14</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 10.13 (s, 1H), 8.85 (s, 1H), 8.07 (d, <i>J</i> = 7.3 Hz, 2H), 7.75 (s, 1H), 7.63–7.43 (m, 2H), 7.26 (dd, <i>J</i> = 22.3, 14.5 Hz, 4H), 6.57–6.42 (m, 1H), 6.27 (d, <i>J</i> = 15.7 Hz, 1H), 5.76 (d, <i>J</i> = 8.3 Hz, 1H), 4.67 (d, <i>J</i> = 13.6 Hz, 1H), 4.49 (d, <i>J</i> = 13.8 Hz, 1H), 3.89 (s, 6H), 3.75 (s, 3H), 3.28 (s, 3H), 2.25 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.14, 163.60, 160.29, 157.62, 153.32, 153.08, 152.66, 141.74, 140.72, 138.35, 138.27, 137.49, 132.30, 131.28, 130.78, 130.61, 130.44, 127.83, 127.27, 119.08, 118.61, 117.78, 117.32, 105.77, 102.67, 60.58, 56.57, 47.07, 28.45, 18.11, 17.23. LC-MS (ESI, <i>m</i>/<i>z</i>): 638.2655 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)benzo[<i>d</i>][1,3]dioxole-5-carboxamide (<b>15</b>)</h4><div class="NLM_p last">Yield 68%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H), 10.01 (s, 1H), 8.75 (s, 1H), 8.07 (s, 2H), 7.73 (s, 1H), 7.65–7.42 (m, 4H), 7.27 (d, <i>J</i> = 7.3 Hz, 1H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 7.06 (d, <i>J</i> = 7.4 Hz, 1H), 6.52–6.40 (m, 1H), 6.27 (d, <i>J</i> = 16.7 Hz, 1H), 6.14 (s, 2H), 5.77 (d, <i>J</i> = 9.2 Hz, 1H), 4.67 (d, <i>J</i> = 13.4 Hz, 1H), 4.48 (d, <i>J</i> = 13.6 Hz, 1H), 3.27 (s, 3H), 2.23 (s, 3H), 2.10 (d, J = 11.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.77, 163.58, 160.53, 157.47, 153.79, 152.74, 150.41, 147.82, 141.80, 138.36, 138.28, 137.60, 132.24, 131.31, 130.83, 130.38, 129.33, 127.58, 127.36, 123.24, 119.06, 118.62, 117.46, 116.93, 108.37, 108.15, 102.57, 102.24, 47.10, 28.42, 18.11, 17.23. LC-MS (ESI, <i>m</i>/<i>z</i>): 592.2265 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Yield 68%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H), 10.00 (s, 1H), 8.83 (s, 1H), 8.07 (s, 2H), 7.73 (s, 1H), 7.54 (s, 4H), 7.28 (s, 1H), 7.19 (s, 1H), 6.99 (d, <i>J</i> = 8.1 Hz, 1H), 6.43 (d, <i>J</i> = 10.2 Hz, 1H), 6.27 (d, <i>J</i> = 15.6 Hz, 1H), 5.78 (s, 1H), 4.67 (d, <i>J</i> = 13.7 Hz, 1H), 4.48 (d, <i>J</i> = 13.7 Hz, 1H), 4.32 (s, 4H), 3.27 (s, 3H), 2.23 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.80, 163.57, 160.29, 157.60, 153.30, 152.67, 146.76, 143.39, 141.77, 138.30, 138.19, 137.69, 132.26, 131.30, 130.81, 130.39, 128.35, 127.60, 127.33, 121.65, 119.08, 118.62, 117.49, 117.29, 117.11, 117.01, 102.63, 64.87, 64.50, 47.07, 28.44, 18.09, 17.23. LC-MS (ESI, <i>m</i>/<i>z</i>): 606.2315 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Yield 78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H), 10.05 (s, 1H), 8.77 (s, 1H), 8.08 (d, <i>J</i> = 6.2 Hz, 2H), 7.71 (d, <i>J</i> = 18.2 Hz, 3H), 7.58–7.43 (m, 2H), 7.35–7.13 (m, 3H), 6.53–6.40 (m, 1H), 6.27 (d, <i>J</i> = 17.0 Hz, 1H), 5.77 (d, <i>J</i> = 9.4 Hz, 1H), 4.67 (d, <i>J</i> = 13.5 Hz, 1H), 4.48 (d, <i>J</i> = 13.9 Hz, 1H), 3.27 (s, 3H), 2.80 (s, 4H), 2.23 (s, 3H), 2.12 (s, 3H), 1.77 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.78, 163.56, 160.54, 157.48, 153.79, 152.73, 141.80, 140.98, 138.36, 137.70, 137.10, 132.66, 132.26, 131.30, 130.81, 130.37, 129.33, 128.66, 127.53, 127.34, 125.16, 119.02, 118.62, 117.42, 116.88, 102.56, 47.11, 29.28, 28.42, 23.06, 22.97, 18.13, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 602.2756 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>18</b>)</h4><div class="NLM_p last">Yield 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 10.23 (s, 1H), 8.76 (s, 1H), 8.25 (s, 1H), 8.16 (d, <i>J</i> = 7.7 Hz, 1H), 8.08 (s, 2H), 7.73 (s, 1H), 7.62 (d, <i>J</i> = 7.5 Hz, 1H), 7.56–7.43 (m, 2H), 7.23 (dd, <i>J</i> = 24.4, 7.9 Hz, 2H), 6.45 (dd, <i>J</i> = 16.5, 10.2 Hz, 1H), 6.27 (d, <i>J</i> = 16.7 Hz, 1H), 5.76 (d, <i>J</i> = 9.9 Hz, 1H), 4.67 (d, <i>J</i> = 13.4 Hz, 1H), 4.48 (d, <i>J</i> = 13.6 Hz, 1H), 3.27 (s, 3H), 2.24 (s, 4H), 2.11 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 630.2328 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,5-bis(trifluoromethyl)benzamide (<b>19</b>)</h4><div class="NLM_p last">Yield 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 10.26 (s, 1H), 8.78 (s, 1H), 8.62 (s, 2H), 8.36 (s, 1H), 8.09 (s, 2H), 7.74 (s, 1H), 7.49 (t, <i>J</i> = 7.2 Hz, 2H), 7.38–7.18 (m, 2H), 6.46 (dd, <i>J</i> = 16.8, 10.2 Hz, 1H), 6.27 (d, <i>J</i> = 16.6 Hz, 1H), 5.76 (d, <i>J</i> = 10.0 Hz, 1H), 4.67 (d, <i>J</i> = 13.9 Hz, 1H), 4.48 (d, <i>J</i> = 14.0 Hz, 1H), 3.28 (s, 3H), 2.26 (s, 3H), 2.11 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 684.2059 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-(dimethylamino)benzamide (<b>20</b>)</h4><div class="NLM_p last">Yield 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H), 9.80 (s, 1H), 8.74 (s, 1H), 8.05 (d, <i>J</i> = 5.4 Hz, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.72 (s, 1H), 7.48 (dd, <i>J</i> = 17.7, 7.5 Hz, 2H), 7.26 (d, <i>J</i> = 8.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.2 Hz, 1H), 6.76 (d, <i>J</i> = 8.5 Hz, 2H), 6.46 (dd, <i>J</i> = 16.6, 10.1 Hz, 1H), 6.26 (d, <i>J</i> = 16.7 Hz, 1H), 5.76 (d, <i>J</i> = 10.0 Hz, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.47 (d, <i>J</i> = 13.8 Hz, 1H), 3.26 (s, 3H), 3.00 (s, 6H), 2.21 (s, 3H), 2.11 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.47, 163.55, 160.57, 157.44, 153.80, 152.77, 141.79, 138.30, 138.09, 132.25, 131.30, 130.79, 130.27, 129.54, 127.37, 127.08, 121.69, 119.01, 118.56, 117.38, 116.80, 111.23, 102.47, 47.08, 28.41, 18.12, 17.25. LC-MS (ESI, <i>m</i>/<i>z</i>): 591.2762 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-fluoro-6-methylbenzamide (<b>21</b>)</h4><div class="NLM_p last">Yield 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 10.24 (s, 1H), 8.80 (s, 1H), 8.09 (d, <i>J</i> = 7.4 Hz, 2H), 7.72 (s, 1H), 7.50 (d, <i>J</i> = 7.9 Hz, 1H), 7.37 (dd, <i>J</i> = 18.7, 7.7 Hz, 2H), 7.26 (d, <i>J</i> = 7.9 Hz, 1H), 7.16 (d, <i>J</i> = 6.3 Hz, 3H), 6.44 (dd, <i>J</i> = 16.8, 10.1 Hz, 1H), 6.26 (d, <i>J</i> = 17.0 Hz, 1H), 5.77 (d, <i>J</i> = 9.8 Hz, 1H), 4.67 (d, <i>J</i> = 13.9 Hz, 1H), 4.47 (d, <i>J</i> = 13.9 Hz, 1H), 3.27 (s, 3H), 2.34 (s, 3H), 2.24 (s, 3H), 2.11 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 580.2319 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-fluoro-5-methylbenzamide (<b>22</b>)</h4><div class="NLM_p">Yield 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 2H), 8.77 (s, 1H), 8.05 (d, <i>J</i> = 14.4 Hz, 2H), 7.72 (s, 1H), 7.59–7.34 (m, 4H), 7.30–7.14 (m, 3H), 6.46 (dd, <i>J</i> = 16.8, 10.2 Hz, 1H), 6.26 (d, <i>J</i> = 16.9 Hz, 1H), 5.76 (d, <i>J</i> = 10.1 Hz, 1H), 4.66 (d, <i>J</i> = 13.8 Hz, 1H), 4.47 (d, <i>J</i> = 14.0 Hz, 1H), 3.27 (s, 3H), 2.35 (s, 3H), 2.23 (s, 3H), 2.10 (d, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.55, 163.10, 160.43, 157.44, 153.80, 152.71, 141.77, 138.48, 138.31, 137.27, 134.13, 133.07, 132.26, 131.30, 130.77, 130.54, 130.33, 127.72, 127.38, 125.14, 119.00, 118.54, 116.67, 116.44, 116.21, 102.64, 47.07, 28.42, 20.50, 18.16, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 580.24 [M + H]<sup>+</sup></div><div class="NLM_p last">Compounds <b>23</b>–<b>26</b> were prepared as follows: To a solution of compound <b>55q</b>–<b>55t</b> (1.0 equiv) in anhydrous THF (1 mL) were added <i>N</i>-Boc amino acid (1.1 equiv), HATU (1.1 equiv), and DIPEA (2.0 equiv) at rt under argon. The reaction mixture was stirred at rt for 1 h. The resulting mixture concentrated to dryness. The residue was diluted with water (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL) and dried anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent provide the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–10%) to give the title compound. The Boc group was deprotected using 4 M HCl in methanol for 1 h. The resulting mixture was concentrated to provide the final product <b>23</b>–<b>26</b>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-<i>N</i>-(5-((6-(5-(2-Amino-3-phenylpropanamido)-2-methylphenyl)-8-methyl-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-<i>d</i>]pyrimidin-2-yl)amino)-2-methylphenyl)acrylamide (<b>23</b>)</h4><div class="NLM_p last">Yield 95%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.99 (s, 1H), 10.46 (s, 1H), 8.47 (s, 3H), 8.16 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.50 (s, 1H), 7.29 (d, <i>J</i> = 23.5 Hz, 8H), 6.50 (s, 1H), 6.25 (d, <i>J</i> = 15.5 Hz, 1H), 5.77 (s, 1H), 4.68 (s, 1H), 4.56 (s, 1H), 4.32 (s, 1H), 3.20 (s, 5H), 2.24 (s, 3H), 2.12 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 591.2791 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-2-Amino-<i>N</i>-(3-(7-(3-amino-4-methylphenylamino)-1-methyl-2-oxo-1,2 dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3-(1<i>H</i>-indol-2-yl)propanamide (<b>24</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.94 (s, 1H), 10.50 (s, 1H), 8.70 (s, 1H), 8.06 (s, 1H), 7.97 (s, 1H), 7.74 (s, 1H), 7.60 (d, <i>J</i> = 7.1 Hz, 1H), 7.54 (s, 1H), 7.32 (s, 2H), 7.26 (d, <i>J</i> = 8.9 Hz, 2H), 7.17 (s, 1H), 7.13 (s, 1H), 7.05 (s, 1H), 6.96 (s, 1H), 6.48 (d, <i>J</i> = 10.3 Hz, 1H), 6.26 (d, <i>J</i> = 17.0 Hz, 1H), 5.75 (d, <i>J</i> = 10.9 Hz, 1H), 4.66 (d, <i>J</i> = 13.5 Hz, 1H), 4.47 (d, <i>J</i> = 14.4 Hz, 1H), 3.25 (s, 3H), 3.17 (s, 1H), 2.85 (s, 1H), 2.20 (s, 3H), 2.11 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 630.2941 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-<i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-amino-4-methylpentanamide (<b>25</b>)</h4><div class="NLM_p last">Yield 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) <i><b>δ</b></i> 11.02 (s, 1H), 10.48 (s, 1H), 8.45 (s, 3H), 8.11 (d, <i>J</i> = 43.8 Hz, 2H), 7.81 (s, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.27 (s, 2H), 6.52 (s, 1H), 6.27 (s, 1H), 5.75 (s, 1H), 4.69 (s, 1H), 4.55 (s, 1H), 4.06 (s, 1H), 3.27 (s, 3H), 2.25 (s, 3H), 2.12 (s, 3H), 1.68 (s, 3H), 0.93 (s, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 557.2817 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-<i>tert</i>-Butyl 5-((3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)amino)-4-amino-5-oxopentanoate (<b>26</b>)</h4><div class="NLM_p last">Yield 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H), 8.74 (s, 1H), 8.05 (d, <i>J</i> = 22.4 Hz, 2H), 7.74 (s, 1H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 7.27 (d, <i>J</i> = 7.9 Hz, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 1H), 6.52–6.43 (m, 1H), 6.26 (d, <i>J</i> = 17.0 Hz, 1H), 5.76 (d, <i>J</i> = 10.1 Hz, 1H), 4.66 (d, <i>J</i> = 13.9 Hz, 1H), 4.48 (d, <i>J</i> = 13.8 Hz, 1H), 3.73 (s, 1H), 3.25 (s, 3H), 2.33 (d, <i>J</i> = 7.0 Hz, 2H), 2.22 (s, 3H), 2.11 (s, 3H), 1.96 (s, 2H), 1.38 (s, 9H). LC-MS (ESI, <i>m</i>/<i>z</i>): 629.3158 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>r</i>,4<i>s</i>)-<i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-propylcyclohexanecarboxamide (<b>27</b>)</h4><div class="NLM_p last">Yield 61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.75 (s, 1H), 8.69 (s, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.73 (s, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 7.9 Hz, 2H), 7.09 (d, <i>J</i> = 7.9 Hz, 1H), 6.48 (dd, <i>J</i> = 16.7, 10.1 Hz, 1H), 6.26 (d, <i>J</i> = 16.7 Hz, 1H), 5.76 (d, <i>J</i> = 9.8 Hz, 1H), 4.65 (d, <i>J</i> = 13.4 Hz, 1H), 4.47 (d, <i>J</i> = 13.8 Hz, 1H), 3.24 (s, 3H), 2.26 (d, <i>J</i> = 11.8 Hz, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 1.80 (s, 4H), 1.42 (d, <i>J</i> = 12.1 Hz, 3H), 1.34–1.28 (m, 2H), 1.18 (d, <i>J</i> = 6.3 Hz, 2H), 0.88 (dd, <i>J</i> = 18.4, 11.3 Hz, 5H). LC-MS (ESI, <i>m</i>/<i>z</i>): 596.3258 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (1<i>r</i>,4<i>r</i>)-<i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-isopropylcyclohexanecarboxamide (<b>28</b>)</h4><div class="NLM_p last">Yield 61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H), 9.71 (s, 1H), 8.70 (s, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.72 (s, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 5.3 Hz, 2H), 7.09 (d, <i>J</i> = 7.9 Hz, 1H), 6.44 (dd, <i>J</i> = 16.8, 10.0 Hz, 1H), 6.27 (d, <i>J</i> = 16.9 Hz, 1H), 5.76 (d, <i>J</i> = 9.6 Hz, 1H), 4.66 (d, <i>J</i> = 13.2 Hz, 1H), 4.46 (d, <i>J</i> = 13.8 Hz, 1H), 3.24 (s, 3H), 2.25 (s, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 1.85 (d, <i>J</i> = 11.7 Hz, 2H), 1.76 (d, <i>J</i> = 10.0 Hz, 2H), 1.41 (d, <i>J</i> = 10.8 Hz, 3H), 1.13–0.92 (m, 3H), 0.91–0.83 (m, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 596.7352 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1<i>s</i>,4<i>s</i>)-<i>N</i>-(3-(7-((3-Acrylamido-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-(trifluoromethyl)cyclohexanecarboxamide (<b>29</b>)</h4><div class="NLM_p last">Yield 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 9.81 (s, 1H), 8.71 (s, 1H), 8.06 (s, 1H), 7.93 (s, 1H), 7.73 (s, 1H), 7.51 (s, 1H), 7.27 (d, <i>J</i> = 7.5 Hz, 2H), 7.12 (s, 1H), 6.56–6.36 (m, 1H), 6.27 (d, <i>J</i> = 16.8 Hz, 1H), 5.78 (s, 1H), 4.66 (d, <i>J</i> = 13.0 Hz, 1H), 4.47 (d, <i>J</i> = 13.0 Hz, 1H), 3.25 (s, 3H), 2.33 (s, 2H), 2.19 (s, 3H), 2.11 (s, 3H), 1.94 (s, 4H), 1.51 (d, <i>J</i> = 11.6 Hz, 2H), 1.30 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.70, 163.55, 160.44, 157.43, 153.75, 152.70, 141.80, 139.16, 138.38, 138.30, 137.69, 132.26, 131.28, 130.78, 130.40, 127.30, 126.80, 118.60, 116.17, 115.64, 102.58, 47.10, 44.23, 28.39, 27.74, 24.33, 18.05, 17.24. LC-MS (ESI, <i>m</i>/<i>z</i>): 622.2635 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (1<i>s</i>,4<i>s</i>)-<i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methylcyclohexanecarboxamide (<b>30</b>)</h4><div class="NLM_p last">Yield 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 9.73 (s, 1H), 8.71 (s, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.72 (s, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (d, <i>J</i> = 6.5 Hz, 2H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.45 (dd, <i>J</i> = 16.6, 10.0 Hz, 1H), 6.27 (d, <i>J</i> = 16.9 Hz, 1H), 5.77 (d, <i>J</i> = 9.9 Hz, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.47 (d, <i>J</i> = 13.6 Hz, 1H), 3.24 (s, 3H), 2.25 (s, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 1.76 (dd, <i>J</i> = 25.3, 11.9 Hz, 4H), 1.44 (d, <i>J</i> = 12.1 Hz, 2H), 1.24 (s, 1H), 0.91 (dd, <i>J</i> = 22.4, 9.4 Hz, 5H). LC-MS (ESI, <i>m</i>/<i>z</i>): 568.6822 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1<i>s</i>,4<i>r</i>)-<i>N</i>-(3-(7-(3-Acrylamido-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-butylcyclohexanecarboxamide (<b>31</b>)</h4><div class="NLM_p last">Yield 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 9.73 (s, 1H), 8.72 (s, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.72 (s, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.26 (d, <i>J</i> = 6.8 Hz, 2H), 7.09 (d, <i>J</i> = 7.7 Hz, 1H), 6.45 (dd, <i>J</i> = 16.8, 10.1 Hz, 1H), 6.26 (d, <i>J</i> = 16.6 Hz, 1H), 5.76 (d, <i>J</i> = 9.6 Hz, 1H), 4.65 (d, <i>J</i> = 13.7 Hz, 1H), 4.46 (d, <i>J</i> = 14.0 Hz, 1H), 3.24 (s, 3H), 2.24 (d, <i>J</i> = 11.1 Hz, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 1.80 (s, 4H), 1.42 (d, <i>J</i> = 11.3 Hz, 3H), 1.27 (s, 2H), 1.19 (s, 3H), 0.88 (d, <i>J</i> = 5.4 Hz, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 610.7623 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Yield 80%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 9.72 (s, 1H), 9.59 (s, 1H), 9.52 (s, 1H), 8.72 (s, 2H), 8.29 (d, <i>J</i> = 15.7 Hz, 2H), 8.16–7.95 (m, 2H), 7.80 (s, 2H), 7.59 (d, <i>J</i> = 7.8 Hz, 2H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 6.54 (s, 1H), 6.24 (d, <i>J</i> = 16.5 Hz, 1H), 5.74 (d, <i>J</i> = 9.7 Hz, 1H), 2.98 (s, 3H), 2.21 (s, 3H), 2.16 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 604.5952 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-(4-Methyl-3-propionamidophenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Yield 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 9.71 (s, 1H), 9.58 (s, 1H), 9.23 (s, 1H), 8.71 (s, 2H), 8.31 (s, 2H), 8.00 (d, <i>J</i> = 12.0 Hz, 2H), 7.80 (s, 2H), 7.59 (s, 1H), 7.48 (s, 1H), 7.27 (s, 1H), 7.11 (s, 1H), 2.98 (s, 3H), 2.34 (s, 2H), 2.21 (s, 3H), 2.14 (s, 3H), 1.11 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 606.2385 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(3-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>34</b>)</h4><div class="NLM_p last">Yield 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H), 9.98 (s, 1H), 9.50 (s, 1H), 8.72 (s, 1H), 8.65 (s, 1H), 7.81 (s, 1H), 7.59–7.53 (m, 2H), 7.50 (s, 1H), 7.46 (d, <i>J</i> = 7.7 Hz, 2H), 7.31–7.22 (m, 2H), 7.16 (d, <i>J</i> = 7.0 Hz, 1H), 6.95 (d, <i>J</i> = 6.9 Hz, 1H), 6.77 (dd, <i>J</i> = 16.6, 10.4 Hz, 1H), 6.57 (s, 1H), 6.27 (s, 1H), 6.22 (s, 1H), 3.85 (s, 3H), 2.86 (s, 3H), 2.27 (s, 3H), 2.19 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.48, 165.57, 165.25, 163.73, 162.07, 161.57, 159.66, 156.67, 139.04, 137.60, 137.02, 136.77, 136.10, 132.55, 131.02, 130.65, 129.73, 127.27, 126.85, 125.30, 124.09, 120.32, 119.34, 118.99, 117.75, 113.36, 105.70, 55.36, 27.79, 18.13, 17.88. LC-MS (ESI, <i>m</i>/<i>z</i>): 566.6642 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(2-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>35</b>)</h4><div class="NLM_p last">Yield 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.09 (s, 1H), 9.70 (s, 1H), 9.56 (s, 1H), 9.49 (s, 1H), 8.71 (s, 2H), 8.05 (s, 1H), 7.76 (s, 1H), 7.64 (d, <i>J</i> = 7.4 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 7.50 (d, <i>J</i> = 7.8 Hz, 2H), 7.23–7.17 (m, 2H), 7.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.07 (t, <i>J</i> = 7.2 Hz, 1H), 6.54 (dd, <i>J</i> = 16.2, 10.6 Hz, 1H), 6.25 (d, <i>J</i> = 16.8 Hz, 1H), 5.74 (d, <i>J</i> = 10.1 Hz, 1H), 3.91 (s, 3H), 2.98 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 566.6651 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(4-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>36</b>)</h4><div class="NLM_p last">Yield 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.81 (s, 1H), 9.65 (s, 1H), 8.76 (s, 1H), 8.04–7.99 (m, 2H), 7.80 (s, 1H), 7.58 (d, <i>J</i> = 8.1 Hz, 1H), 7.54 (s, 1H), 7.41 (s, 2H), 7.29 (s, 2H), 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (d, <i>J</i> = 7.9 Hz, 2H), 6.60 (dd, <i>J</i> = 16.4, 10.4 Hz, 1H), 6.24 (d, <i>J</i> = 17.0 Hz, 1H), 5.73 (d, <i>J</i> = 10.1 Hz, 1H), 3.84 (s, 3H), 2.98 (d, <i>J</i> = 3.7 Hz, 3H), 2.19 (s, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.02, 165.83, 165.14, 163.70, 162.27, 138.48, 137.79, 136.50, 136.45, 132.46, 131.17, 130.44, 130.07, 129.98, 129.34, 127.27, 126.63, 125.91, 119.35, 118.62, 117.28, 114.03, 100.77, 55.90, 27.80, 17.94, 17.84. LC-MS(ESI, <i>m</i>/<i>z</i>): 566.6601 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(3,4-dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>37</b>)</h4><div class="NLM_p last">Yield 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 9.82 (s, 2H), 9.57 (s, 1H), 8.86 (s, 1H), 8.74 (s, 1H), 8.04 (s, 1H), 7.78 (s, 1H), 7.59 (dd, <i>J</i> = 36.9, 11.4 Hz, 4H), 7.27–7.08 (m, 3H), 6.69–6.12 (m, 1H), 5.74 (d, <i>J</i> = 9.6 Hz, 2H), 3.91–3.83 (m, 6H), 3.02 (m, 3H), 2.24 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.71, 165.22, 162.22, 152.07, 148.74, 137.72, 136.47, 132.34, 130.53, 129.43, 127.41, 121.55, 119.48, 117.44, 111.52, 100.92, 56.14, 27.80, 17.80. LC-MS (ESI, <i>m</i>/<i>z</i>): 598.6631 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(benzo[<i>d</i>][1,3]dioxole-5-carboxamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>38</b>)</h4><div class="NLM_p last">Yield 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 9.69 (s, 1H), 9.54 (d, <i>J</i> = 24.5 Hz, 2H), 8.72 (s, 2H), 8.06 (s, 1H), 7.79 (s, 1H), 7.60 (s, 2H), 7.54 (s, 2H), 7.21 (d, <i>J</i> = 6.6 Hz, 1H), 7.14 (d, <i>J</i> = 7.4 Hz, 1H), 7.07 (s, 1H), 6.54 (s, 1H), 6.25 (d, <i>J</i> = 17.1 Hz, 1H), 6.14 (s, 2H), 5.74 (d, <i>J</i> = 10.0 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.17, 164.82, 162.46, 160.50, 157.33, 150.50, 147.87, 138.91, 137.65, 136.62, 136.38, 132.33, 130.48, 130.41, 129.49, 129.19, 123.28, 119.34, 118.46, 117.18, 116.90, 108.39, 108.15, 102.27, 100.62, 100.55, 99.99, 29.50, 17.93, 17.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 580.6071 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(3,5-dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>39</b>)</h4><div class="NLM_p last">Yield 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 1H), 9.81 (s, 1H), 9.67 (s, 1H), 8.75 (s, 2H), 8.03 (s, 1H), 7.78 (s, 1H), 7.59 (d, <i>J</i> = 8.2 Hz, 1H), 7.54 (s, 1H), 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (s, 3H), 6.70 (s, 1H), 6.60 (s, 1H), 6.23 (d, <i>J</i> = 16.4 Hz, 1H), 5.73 (d, <i>J</i> = 8.8 Hz, 1H), 3.82 (s, 6H), 2.97 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.11, 165.35, 162.36, 160.78, 138.49, 137.42, 137.35, 136.49, 136.36, 133.37, 132.38, 130.52, 129.82, 126.78, 125.90, 119.63, 118.80, 117.29, 117.07, 106.09, 103.85, 100.76, 55.91, 29.45, 27.83, 17.86. LC-MS (ESI, <i>m</i>/<i>z</i>): 596.6492 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>40</b>)</h4><div class="NLM_p last">Yield 54%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.08 (s, 2H), 9.96 (s, 1H), 9.59 (s, 1H), 9.08 (s, 1H), 8.77 (s, 1H), 8.03 (s, 1H), 7.82 (s, 1H), 7.55 (s, 4H), 7.21 (s, 2H), 6.99 (s, 1H), 6.60 (s, 1H), 6.26 (d, <i>J</i> = 16.3 Hz, 1H), 5.76 (s, 1H), 4.32 (s, 4H), 3.01 (s, 3H), 2.20 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.09, 164.85, 163.76, 161.91, 146.83, 143.41, 137.74, 136.65, 136.19, 132.34, 130.71, 130.54, 129.41, 128.16, 126.93, 121.69, 119.24, 118.72, 117.31, 117.16, 101.34, 64.88, 64.51, 28.21, 18.43, 17.17. LC-MS (ESI, <i>m</i>/<i>z</i>): 594.63351 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>41</b>)</h4><div class="NLM_p last">Yield 63%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 9.75 (s, 1H), 9.61 (s, 1H), 9.57 (s, 1H), 8.75 (s, 1H), 8.71 (s, 1H), 8.05 (s, 1H), 7.77 (s, 1H), 7.61 (d, <i>J</i> = 7.8 Hz, 1H), 7.55 (d, <i>J</i> = 7.8 Hz, 1H), 7.33 (s, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H), 6.59 (dd, <i>J</i> = 15.0, 8.9 Hz, 1H), 6.24 (d, <i>J</i> = 16.9 Hz, 1H), 5.73 (d, <i>J</i> = 10.0 Hz, 1H), 3.88 (s, 6H), 3.74 (s, 3H), 2.97 (d, <i>J</i> = 4.5 Hz, 3H), 2.21 (s, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.19, 165.15, 163.68, 162.46, 160.44, 157.31, 153.07, 140.73, 138.83, 137.50, 136.71, 136.38, 132.39, 130.47, 130.41, 129.70, 126.73, 125.71, 119.72, 118.82, 118.77, 117.20, 116.96, 105.81, 100.63, 60.58, 56.60, 27.81, 18.41, 17.15, 12.49. LC-MS (ESI, <i>m</i>/<i>z</i>): 626.6752 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-(4-Methyl-3-propionamidophenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>42</b>)</h4><div class="NLM_p last">Yield 70%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.38 (s, 1H), 9.82 (s, 1H), 9.53 (s, 1H), 9.41 (s, 1H), 8.79 (s, 2H), 8.71 (s, 1H), 8.00 (s, 1H), 7.80 (s, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.38 (s, 1H), 7.21 (d, <i>J</i> = 8.3 Hz, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 3.88 (s, 6H), 3.72 (s, 3H), 2.97 (s, 3H), 2.34 (d, <i>J</i> = 7.3 Hz, 2H), 2.20 (s, 3H), 2.13 (s, 3H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.41, 166.24, 165.14, 162.48, 160.45, 157.50, 153.02, 140.69, 138.75, 137.56, 136.80, 136.59, 130.35, 130.22, 129.74, 125.81, 119.89, 118.93, 117.26, 116.89, 105.93, 100.44, 60.57, 56.65, 29.23, 27.78, 17.97, 17.77, 10.49. LC-MS (ESI, <i>m</i>/<i>z</i>): 628.2663 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(5-(2-fluoro-5-methylbenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was prepared from crude intermediates <b>60j</b>, <b>61j</b>, and <b>62j</b>, which were used directly with not purification in each step. Yield 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.72 (s, 1H), 9.60 (s, 1H), 9.51 (s, 1H), 8.71 (s, 2H), 8.05 (s, 1H), 7.74 (s, 1H), 7.55 (d, <i>J</i> = 7.4 Hz, 1H), 7.47 (s, 2H), 7.37 (s, 1H), 7.22 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (d, <i>J</i> = 8.5 Hz, 1H), 6.53 (s, 1H), 6.24 (d, <i>J</i> = 16.5 Hz, 1H), 5.74 (d, <i>J</i> = 10.0 Hz, 1H), 2.97 (s, 3H), 2.35 (s, 3H), 2.17 (d, <i>J</i> = 14.0 Hz, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 568.2421 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>44</b>)</h4><div class="NLM_p last">Yield 51%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.84 (s, 1H), 9.60 (s, 1H), 9.52 (s, 1H), 8.76 (s, 1H), 8.68 (s, 1H), 8.27 (s, 1H), 8.08 (d, <i>J</i> = 10.6 Hz, 2H), 7.99 (s, 1H), 7.83 (s, 1H), 7.58 (d, <i>J</i> = 25.1 Hz, 2H), 7.45 (s, 2H), 7.14 (s, 1H), 6.55 (s, 1H), 6.25 (d, <i>J</i> = 17.6 Hz, 1H), 5.74 (s, 1H), 2.98 (s, 3H), 2.33 (s, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.29, 165.75, 163.66, 162.42, 160.44, 157.35, 140.48, 138.86, 138.76, 136.96, 136.38, 132.62, 132.35, 130.85, 130.41, 130.30, 126.75, 126.64, 125.58, 124.28, 120.33, 117.24, 116.90, 100.52, 27.79, 18.54, 17.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 604.5953 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-(3-Acrylamido-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxyphenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>45</b>)</h4><div class="NLM_p last">Yield 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.09 (s, 1H), 9.79 (s, 1H), 9.58 (s, 1H), 9.48 (s, 1H), 8.74 (s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.96 (s, 1H), 7.79 (s, 1H), 7.55 (s, 1H), 7.43 (s, 1H), 7.26 (s, 2H), 7.15 (s, 1H), 6.54 (s, 1H), 6.24 (d, <i>J</i> = 16.7 Hz, 1H), 5.75 (s, 1H), 3.78 (s, 6H), 3.65 (s, 3H), 2.97 (s, 3H), 2.32 (s, 3H), 2.16 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 626.6762 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Ethyl 4-(Methylamino)-2-(methylthio)pyrimidine-5-carboxylate (<b>47</b>)</h4><div class="NLM_p last">To a solution of ethyl 4-chloro-2 (methylthio)pyrimidine-5-carboxylate <b>1</b> (10.0 g, 43.1 mmol) in THF (150 mL) were added TEA (24 mL, 172.0 mmol) and methylamine hydrochloride (8.73 g, 129.0 mmol) at 0 °C under argon. The reaction mixture was stirred at 0 °C for 1 h. Then it was allowed to warm to room temperature for overnight (14 h). The reaction mixture was concentrated to remove the THF. The residue was diluted with water (100 mL) and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with water (2 × 80 mL) and brine (80 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded crude <b>47</b> as white solid (9.78 g, yield 98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (s, 1H), 8.25 (s, 1H), 4.34–4.22 (m, 2H), 2.97 (d, <i>J</i> = 3.2 Hz, 3H), 2.49 (s, 3H), 1.30 (t, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.40, 166.23, 160.15, 158.10, 101.25, 60.99, 27.77, 14.51, 14.03. LC-MS (ESI, <i>m</i>/<i>z</i>): 228.0732 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol (<b>48</b>)</h4><div class="NLM_p last">To a solution of compound <b>47</b> (9.0 g, 39.6 mmol) in THF (50 mL) was added lithium aluminum hydride (1.8 g, 47.6 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and then treated with H<sub>2</sub>O (1.8 mL) and 1.8 mL of NaOH solution (10%). The mixture was stirred at room temperature for 30 min and then filtered through a pad of Celite. The solid was washed with CH<sub>2</sub>Cl<sub>2</sub> in MeOH (50%, 200 mL). The filtrate was concentrated to afford the crude product <b>48</b> as yellow solid (6.1 g, 84% yield), which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79 (s, 1H), 7.02 (s, 1H), 2.86 (s, 3H), 2.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.30, 160.58, 152.10, 113.88, 58.01, 27.62, 13.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 186.0633 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde (<b>49</b>)</h4><div class="NLM_p last">To a solution of <b>48</b> (6.0 g, 32.4 mmol) in anhydrous DCM (100 mL) was added activated MnO<sub>2</sub> (28.0 g, 324 mmol) at room temperature under argon. Then the reaction mixture was stirred at room temperature for 6 h. The resulting mixture was filtered and washed with DCM (2 × 50 mL). Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with petroleum in ethyl acetate 10–30%) to give <b>49</b> as white solid (5.13 g, yield 87%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 2.97 (s, 3H), 2.48 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 191.84, 176.32, 163.54, 158.80, 109.83, 27.44, 14.08. LC-MS (ESI, <i>m</i>/<i>z</i>): 184.0472 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl (4-Methyl-3-(((4-(methylamino)-2-(methylthio)pyrimidin-5-yl)methyl)amino)phenyl) carbamate (<b>50</b>)</h4><div class="NLM_p last">To a solution of <b>49</b> (5.0 g, 27.3 mmol) and <i>tert</i>-butyl (3-amino-4-methylphenyl)carbamate (6.4 g, 28.7 mmol) in methanol (80 mL) was added acetic acid (3.2 mL, 54.6 mmol) at 0 °C under argon. The reaction mixture was stirred at 0 °C for 30 min. Then NaBH<sub>3</sub>(CN) was portion added. The reaction mixture was stirred at 0 °C for 1 h. Then it was allowed to warm to room temperature for 24 h. The resulting mixture was concentrated to remove the solvent. The residue was diluted with water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with petroleum in ethyl acetate 25–80%) to afford <b>50</b> as white solid (7.8 g, yield 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.03 (s, 1H), 7.91 (s, 1H), 7.13 (s, 1H), 6.83 (s, 2H), 6.57 (s, 1H), 5.38 (s, 1H), 4.07 (s, 2H), 2.92 (d, <i>J</i> = 3.3 Hz, 3H), 2.44 (s, 3H), 2.05 (s, 3H), 1.46 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.80, 160.59, 153.14, 153.06, 146.21, 138.84, 130.15, 116.13, 110.81, 106.25, 100.52, 78.90, 41.13, 28.63, 27.86, 17.54, 13.79. LC-MS (ESI, <i>m</i>/<i>z</i>): 390.1892 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (4-Methyl-3-(1-methyl-7-(methylthio)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)carbamate (<b>51</b>)</h4><div class="NLM_p last">To a solution of <b>50</b> (7.0 g, 18.0 mmol) in anhydrous dioxane (50 mL) was added DIPEA (11.6 mL, 54.0 mmol) at 0 °C under argon. Then a solution of triphosgene (1.81 g, 6.1 mmol) in dioxane (20 mL) was added. The reaction mixture was stirred at 0 °C for 1 h. Then it was allowed to warm to room temperature for 24 h. The resulting mixture was concentrated to remove the solvent. The residue was diluted with water (80 mL) and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with water (80 mL) and brine (80 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–2%) to afford <b>51</b> as white solid (5.7 g, yield 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 2H), 8.25 (s, 2H), 7.55 (s, 2H), 7.23 (s, 2H), 7.17 (d, <i>J</i> = 8.0 Hz, 2H), 4.72 (d, <i>J</i> = 14.5 Hz, 2H), 4.53 (d, <i>J</i> = 14.5 Hz, 2H), 3.30 (s, 6H), 2.06 (s, 6H), 1.48 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.30, 156.85, 153.22, 152.74, 152.14, 141.41, 138.90, 131.16, 129.05, 118.10, 117.15, 108.27, 79.56, 46.85, 28.58, 28.49, 17.01, 14.06. LC-MS (ESI, <i>m</i>/<i>z</i>): 416.1712 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>tert</i>-Butyl (4-Methyl-3-(1-methyl-7-(methylsulfinyl)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)carbamate (<b>52</b>)</h4><div class="NLM_p last">To a solution of <b>51</b> (5.5 g, 13.2 mmol) in DCM (70 mL) was added m-CBPA (2.4 g, 13.86 mmol) at 0 °C under argon. The reaction mixture was stirred at 0 °C for 1 h. Then it was allowed to warm to room temperature for 2 h. The resulting mixture was diluted with DCM (30 mL), washed with water (30 mL) and brine (30 mL), and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–2%) to afford <b>52</b> as white solid (5.5 g, yield 94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.45 (s, 1H), 8.54 (s, 1H), 7.60 (s, 1H), 7.24 (s, 1H), 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 4.86 (d, <i>J</i> = 15.1 Hz, 1H), 4.69 (d, <i>J</i> = 15.3 Hz, 1H), 3.35 (s, 3H), 2.91 (s, 3H), 2.09 (s, 3H), 1.48 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.34, 158.00, 157.98, 153.23, 153.15, 151.71, 141.15, 138.95, 131.22, 129.12, 118.27, 117.18, 113.76, 79.57, 55.37, 47.03, 28.79, 28.58, 17.01. LC-MS (ESI, <i>m</i>/<i>z</i>): 432.1701 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 5-(6-(5-<i>tert</i>-Butyl Carbamate-2-methylphenyl)-8-methyl-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-<i>d</i>]pyrimidin-2-ylamino)-2-methylphenylcarbamate (<b>53</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl (5-amino-2-methylphenyl)carbamate (3.2 g, 14.4 mmol) in THF (40 mL) was added LHMDS (2.1 g, 14.4 mmol) at −78 °C under argon. The reaction was then warmed to rt for 40 min. The reaction was cooled to −78 °C. Compound <b>52</b> (2.1 g, 4.8 mmol) was added for 30 min. The reaction was warmed to rt for 1.5 h. The reaction mixture was quenched by slow addition of saturated ammonium chloride. The residue was diluted with water (80 mL) and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with water (80 mL) and brine (80 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–2%) to afford <b>53</b> as white solid (2.3 g, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.44 (s, 1H), 8.25 (s, 1H), 7.57 (s, 1H), 7.25 (d, <i>J</i> = 7.7 Hz, 1H), 7.18 (d, <i>J</i> = 8.1 Hz, 1H), 6.92 (d, <i>J</i> = 7.8 Hz, 1H), 6.47 (d, <i>J</i> = 7.9 Hz, 1H), 6.40 (s, 1H), 5.06 (s, 1H), 4.75 (d, <i>J</i> = 14.6 Hz, 1H), 4.56 (d, <i>J</i> = 14.7 Hz, 1H), 3.28 (s, 3H), 2.07 (d, <i>J</i> = 2.7 Hz, 6H), 1.47 (d, <i>J</i> = 14.6 Hz, 18H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.94, 157.68, 153.63, 153.24, 153.09, 152.10, 147.68, 141.42, 140.70, 138.92, 131.16, 131.00, 129.13, 123.30, 118.13, 117.25, 114.56, 113.96, 108.73, 80.99, 79.54, 55.35, 46.98, 28.59, 28.27, 17.06. LC-MS (ESI, <i>m</i>/<i>z</i>): 590.3032 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-(5-Amino-2-methylphenyl)-7-((3-amino-4-methylphenyl)amino)-1-methyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>54</b>)</h4><div class="NLM_p last">To a solution of <b>53</b> (250 mg, 0.42 mmol, 1.0 equiv) was added 5 mol/L HCl in 2-propanol (5 mL). The reaction was stirred for 4 h at rt. Evaporation of the solvent afforded compound <b>54</b> as white solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (s, 1H), 8.03 (s, 1H), 6.94 (s, 1H), 6.88 (s, 2H), 6.51 (s, 2H), 6.34 (s, 1H), 5.12 (s, 4H), 4.58 (d, <i>J</i> = 11.4 Hz, 1H), 4.40 (d, <i>J</i> = 12.7 Hz, 1H), 3.26 (s, 3H), 2.09 (s, 3H), 1.98 (s, 3H). LC-MS(ESI, <i>m</i>/<i>z</i>): 390.1976 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-(3-(7-(3-Amino-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>55a</b>)</h4><div class="NLM_p">To a solution of <b>54</b> (50 mg, 0.085 mmol) in DMF (1 mL) were added 3-(trifluoromethyl)benzoic acid (19 mg, 0.102 mmol), HATU (39 mg, 0.102 mmol), and DIPEA (0.045 mL, 0.225 mmol) at room temperature under argon. The reaction mixture was stirred at room temperature for 14 h. The resulting mixture was concentrated to dryness. The residue was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by silica gel flash chromatography (eluting with MeOH in DCM 0–5%) to give the product <b>55a</b> as white solid (40 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.91 (s, 1H), 10.72 (s, 1H), 8.34 (s, 2H), 8.32 (s, 1H), 8.27 (s, 1H), 7.97 (d, <i>J</i> = 7.5 Hz, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.79 (t, <i>J</i> = 7.6 Hz, 1H), 7.69 (d, <i>J</i> = 8.1 Hz, 1H), 7.57 (d, <i>J</i> = 7.9 Hz, 1H), 7.33 (dd, <i>J</i> = 8.1, 3.8 Hz, 2H), 4.76 (d, <i>J</i> = 14.4 Hz, 1H), 4.60 (d, <i>J</i> = 14.5 Hz, 1H), 2.37 (s, 3H), 2.15 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.37, 159.62, 151.49, 141.00, 138.19, 137.11, 136.00, 132.37, 132.01, 131.35, 131.28, 130.21, 129.79, 129.47, 128.64, 127.64, 125.80, 124.76, 124.73, 123.09, 120.77, 120.64, 119.71, 116.23, 104.28, 46.54, 29.59, 17.22, 17.17. LC-MS (ESI, <i>m</i>/<i>z</i>): 562.1109 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>55b</b>–<b>55y</b> were prepared following the synthetic procedure of <b>55a</b>.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-methoxybenzamide (<b>55b</b>)</h4><div class="NLM_p last">Yield 63%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 8.72 (s, 1H), 8.06 (s, 2H), 7.64 (d, <i>J</i> = 7.1 Hz, 1H), 7.50 (t, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 7.6 Hz, 1H), 7.17 (t, <i>J</i> = 7.2 Hz, 2H), 7.07 (t, <i>J</i> = 7.3 Hz, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.49 (d, <i>J</i> = 6.2 Hz, 2H), 5.04 (s, 2H), 4.59 (d, <i>J</i> = 13.8 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 3.90 (s, 3H), 3.26 (s, 3H), 2.23 (s, 3H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.66, 160.45, 157.53, 156.92, 153.69, 152.59, 148.14, 142.13, 138.50, 137.45, 132.38, 131.33, 130.46, 130.11, 127.42, 125.56, 121.95, 120.97, 116.64, 116.18, 113.94, 112.98, 112.48, 102.66, 56.36, 47.14, 28.37, 18.13, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 524.2345 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methoxybenzamide (<b>55c</b>)</h4><div class="NLM_p last">yield 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.72 (s, 1H), 8.24 (s, 1H), 8.16 (d, <i>J</i> = 7.7 Hz, 1H), 8.07 (d, <i>J</i> = 9.9 Hz, 2H), 7.62 (d, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.49 (d, <i>J</i> = 6.7 Hz, 2H), 5.03 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.2 Hz, 1H), 3.25 (s, 3H), 2.24 (s, 3H), 1.97 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 524.2322 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,4-dimethoxybenzamide (<b>55d</b>)</h4><div class="NLM_p last">Yield 43%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.01 (s, 1H), 8.77 (s, 1H), 8.06 (s, 2H), 7.63 (s, 1H), 7.54 (s, 1H), 7.45 (s, 1H), 7.20 (s, 1H), 7.10 (s, 1H), 6.99 (s, 1H), 6.58 (s, 2H), 4.61 (d, <i>J</i> = 11.6 Hz, 1H), 4.42 (d, <i>J</i> = 13.1 Hz, 1H), 3.85 (s, 6H), 3.26 (s, 4H), 2.24 (s, 3H), 2.00 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.16, 160.38, 157.61, 153.43, 152.58, 152.01, 148.75, 146.60, 142.14, 138.30, 137.67, 131.44, 130.39, 127.59, 123.21, 121.45, 117.59, 117.06, 114.74, 113.83, 111.48, 111.39, 102.66, 56.51, 56.14, 56.09, 47.09, 28.39, 18.11, 16.81. LC-MS (ESI, <i>m</i>/<i>z</i>): 554.2450 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,5-dimethoxybenzamide (<b>55e</b>)</h4><div class="NLM_p last">Yield 54%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 8.73 (s, 1H), 8.06 (s, 2H), 7.46 (d, <i>J</i> = 6.5 Hz, 1H), 7.19 (d, <i>J</i> = 7.7 Hz, 1H), 7.11 (s, 2H), 6.94 (d, <i>J</i> = 6.8 Hz, 1H), 6.72 (s, 1H), 6.51 (s, 2H), 5.06 (s, 2H), 4.60 (d, <i>J</i> = 13.9 Hz, 1H), 4.41 (d, <i>J</i> = 13.8 Hz, 1H), 3.83 (s, 6H), 3.25 (s, 3H), 2.24 (s, 3H), 1.98 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 554.2441 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,4-dimethoxybenzamide (<b>55f</b>)</h4><div class="NLM_p last">Yield 58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 8.73 (s, 1H), 8.07 (d, <i>J</i> = 7.8 Hz, 2H), 7.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.16 (dd, <i>J</i> = 19.2, 10.1 Hz, 4H), 6.93 (d, <i>J</i> = 7.7 Hz, 1H), 6.50 (s, 2H), 5.01 (s, 2H), 4.60 (d, <i>J</i> = 13.8 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 3.84 (d, <i>J</i> = 20.2 Hz, 6H), 3.26 (s, 3H), 2.23 (s, 3H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.01, 160.42, 157.52, 153.70, 153.01, 152.59, 148.17, 146.31, 142.12, 138.51, 137.48, 131.99, 131.33, 130.49, 127.40, 124.66, 121.93, 120.54, 116.47, 116.04, 115.04, 113.93, 112.96, 102.68, 61.52, 56.44, 47.14, 28.39, 18.13, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 554.2452 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,5-dimethoxybenzamide (<b>55g</b>)</h4><div class="NLM_p last">Yield 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 8.72 (s, 1H), 8.06 (s, 2H), 7.40 (d, <i>J</i> = 7.6 Hz, 1H), 7.32–7.02 (m, 4H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.50 (s, 2H), 5.11 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.2 Hz, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 3.25 (s, 3H), 2.22 (s, 3H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.12, 160.44, 157.54, 153.67, 153.52, 152.59, 151.09, 148.01, 142.13, 138.52, 137.32, 131.33, 130.49, 127.51, 125.83, 122.05, 117.71, 116.67, 116.23, 115.09, 114.02, 113.05, 102.68, 56.95, 56.05, 47.14, 28.37, 18.13, 16.77. LC-MS (ESI, <i>m</i>/<i>z</i>): 554.2431 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,4,5-trimethoxybenzamide (<b>55h</b>)</h4><div class="NLM_p last">Yield 58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 8.74 (s, 1H), 8.04 (d, <i>J</i> = 11.9 Hz, 2H), 7.45 (s, 1H), 7.28 (s, 2H), 7.20 (d, <i>J</i> = 7.8 Hz, 1H), 6.95 (s, 1H), 6.51 (s, 2H), 5.34 (s, 2H), 4.60 (d, <i>J</i> = 13.7 Hz, 1H), 4.41 (d, <i>J</i> = 13.9 Hz, 1H), 3.88 (s, 6H), 3.74 (s, 3H), 3.25 (s, 3H), 2.24 (s, 3H), 1.98 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.11, 160.48, 157.59, 153.61, 153.08, 152.59, 147.74, 142.13, 140.73, 138.44, 137.43, 131.35, 130.63, 130.40, 127.73, 122.27, 117.70, 117.14, 114.16, 113.21, 105.76, 102.70, 60.59, 56.58, 56.51, 47.12, 28.37, 18.12, 16.77. LC-MS (ESI, <i>m</i>/<i>z</i>): 584.2552 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)benzo[<i>d</i>][1,3]dioxole-5-carboxamide (<b>55i</b>)</h4><div class="NLM_p last">Yield 60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.00 (s, 1H), 8.73 (s, 1H), 8.06 (s, 2H), 7.64–7.50 (m, 2H), 7.44 (d, <i>J</i> = 7.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.7 Hz, 1H), 7.06 (d, <i>J</i> = 7.8 Hz, 1H), 6.95 (d, <i>J</i> = 7.2 Hz, 1H), 6.52 (s, 2H), 6.14 (s, 2H), 5.19 (s, 2H), 4.60 (d, <i>J</i> = 13.6 Hz, 1H), 4.41 (d, <i>J</i> = 13.9 Hz, 1H), 3.25 (s, 3H), 2.23 (s, 3H), 1.98 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.74, 160.48, 157.56, 153.62, 152.59, 150.41, 147.82, 142.13, 138.38, 137.61, 131.35, 130.37, 129.35, 127.53, 123.23, 122.22, 117.41, 116.88, 114.12, 113.16, 108.38, 108.15, 102.64, 102.24, 47.13, 28.37, 18.12, 16.77. LC-MS (ESI, <i>m</i>/<i>z</i>): 538.2126 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamide (<b>55j</b>)</h4><div class="NLM_p last">Yield 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.77 (s, 1H), 8.06 (s, 2H), 7.49 (d, <i>J</i> = 28.9 Hz, 3H), 7.18 (s, 1H), 7.00 (s, 2H), 6.59 (s, 2H), 4.61 (d, <i>J</i> = 13.5 Hz, 1H), 4.42 (d, <i>J</i> = 13.9 Hz, 1H), 4.32 (s, 4H), 3.24 (s, 3H), 2.22 (s, 3H), 2.00 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.77, 160.35, 157.59, 153.33, 152.57, 146.75, 143.39, 142.15, 138.27, 137.67, 131.45, 130.37, 128.34, 127.53, 121.64, 117.29, 117.10, 116.91, 113.98, 102.64, 64.87, 64.50, 56.50, 47.09, 28.39, 18.11, 16.82. LC-MS (ESI, <i>m</i>/<i>z</i>): 552.2290 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide (<b>55k</b>)</h4><div class="NLM_p last">Yield 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.05 (s, 1H), 8.76 (s, 1H), 8.09 (s, 2H), 7.69 (s, 2H), 7.46 (s, 1H), 7.19 (s, 2H), 6.96 (s, 1H), 6.54 (s, 2H), 5.36 (s, 2H), 4.59 (s, 1H), 4.44 (s, 1H), 3.26 (s, 3H), 2.81 (s, 4H), 2.24 (s, 3H), 1.99 (s, 3H), 1.78 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.77, 160.45, 157.58, 153.56, 152.59, 147.40, 142.14, 140.99, 138.35, 137.70, 137.10, 132.66, 131.38, 130.37, 129.33, 128.66, 127.50, 125.16, 122.57, 117.39, 116.85, 114.35, 113.41, 102.64, 47.12, 29.28, 28.38, 23.06, 22.97, 18.12, 16.79. LC-MS (ESI, <i>m</i>/<i>z</i>): 548.2678 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>55l</b>)</h4><div class="NLM_p last">Yield 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.72 (s, 1H), 8.24 (s, 1H), 8.16 (d, <i>J</i> = 7.7 Hz, 1H), 8.07 (d, <i>J</i> = 9.9 Hz, 2H), 7.62 (d, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.49 (d, <i>J</i> = 6.7 Hz, 2H), 5.03 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.2 Hz, 1H), 3.25 (s, 3H), 2.24 (s, 3H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.21, 160.47, 157.56, 153.67, 152.59, 148.15, 142.11, 140.18, 138.49, 137.24, 133.47, 132.89, 131.97, 131.33, 130.46, 127.87, 125.38, 125.33, 121.93, 117.47, 116.93, 113.95, 112.97, 102.72, 47.13, 28.36, 19.26, 18.14, 16.75. LC-MS (ESI, <i>m</i>/<i>z</i>): 576.2235 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3,5-bis(trifluoromethyl)benzamide (<b>55m</b>)</h4><div class="NLM_p last">Yield 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.74 (s, 1H), 8.62 (s, 2H), 8.36 (s, 1H), 8.07 (d, <i>J</i> = 9.9 Hz, 2H), 7.47 (d, <i>J</i> = 8.2 Hz, 1H), 7.23 (d, <i>J</i> = 8.2 Hz, 1H), 6.93 (d, <i>J</i> = 8.3 Hz, 1H), 6.49 (d, <i>J</i> = 6.6 Hz, 2H), 5.03 (s, 2H), 4.60 (d, <i>J</i> = 14.2 Hz, 1H), 4.41 (d, <i>J</i> = 14.2 Hz, 1H), 3.25 (s, 3H), 2.25 (s, 3H), 1.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.71, 160.44, 157.59, 153.66, 152.58, 148.14, 142.11, 138.59, 137.67, 136.84, 131.33, 131.09, 130.76, 130.58, 129.00, 128.31, 125.52, 124.98, 122.27, 121.93, 117.56, 117.01, 113.97, 112.97, 102.81, 47.12, 28.38, 18.17, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 630.1982 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-(dimethylamino)benzamide (<b>55n</b>)</h4><div class="NLM_p last">Yield 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.80 (s, 1H), 8.71 (s, 1H), 8.04 (s, 2H), 7.86 (d, <i>J</i> = 8.3 Hz, 2H), 7.45 (d, <i>J</i> = 7.9 Hz, 1H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 6.93 (d, <i>J</i> = 8.5 Hz, 1H), 6.76 (d, <i>J</i> = 8.6 Hz, 2H), 6.49 (s, 2H), 5.01 (s, 2H), 4.58 (d, <i>J</i> = 13.9 Hz, 1H), 4.40 (d, <i>J</i> = 14.0 Hz, 1H), 3.23 (s, 3H), 3.00 (s, 6H), 2.21 (s, 3H), 1.97 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 537.2654 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-fluoro-6-methylbenzamide (<b>55o</b>)</h4><div class="NLM_p last">Yield 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 8.76 (s, 1H), 8.08 (d, <i>J</i> = 11.5 Hz, 2H), 7.50–7.30 (m, 2H), 7.26–7.08 (m, 3H), 6.92 (d, <i>J</i> = 7.7 Hz, 1H), 6.49 (s, 2H), 5.02 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.40 (d, <i>J</i> = 14.0 Hz, 1H), 3.24 (s, 3H), 2.33 (s, 3H), 2.23 (s, 3H), 1.96 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 526.2295 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(3-(7-(3-Amino-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-2-fluoro-5-methylbenzamide (<b>55p</b>)</h4><div class="NLM_p last">Yield 45%. <sup>1</sup>H NMR (400 M/Hz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H), 8.74 (s, 1H), 8.05 (d, <i>J</i> = 7.0 Hz, 2H), 7.42 (dd, <i>J</i> = 25.4, 7.0 Hz, 3H), 7.29–7.13 (m, 2H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 6.49 (s, 2H), 5.02 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 3.25 (s, 3H), 2.35 (s, 3H), 2.22 (s, 3H), 1.96 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.08, 160.40, 157.51, 153.68, 152.58, 148.19, 142.11, 138.51, 137.27, 134.16, 133.06, 131.32, 130.52, 130.33, 127.65, 125.30, 125.14, 121.87, 116.63, 116.43, 116.21, 116.12, 113.90, 112.93, 102.71, 47.12, 28.37, 20.50, 18.15, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 526.2295 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>S</i>)-<i>tert</i>-Butyl(1-((3-(7-((3-amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (<b>55q</b>)</h4><div class="NLM_p last">Yield 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.94 (s, 1H), 8.68 (s, 1H), 8.06 (s, 1H), 7.96 (s, 1H), 7.36–7.25 (m, 4H), 7.20 (s, 2H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 7.09 (d, <i>J</i> = 8.1 Hz, 1H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 6.49 (s, 2H), 5.00 (s, 2H), 4.59 (d, <i>J</i> = 13.8 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 4.32 (s, 1H), 3.23 (s, 3H), 2.98 (d, <i>J</i> = 10.2 Hz, 1H), 2.88–2.79 (m, 1H), 2.21 (s, 3H), 1.97 (s, 3H), 1.33 (s, 9H). LC-MS (ESI, <i>m</i>/<i>z</i>): 637.2680 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>S</i>)-<i>tert</i>-Butyl(1-((3-(7-((3-amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)amino)-3-(1<i>H</i>-indol-2-yl)-1-oxopropan-2-yl)carbamate (<b>55r</b>)</h4><div class="NLM_p last">Yield 44%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 9.96 (s, 1H), 8.68 (s, 1H), 8.06 (s, 1H), 7.98 (s, 1H), 7.67 (d, <i>J</i> = 7.3 Hz, 1H), 7.33 (d, <i>J</i> = 7.7 Hz, 1H), 7.26 (d, <i>J</i> = 7.4 Hz, 1H), 7.23–7.11 (m, 2H), 7.07 (t, <i>J</i> = 7.4 Hz, 1H), 7.03–6.89 (m, 3H), 6.50 (s, 2H), 5.00 (s, 2H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.3 Hz, 2H), 3.24 (s, 3H), 3.12 (d, <i>J</i> = 9.2 Hz, 1H), 3.01 (d, <i>J</i> = 9.3 Hz, 1H), 2.21 (s, 3H), 1.97 (s, 3H), 1.34 (s, 9H). LC-MS (ESI, <i>m</i>/<i>z</i>): 676.2770 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>S</i>)-<i>tert</i>-Butyl(1-((3-(7-((3-amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>55s</b>)</h4><div class="NLM_p last">Yield 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.86 (s, 1H), 8.67 (s, 1H), 8.05 (s, 1H), 7.98 (s, 1H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 7.12 (d, <i>J</i> = 8.1 Hz, 1H), 7.01 (d, <i>J</i> = 7.2 Hz, 1H), 6.93 (d, <i>J</i> = 7.6 Hz, 1H), 6.49 (s, 2H), 5.00 (s, 2H), 4.59 (d, <i>J</i> = 13.8 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 4.12 (s, 1H), 3.22 (s, 3H), 2.20 (s, 3H), 1.97 (s, 3H), 1.58 (d, <i>J</i> = 48.2 Hz, 2H), 1.39 (s, 9H), 1.35–1.30 (m, 1H), 0.90 (s, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 603.3265 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>S</i>)-<i>tert</i>-Butyl-5-((3-(7-((3-amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)amino)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-oxopentanoate (<b>55t</b>)</h4><div class="NLM_p last">Yield 61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.87 (s, 1H), 8.68 (s, 1H), 8.04 (d, <i>J</i> = 19.4 Hz, 2H), 7.22 (s, 1H), 7.14 (s, 1H), 7.04 (s, 1H), 6.94 (s, 1H), 6.50 (s, 2H), 5.06 (s, 2H), 4.60 (d, <i>J</i> = 13.6 Hz, 1H), 4.41 (d, <i>J</i> = 14.3 Hz, 1H), 4.09 (s, 1H), 3.23 (s, 3H), 2.24 (d, <i>J</i> = 20.4 Hz, 5H), 1.97 (s, 3H), 1.86 (d, <i>J</i> = 28.9 Hz, 2H), 1.40 (s, 18H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.02, 170.87, 160.32, 157.48, 155.85, 153.70, 152.56, 148.07, 142.13, 138.47, 137.20, 131.34, 130.48, 126.76, 122.02, 115.98, 115.55, 113.99, 113.03, 102.71, 80.21, 78.62, 54.77, 47.14, 31.91, 28.65, 28.37, 28.21, 27.69, 18.05, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 675.3542 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (1<i>r</i>,4<i>s</i>)-<i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-propylcyclohexanecarboxamide (<b>55u</b>)</h4><div class="NLM_p last">Yield 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.74 (s, 1H), 8.66 (s, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.24 (d, <i>J</i> = 7.7 Hz, 1H), 7.09 (d, <i>J</i> = 7.4 Hz, 1H), 6.93 (d, <i>J</i> = 6.4 Hz, 1H), 6.49 (s, 2H), 5.01 (s, 2H), 4.58 (d, <i>J</i> = 14.3 Hz, 1H), 4.40 (d, <i>J</i> = 14.4 Hz, 1H), 3.22 (s, 3H), 2.27 (s, 1H), 2.18 (s, 3H), 1.97 (s, 3H), 1.80 (s, 4H), 1.42 (d, J = 11.9 Hz, 3H), 1.30 (s, 2H), 1.17 (s, 2H), 0.97–0.84 (m, 5H). LC-MS (ESI, <i>m</i>/<i>z</i>): 542.3145 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>N</i>-(3-(7-(3-Amino-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-isopropylcyclohexanecarboxamide (<b>55v</b>)</h4><div class="NLM_p last">Yield 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 8.68 (s, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.93 (d, <i>J</i> = 7.3 Hz, 1H), 6.49 (s, 2H), 5.03 (s, 2H), 4.58 (d, <i>J</i> = 13.6 Hz, 1H), 4.40 (d, <i>J</i> = 14.1 Hz, 1H), 3.22 (s, 3H), 2.25 (s, 1H), 2.18 (s, 3H), 1.97 (s, 3H), 1.85 (d, <i>J</i> = 11.6 Hz, 2H), 1.77 (s, 2H), 1.41 (d, <i>J</i> = 9.9 Hz, 3H), 1.07–0.96 (m, 3H), 0.86 (d, <i>J</i> = 6.0 Hz, 6H). LC-MS (ESI, <i>m</i>/<i>z</i>): 542.3243 [M + H]<sup>+</sup></div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (1<i>s</i>,4<i>s</i>)-<i>N</i>-(3-(7-((3-Amino-4-methylphenyl)amino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-(trifluoromethyl)cyclohexanecarboxamide (<b>55w</b>)</h4><div class="NLM_p last">Yield 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 8.67 (s, 1H), 8.04 (s, 1H), 7.93 (s, 1H), 7.24 (d, <i>J</i> = 7.8 Hz, 1H), 7.10 (d, <i>J</i> = 8.1 Hz, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.50 (s, 2H), 5.09 (s, 2H), 4.59 (d, <i>J</i> = 13.6 Hz, 1H), 4.40 (d, <i>J</i> = 14.2 Hz, 1H), 3.22 (s, 3H), 2.33 (s, 2H), 2.18 (s, 3H), 1.95 (d, <i>J</i> = 12.9 Hz, 7H), 1.56–1.44 (m, 2H), 1.30 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.70, 160.40, 157.51, 153.64, 152.59, 148.04, 142.13, 138.40, 137.70, 131.33, 130.39, 126.73, 122.02, 116.13, 115.60, 114.00, 113.03, 102.65, 47.14, 44.22, 28.35, 27.74, 24.34, 18.05, 16.76. LC-MS (ESI, <i>m</i>/<i>z</i>): 568.2578 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(3-(7-(3-Amino-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-methylcyclohexanecarboxamide (<b>55x</b>)</h4><div class="NLM_p last">Yield 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (s, 1H), 8.68 (s, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.25 (d, <i>J</i> = 7.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.0 Hz, 1H), 6.92 (d, <i>J</i> = 8.2 Hz, 1H), 6.49 (s, 2H), 5.04 (s, 2H), 4.58 (d, <i>J</i> = 13.9 Hz, 1H), 4.40 (d, <i>J</i> = 14.0 Hz, 1H), 3.22 (s, 3H), 2.26 (s, 1H), 2.17 (s, 3H), 1.96 (s, 3H), 1.76 (dd, <i>J</i> = 24.1, 12.0 Hz, 4H), 1.40 (dd, <i>J</i> = 29.3, 16.2 Hz, 3H), 0.90 (t, <i>J</i> = 15.8 Hz,5H). LC-MS (ESI,<i>m</i>/<i>z</i>): 514.2930 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (1<i>r</i>,4<i>s</i>)-<i>N</i>-(3-(7-(3-Amino-4-methylphenylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-4-butylcyclohexanecarboxamide (<b>55y</b>)</h4><div class="NLM_p last">Yield 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.73 (s, 1H), 8.69 (s, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.09 (d, <i>J</i> = 8.2 Hz, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.49 (s, 2H), 5.03 (s, 2H), 4.58 (d, <i>J</i> = 14.0 Hz, 1H), 4.40 (d, <i>J</i> = 14.0 Hz, 1H), 3.22 (s, 3H), 2.24 (d, <i>J</i> = 11.1 Hz, 1H), 2.18 (s, 3H), 1.96 (s, 3H), 1.80 (s, 4H), 1.55–1.35 (m, 3H), 1.19 (s, 3H), 0.88 (d, <i>J</i> = 4.9 Hz, 5H). LC-MS (ESI, <i>m</i>/<i>z</i>): 556.3400 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 4-(Methylamino)-2-(methylthio)pyrimidine-5-carboxylic Acid (<b>56</b>)</h4><div class="NLM_p last">To a solution of compound <b>47</b> (0.98 g, 4.3 mmol, 1,0 equiv) in methanol (10 mL) and water (2 mL) was added NaOH (0.18 g, 4.4 mmol, 1.02 equiv) at room temperature under argon. The reaction mixture was stirred at room temperature for 20 h. The resulting mixture was concentrated to dryness. The residue was diluted with water (50 mL), acidified by 1 N HCl to pH 3. The white precipitate was filtered and dried to provide the product as a white solid (0.70 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.48 (s, 1H), 8.35 (s, 1H), 2.96 (d, <i>J</i> = 3.9 Hz, 3H), 2.47 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.07, 168.31, 160.62, 158.32, 101.76, 27.59, 14.00. LC-MS (ESI, <i>m</i>/<i>z</i>): 200.0423 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> <i>tert</i>-Butyl 4-Methyl-3-(4-(methylamino)-2-(methylthio)-pyrimidine-5-carboxamido)phenylcarbamate (<b>57</b>)</h4><div class="NLM_p last">To a solution of compound <b>56</b> (4.0 g, 20.0 mmol, 1.00 equiv) in anhydrous DMF (20 mL) were added <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate (4.98 g, 3.6 mmol, 1.10 equiv), HATU (9.88 g, 26.0 mmol, 1.2 equiv), and DIPEA (12 mL, 70.0 mmol, 3.5 equiv) at room temperature under argon. The reaction mixture was stirred at room temperature for 20 h. The resulting mixture was concentrated to dryness. The residue was diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with water (100 mL) and brine (100 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by flash column chromatography (eluting with MeOH in DCM 0–5%) to offer <b>57</b> as a white solid (6.60 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.89 (s, 1H), 9.33 (s, 1H), 8.67 (s, 2H), 7.51 (s, 1H), 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 2.96 (d, <i>J</i> = 3.1 Hz, 3H), 2.52 (s, 3H), 2.13 (s, 3H), 1.48 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.60, 165.68, 160.55, 155.22, 153.24, 138.04, 136.26, 130.63, 127.94, 117.00, 116.72, 104.82, 79.40, 28.60, 27.58, 17.72, 13.98. LC-MS (ESI, <i>m</i>/<i>z</i>): 404.1685 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>N</i>-(5-Amino-2-methylphenyl)-4-(methylamino)-2-(methylthio)-pyrimidine-5-carboxamide (<b>58</b>)</h4><div class="NLM_p last">To a solution of compound <b>57</b> (4.03 g, 10.0 mmol, 1.00 equiv) in methanol (15 mL) was added 10 mL of 4 M HCl (in methanol) at room temperature under argon. The reaction mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated to provide <b>58</b> as an off-white solid (4.2 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (s, 1H), 9.51 (s, 1H), 9.00 (s, 1H), 7.41 (s, 1H),7.26 (s, 1H), 3.08 (s, 3H), 2.64 (s, 3H), 2.25 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.07, 163.84, 159.40, 147.58, 136.68, 134.31, 132.62, 131.88, 131.10, 129.92, 121.65, 104.86, 28.66, 18.17, 14.02. LC-MS (ESI, <i>m</i>/<i>z</i>): 304.1163 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>N</i>-(2-Methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59a</b>)</h4><div class="NLM_p">To a solution of compound <b>58</b> (303 mg, 1.0 mmol, 1.0 equiv) in anhydrous THF (5 mL) was added a solution of 3-(trifluoromethyl)benzoyl chloride (219 mg, 1.05 mmol, 1.05 equiv) and DIPEA (0.53 mL, 3.0 mmol, 3.0 equiv) at 0 °C under argon. The reaction mixture was stirred at 0 °C under argon for 2 h. The resulting mixture was concentrated to dryness. The residue was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water and brine and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by flash column chromatography (eluting with MeOH in DCM 0–5%) to offer <b>59a</b> as white solid (380 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51(s, 1H), 9.56 (s, 1H), 8.83 (s, 1H), 8.41–8.23 (m, 3H), 7.97 (d, <i>J</i> = 6.6 Hz, 1H), 7.80 (d, <i>J</i> = 6.8 Hz, 1H), 7.64 (d, <i>J</i> = 7.0 Hz, 1H), 7.26 (d, <i>J</i> = 7.3 Hz, 1H), 4.14 (s, 3H), 2.60 (s, 3H), 2.30 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.28, 160.68, 159.45, 137.46, 136.52, 136.19, 132.32, 130.67, 130.12, 129.79, 128.52, 124.69, 117.75, 116.03, 111.46,55.28, 17.29, 13.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 476.1235 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>59b</b>–<b>59j</b> were prepared following the synthetic procedure of <b>59a</b>.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>-(5-(3-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 9.98 (s, 1H), 8.70 (s, 1H), 8.66 (s, 1H), 7.84 (s, 1H), 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.56 (d, <i>J</i> = 6.8 Hz, 1H), 7.52 (s, 1H), 7.46 (d, <i>J</i> = 6.6 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz,1H), 7.17 (t, <i>J</i> = 8.9 Hz, 2H), 3.85 (s, 3H), 2.96 (d, <i>J</i> = 4.2 Hz, 3H), 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.63, 165.77, 165.56, 160.56, 159.66, 155.25, 137.60, 136.76, 136.18, 130.62, 130.13,129.99, 129.72, 122.02, 120.33, 119.38, 118.90, 117.74, 114.41, 113.36, 104.88, 55.80, 27.38, 17.72, 13.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 438.1537 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>N</i>-(5-(2-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59c</b>)</h4><div class="NLM_p last">Yield 89%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (s, 1H), 8.13 (d, <i>J</i> = 7.2 Hz, 1H), 7.75 (s, 1H), 7.45 (dd, <i>J</i> = 19.1, 12.3 Hz, 1H), 7.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.09–7.01 (m, 1H), 6.97 (d, <i>J</i> = 8.0 Hz, 1H), 3.99 (s, 3H), 3.00 (s, 3H), 2.51 (s, 3H), 2.24 (d, <i>J</i> = 28.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.33, 166.08, 163.51, 160.55, 157.25, 153.78, 136.32, 135.46, 133.34, 132.19, 130.86, 129.33, 121.51, 121.41, 118.79, 118.16, 111.53, 104.18, 56.16, 27.08, 17.44, 14.00. LC-MS (ESI, <i>m</i>/<i>z</i>): 438.1560 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>N</i>-(5-(4-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59d</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 7.74 (d, <i>J</i> = 7.3 Hz, 2H), 7.63 (s, 1H), 7.28 (d, <i>J</i> = 6.4 Hz, 1H), 7.03 (d, <i>J</i> = 7.5 Hz, 1H), 6.82 (d, <i>J</i> = 7.4 Hz, 2H), 3.78 (s, 3H), 2.96 (s, 3H), 2.49 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.27, 166.21, 166.08, 162.32, 160.46, 153.83, 136.45, 135.09, 130.69, 129.43, 129.17, 126.75, 119.13, 118.52, 113.61, 104.06, 55.32, 27.05, 17.30, 13.97. LC-MS (ESI, <i>m</i>/<i>z</i>): 438.1522 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(5-(3,4-Dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59e</b>)</h4><div class="NLM_p last">Yield 85%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.95 (s, 1H), 8.88 (s, 1H), 8.83 (s, 1H), 8.74 (s, 1H), 8.16 (s, 1H), 7.72 (s, 2H), 7.59 (d, <i>J</i> = 7.5 Hz, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.10 (d, <i>J</i> = 8.1 Hz, 1H), 4.21 (s, 3H), 4.17 (s, 3H), 3.32 (d, <i>J</i> = 4.2 Hz, 3H), 2.86 (s, 3H), 2.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.53, 162.15, 161.83, 156.59, 149.92, 147.99, 144.88, 132.48, 131.34, 126.76, 124.71, 123.08, 116.24,114.80, 113.96, 106.69, 106.28, 100.14, 56.49, 52.02, 23.33, 13.46, 10.16. LC-MS (ESI, <i>m</i>/<i>z</i>): 468.26329 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-(5-(Benzo[<i>d</i>][1,3]dioxole-5-carboxamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59f</b>)</h4><div class="NLM_p last">Yield 80%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.73 (s,1H), 7.92 (s, 1H), 7.76–7.65 (m, 2H), 7.64 (s, 1H), 7.45 (d, <i>J</i> = 5.1 Hz, 1H), 7.12 (d, <i>J</i> = 4.7 Hz, 1H), 6.31 (s, 2H), 3.10 (s, 2H), 2.85 (s, 3H), 2.49 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 177.26, 169.44, 169.23, 163.58, 156.83, 153.63, 150.92, 139.59, 138.17, 133.77, 133.18, 131.68, 125.45, 122.54, 122.11, 110.91, 110.79, 107.05, 104.81, 41.42, 30.04, 20.29, 16.89. LC-MS (ESI, <i>m</i>/<i>z</i>): 452.1319 [M + H]<sup><b>+</b></sup>.</div></div><div id="sec5_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>N</i>-(5-(3,5-Dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59g</b>)</h4><div class="NLM_p last">Yield 84%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.19 (s, 1H), 6.96 (d, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 8.0 Hz, 1H), 6.55 (s, 2H), 6.11 (s, 1H), 4.10 (s, 6H), 2.56 (s, 3H), 2.06 (s, 3H), 1.73 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 176.97, 169.65, 169.21, 163.56, 163.32, 156.55, 139.54, 139.27, 137.96, 133.41, 133.24, 122.37, 122.11, 108.09, 106.77, 106.45, 57.96, 29.56, 19.83, 16.35. LC-MS (ESI, <i>m</i>/<i>z</i>): 468.1630 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> <i>N</i>-(5-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59h</b>)</h4><div class="NLM_p last">Yield 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 9.95 (s, 1H), 8.68 (d, <i>J</i> = 12.8 Hz, 2H), 7.83 (s, 1H), 7.56 (s, 3H), 7.23 (s, 1H), 7.00 (s, 1H), 4.32 (s, 4H), 2.97 (s, 3H), 2.52 (d, <i>J</i> = 4.6 Hz, 3H), 2.20 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.63, 165.75, 164.85, 160.55, 155.22, 146.83, 143.41, 137.78, 136.13, 130.58, 129.46, 128.16, 121.67, 119.23, 118.77, 117.30, 117.14, 104.89, 64.87, 64.50, 27.58, 17.86, 13.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 467.1485 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>N</i>-(2-Methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>59i</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.54–8.45 (m, 1H), 7.81–7.72 (m, 1H), 7.51–7.41 (m, 1H), 7.29–7.15 (m, 3H), 3.93–3.88 (m, 6H), 3.87–3.84 (m, 3H), 3.07–3.02 (m, 3H), 2.58–2.53 (m, 3H), 2.25–2.19 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 176.83, 169.20, 169.08, 163.16, 156.46, 155.54, 143.37, 139.28, 137.90, 133.18, 132.99, 132.63, 122.17, 122.06, 107.61, 106.65, 62.70, 58.27, 29.24, 19.66, 15.93. LC-MS (ESI, <i>m</i>/<i>z</i>): 498.1782 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 2-(4-Methyl-3-propionamidophenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>59j</b>)</h4><div class="NLM_p last">Yield 70%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.38 (s, 1H), 9.82 (s, 1H), 9.53 (s, 1H), 9.41 (s, 1H), 8.79 (s, 2H), 8.71 (s, 1H), 8.00 (s, 1H), 7.80 (s, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.38 (s, 1H), 7.21 (d, <i>J</i> = 8.3 Hz, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 3.88 (s, 6H), 3.72 (s, 3H), 2.97 (s, 3H), 2.34 (d, <i>J</i> = 7.3 Hz, 2H), 2.20 (s, 3H), 2.13 (s, 3H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.41, 166.24, 165.14, 162.48, 160.45, 157.50, 153.02, 140.69, 138.75, 137.56, 136.80, 136.59, 130.35, 130.22, 129.74, 125.81, 119.89, 118.93, 117.26, 116.89, 105.93, 100.44, 60.57, 56.65, 29.23, 27.78, 17.97, 17.77, 10.49. LC-MS (ESI, <i>m</i>/<i>z</i>): 628.2663 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>N</i>-(2-Methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60a</b>)</h4><div class="NLM_p">To a solution of <b>59a</b> (238 mg, 0.5 mmol, 1.0 equiv) in DCM (10 mL) was added m-CBPA (181 mg, 1.05 mmol, 2.10 equiv) at 0 °C under argon. The reaction mixture was stirred at 0 °C for 2 h, then was allowed to warm to room temperature for 20 h. The resulting mixture was diluted with DCM (30 mL), washed with water (30 mL) and brine (30 mL), and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by flash chromatography (eluting with MeOH in DCM 0–2%) to give the compound <b>60a</b> as a white solid (157 mg, yield 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 10.26 (s, 1H), 8.91 (s, 1H), 8.82 (s, 1H), 8.32 (s, 1H), 8.28 (d, <i>J</i> = 7.4 Hz, 1H), 7.98 (d, <i>J</i> = 7.3 Hz, 1H), 7.88 (s, 1H), 7.84–7.77 (m, 1H), 7.61 (d, <i>J</i> = 7.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 1H), 3.37 (s, 3H), 3.01 (s, 3H), 2.24 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.68, 164.38, 161.39, 155.60, 137.33, 136.18, 135.81, 132.30, 130.85, 130.20, 129.92, 128.60, 124.68, 119.28, 111.37, 39.16, 28.17, 17.87. LC-MS (ESI, <i>m</i>/<i>z</i>): 508.1190 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>60b</b>–<b>60j</b> and <b>66a</b>–<b>66b</b> were prepared following the synthetic procedure of <b>60a</b>.</div></div><div id="sec5_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i>-(5-(3-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60b</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.27 (s, 1H), 8.64 (s, 1H), 8.38 (s, 1H), 8.28 (s, 1H), 8.05 (s, 1H), 7.33 (s, 2H), 7.25 (d, <i>J</i> = 6.9 Hz, 1H), 7.10–6.93 (m, 3H), 3.77 (s, 3H), 3.21 (s, 3H), 2.88 (s, 3H), 2.04 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.67, 165.98, 164.82, 160.86, 159.68, 154.38, 136.15, 135.78, 134.93, 130.80, 130.26, 129.58, 119.44, 118.87, 117.90, 117.08, 112.68, 111.01, 55.48, 38.56, 27.73, 17.64. LC-MS (ESI, <i>m</i>/<i>z</i>): 470.1426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>N</i>-(5-(2-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60c</b>)</h4><div class="NLM_p last">Yield 60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 10.16 (s, 1H), 8.92 (s, 1H), 8.86 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 7.52 (s, 2H), 7.26 (d, <i>J</i> = 7.9 Hz, 1H), 7.18 (d, <i>J</i> = 6.8 Hz, 1H), 7.08 (s, 1H), 3.91 (s, 3H), 3.02 (s, 3H), 2.38 (s, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.66, 164.85, 164.37, 161.41, 156.97, 155.64, 137.62, 135.85, 132.53, 130.85, 130.15, 129.52, 128.38, 125.29, 120.99, 118.49, 112.49, 111.25, 56.47, 39.17, 28.01, 17.88. LC-MS(ESI, <i>m</i>/<i>z</i>): 470.1735 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>N</i>-(5-(4-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60d</b>)</h4><div class="NLM_p last">Yield 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 10.13 (s, 1H), 8.91 (s, 1H), 8.84 (s, 1H), 7.98 (d, <i>J</i> = 7.4 Hz, 3H), 7.88 (s, 1H), 7.59 (d, <i>J</i> = 6.7 Hz, 1H), 7.26 (d, <i>J</i> = 7.5 Hz, 1H), 7.07 (d, <i>J</i> = 7.5 Hz, 3H), 3.85 (s, 3H), 3.38 (s, 3H), 3.01 (s, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 165.26, 164.34, 162.38, 161.39, 155.57, 137.91, 135.68, 130.72, 130.03, 129.30, 127.36, 119.09, 114.08, 111.34, 55.90, 39.16, 28.17, 17.85. LC-MS (ESI, <i>m</i>/<i>z</i>): 470.1430 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> <i>N</i>-(5-(3,4-Dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60e</b>)</h4><div class="NLM_p last">Yield 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.25 (s, 1H), 10.10 (s, 1H), 8.90 (s, 1H), 8.83 (s, 1H), 7.85 (s, 1H), 7.64 (d, <i>J</i> = 7.5 Hz, 1H), 7.60 (d, <i>J</i> = 8.6 Hz, 1H), 7.56 (s, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 2H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 3.86 (s, 6H), 3.38 (s, 3H), 3.01 (d, <i>J</i> = 3.6 Hz, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.64, 165.25, 164.35, 161.38, 155.55, 152.13, 148.78, 137.83, 135.68, 133.17, 131.11, 130.72, 129.35, 128.38, 127.35, 121.53, 119.26, 111.50, 56.15, 39.15, 28.17, 17.83. LC-MS (ESI, <i>m</i>/<i>z</i>): 500.1535 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>N</i>-(5-(Benzo[<i>d</i>][1,3]dioxole-5-carboxamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60f</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 10.10 (s, 1H), 8.91 (s, 1H), 8.84 (s, 1H), 7.87 (s, 1H), 7.57 (dd, <i>J</i> = 18.1, 9.8 Hz, 3H), 7.26 (d, <i>J</i> = 7.8 Hz, 1H), 7.06 (d, <i>J</i> = 7.8 Hz, 1H), 6.14 (s, 2H), 3.38 (s, 3H), 3.01 (d, <i>J</i> = 3.1 Hz, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 164.86, 164.35, 161.39, 155.57, 150.52, 147.85, 137.79, 135.69, 130.73, 129.42, 129.11, 123.30, 119.10, 111.34, 108.39, 108.16, 102.29, 39.15, 28.16, 17.85. LC-MS (ESI, <i>m</i>/<i>z</i>): 484.1222 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>N</i>-(5-(3,5-Dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60g</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 9.66 (s, 1H), 9.24 (s, 1H), 8.70 (s, 2H), 7.79 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 3H), 6.94 (d, <i>J</i> = 7.8 Hz, 1H), 6.83 (d, <i>J</i> = 7.9 Hz, 1H), 6.72 (s, 1H), 4.73 (s, 2H), 3.84 (s, 6H), 3.39 (s, 5H), 3.00 (d, <i>J</i> = 3.1 Hz, 3H), 2.21 (s, 3H), 2.02 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 165.38, 164.37, 161.39,160.86, 155.58, 137.56, 137.33, 135.72, 131.09, 130.76, 129.67, 129.30, 119.28, 111.33, 106.08, 103.81, 55.96, 55.49, 28.44, 28.16, 17.85, 17.72. LC-MS (ESI, <i>m</i>/<i>z</i>): 500.1530 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>N</i>-(5-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60h</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (d, <i>J</i> = 12.6 Hz, 2H), 9.85 (s, 1H), 9.17 (s, 1H), 8.41 (s, 1H), 7.80 (s, 1H), 7.28–7.18 (m, 2H), 6.99 (d, <i>J</i> = 7.3 Hz, 2H), 4.32 (s, 4H), 2.93 (s, 3H), 2.50 (s, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.89, 164.62, 155.57, 153.77, 146.84, 146.58, 143.42, 137.84, 135.92, 130.62, 129.41, 128.17, 121.66, 119.14, 118.84, 117.31, 117.14, 64.89, 64.51, 46.12, 28.21, 17.84. LC-MS (ESI, <i>m</i>/<i>z</i>): 498.1375 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> <i>N</i>-(2-Methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>60i</b>)</h4><div class="NLM_p last">Yield 82%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.28 (s, 1H), 10.18 (s, 1H), 8.92 (s, 1H), 8.84 (s, 1H), 7.85 (s, 1H), 7.62 (d, <i>J</i> = 6.1 Hz, 1H), 7.32 (s, 3H), 3.89 (s, 6H), 3.75 (s, 3H), 3.39 (s, 3H), 3.02 (s, 3H), 2.25 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.65, 165.23, 164.40, 161.39, 155.57, 153.11, 140.81, 137.59, 135.73, 130.77, 130.36, 129.63, 119.42, 111.34, 105.75, 60.85, 56.13, 28.52, 18.00, 15.43. LC-MS (ESI, <i>m</i>/<i>z</i>): 530.1645 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 2-(4-Methyl-3-nitrophenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>61a</b>)</h4><div class="NLM_p">To a solution of <b>60a</b> (100 mg, 0.20 mmol, 1.0 equiv) in ahydrous dioxane (2 mL) were added 4-methyl-3-nitroaniline (304 mg, 2.00 mmol, 10.0 equiv) and TFA (0.06 mL, 2.0 mmol, 10.0 equiv) at room temperature under argon. The reaction mixture was then heated to 120 °C for 2 h. The resulting mixture was diluted with DCM (10 mL), washed with water (10 mL) and brine (10 mL), and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by flash chromatography (eluting with MeOH in DCM 0–2%) to give the title compound <b>61a</b> as a white solid (76 mg, yield 66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 10.48 (s, 1H), 9.93 (s, 1H), 9.13 (s, 1H), 8.86 (s, 1H), 8.77 (s, 1H), 8.35–8.26 (m, 2H), 7.97 (d, <i>J</i> = 7.1 Hz, 1H), 7.86 (s, 1H), 7.80 (d, <i>J</i> = 7.5 Hz, 2H), 7.58 (d, <i>J</i> = 7.3 Hz, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (d, <i>J</i> = 8.1 Hz, 1H), 3.07 (s, 3H), 2.50 (s, 3H), 2.23 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.03, 164.33, 161.96, 149.06, 138.72, 137.29, 136.23, 133.39, 132.27, 130.72, 130.16, 129.98, 128.42, 127.01, 124.90, 124.67, 123.04, 119.39, 118.94, 115.55, 102.03, 99.99, 28.29, 19.65, 17.90. LC-MS (ESI, <i>m</i>/<i>z</i>): 580.1850 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>61b</b>–<b>61j</b> and <b>67a</b>–<b>67b</b> were prepared following the synthetic procedure of <b>61a</b>.</div></div><div id="sec5_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>N</i>-(5-(3-Methoxybenzamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)pyrimidine-5-carboxamide (<b>61b</b>)</h4><div class="NLM_p last">Yield 86%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.65 (s, 1H), 10.24 (s, 1H), 9.95 (s, 1H), 9.18 (s, 1H), 8.86 (s, 1H), 8.77 (s, 1H), 7.85 (s, 1H), 7.79 (d, <i>J</i> = 8.0 Hz, 1H), 7.56 (s, 2H), 7.50 (s, 1H), 7.47 (s, 1H), 7.45 (s, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 7.7 Hz, 1H), 3.85 (s, 3H), 3.06 (s, 4H), 2.50 (s, 3H), 2.22 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.58, 164.89, 161.88, 159.66, 149.02, 137.60, 136.78, 136.12, 133.42, 130.65, 130.00, 129.66, 127.17, 124.95, 120.32, 119.29, 118.88, 117.71, 115.60, 113.37, 102.04, 55.79, 28.34, 19.70, 17.89. LC-MS (ESI, <i>m</i>/<i>z</i>): 542.2083 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>N</i>-(5-(2-Methoxybenzamido)-2-methylphenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>61c</b>)</h4><div class="NLM_p last">Yield 76%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 10.12 (s, 1H), 9.95 (s, 1H), 9.17 (s, 1H), 8.86 (s, 1H), 8.76 (s, 1H), 7.82 (s, 2H), 7.64 (d, <i>J</i> = 6.8 Hz, 1H), 7.55–7.43 (m, 3H), 7.21 (dd, <i>J</i> = 18.5, 8.2 Hz, 2H), 7.08 (d, <i>J</i> = 6.7 Hz, 1H), 3.91 (s, 3H), 3.06 (s, 3H), 2.50 (s, 3H), 2.20 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.95, 164.81, 161.91, 156.95, 149.03, 138.65, 137.57, 136.26, 133.41, 132.46, 130.72, 130.12, 129.55, 127.06, 125.39, 124.91, 120.97, 118.57, 118.19, 115.54, 112.48, 101.98, 56.36, 28.31, 19.69, 17.91. LC-MS (ESI, <i>m</i>/<i>z</i>): 542.2080 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> <i>N</i>-(5-(4-Methoxybenzamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)pyrimidine-5-carboxamide (<b>61d</b>)</h4><div class="NLM_p last">Yield 78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 10.10 (s, 1H), 9.89 (s, 1H), 9.03 (s, 1H), 8.87 (s, 1H), 8.74 (s, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.81 (d, <i>J</i> = 9.6 Hz, 2H), 7.54 (d, <i>J</i> = 8.2 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 7.07 (d, <i>J</i> = 8.6 Hz, 2H), 3.85 (s, 3H), 3.04 (d, <i>J</i> = 3.7 Hz, 3H), 2.20 (s, 3H), 2.00 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.84,165.26, 162.36, 162.04, 158.65, 153.87, 149.07, 138.96, 137.80, 136.19, 133.36, 130.59, 130.01, 129.41, 127.38, 126.69, 124.83, 119.25, 118.77, 115.37, 114.07, 60.41, 55.69, 21.44, 14.80. LC-MS (ESI, <i>m</i>/<i>z</i>): 542.2090 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> <i>N</i>-(5-(3,4-Dimethoxybenzamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)pyrimidine-5-carboxamide (<b>61e</b>)</h4><div class="NLM_p last">Yield 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 10.09 (s, 1H), 9.92 (s, 1H), 9.14 (s, 1H), 8.86 (s, 1H), 8.76 (s, 1H), 7.80 (d, <i>J</i> = 13.2 Hz, 2H), 7.63 (d, <i>J</i> = 8.1 Hz, 1H), 7.56 (d, <i>J</i> = 8.0 Hz, 2H), 7.46 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 3.85 (s, 6H), 3.06 (s, 3H), 2.50 (s, 3H), 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.24, 164.98, 161.93, 152.10, 149.03, 148.77, 137.77, 136.10, 133.41, 130.60, 129.40, 127.40, 127.05, 124.91, 121.51, 119.37, 118.91, 115.53, 111.48, 111.40, 102.01, 56.10, 28.30, 19.69, 17.91. LC-MS(ESI, <i>m</i>/<i>z</i>): 572.2185 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> <i>N</i>-(5-(Benzo[<i>d</i>][1,3]dioxole-5-carboxamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)pyrimidine-5-carboxamide (<b>61f</b>)</h4><div class="NLM_p last">Yield 79%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 10.07 (s, 1H), 9.95 (s, 1H), 9.27 (s, 1H), 8.84 (s, 1H), 8.78 (s, 1H), 7.85 (s, 1H), 7.75 (d, <i>J</i> = 7.2 Hz, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.54 (d, <i>J</i> = 9.5 Hz, 2H), 7.44 (d, <i>J</i> = 7.9 Hz, 1H), 7.23 (d, <i>J</i> = 7.9 Hz, 1H), 7.04 (d, <i>J</i> = 7.8 Hz, 1H), 6.13 (s, 2H), 3.06 (s, 3H), 2.49 (s, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.83, 161.76, 159.62, 150.49, 148.89, 147.89, 147.83, 137.74, 135.98, 133.43, 130.62, 129.44, 129.14, 124.94, 123.27, 119.18, 115.66, 108.34, 108.15, 102.26, 102.11, 28.23, 19.93, 17.85. LC-MS (ESI, <i>m</i>/<i>z</i>): 556.1870 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> <i>N</i>-(5-(3,5-Dimethoxybenzamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)pyrimidine-5-carboxamide (<b>61g</b>)</h4><div class="NLM_p last">Yield 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.46 (s, 1H), 10.19 (s, 1H), 9.92 (s, 1H), 9.09 (s, 1H), 8.85 (s, 1H), 8.74 (s, 1H), 7.79 (d, <i>J</i> = 9.7 Hz, 2H), 7.55 (d, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.1 Hz, 1H), 7.25 (d, <i>J</i> = 8.2 Hz, 1H), 7.10 (s, 2H), 6.71 (s, 1H), 3.82 (s, 9H), 2.51 (s, 3H), 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.40, 165.07, 161.95, 160.85, 149.04, 138.71, 137.46, 137.36, 136.16, 133.40, 130.66, 129.77, 127.00, 124.92, 119.42, 118.95, 115.51, 106.05, 103.78, 101.99, 55.96, 28.26, 19.66, 17.87. LC-MS (ESI, <i>m</i>/<i>z</i>): 572.2183 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> <i>N</i>-(5-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(4-methyl-3-nitrophenylamino)-4-(methylamino)-pyrimidine-5-carboxamide (<b>61h</b>)</h4><div class="NLM_p last">Yield 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 10.06 (s, 1H), 9.92 (s, 1H), 9.16 (s, 1H), 8.86 (s, 1H), 8.77 (s, 1H), 7.83 (d, <i>J</i> = 12.8 Hz, 2H), 7.51 (d, <i>J</i> = 25.3 Hz, 3H), 7.24 (s, 1H), 7.00 (s, 1H), 4.32 (s, 4H), 3.06 (s, 3H), 2.51 (s, 3H), 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.86, 161.93, 152.17, 149.05, 146.85, 143.42, 138.57, 137.78, 136.07, 133.42, 130.60, 129.42, 128.16, 127.11, 124.97, 121.66, 119.19, 118.75, 117.31, 117.14, 115.62, 102.06, 64.89, 64.52, 28.33, 19.70, 17.88. LCMS (ESI, <i>m</i>/<i>z</i>): 570.2030 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 2-(4-Methyl-3-nitrophenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>61i</b>)</h4><div class="NLM_p last">Yield 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 10.15 (s, 1H), 9.95 (s, 1H), 9.22 (s, 1H), 8.86 (s, 1H), 8.78 (s, 1H), 7.80 (s, 1H), 7.77 (s, 1H), 7.57 (d, <i>J</i> = 7.5 Hz, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.30 (s, 2H), 7.26 (d, <i>J</i> = 8.1 Hz, 1H), 3.88 (s, 6H), 3.74 (s, 3H), 3.07 (s, 3H), 2.50 (s, 3H), 2.23 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.18, 164.82, 161.85, 153.09, 148.98, 140.78, 138.37, 137.55, 136.09, 133.42, 130.65, 130.42, 129.62, 127.25, 124.94, 119.49, 119.06, 115.61, 105.73, 102.03, 60.63, 56.13, 28.09, 20.07, 17.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 602.2293 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62a</b>)</h4><div class="NLM_p">To a solution of <b>61a</b> (50 mg, 0.085 mmol, 1.00 equiv) in methanol (5 mL) was added SnCl<sub>2</sub>·2H<sub>2</sub>O (191 mg, 0.85 mg, 10.0 equiv) at room temperature under argon. The reaction mixture was then heated to reflux for 14 h. The resulting mixture was then concentrated to dryness. The residue was diluted with water (50 mL) and added to 1 N NaOH to pH about 10. The mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL) and dried over anhydrous MgSO<sub>4</sub>. Evaporation of the solvent afforded the crude product, which was purified by flash column chromatography (eluting with MeOH in DCM 0–5%) to yield <b>62a</b> as a white solid (37 mg, 79%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 9.68 (s, 1H), 9.27 (s, 1H), 8.69 (s, 2H), 8.30 (d, <i>J</i> = 10.0 Hz, 2H), 7.97 (s, 1H), 7.81 (s, 2H), 7.59 (d, <i>J</i> = 6.2 Hz, 1H), 7.26 (d, <i>J</i> = 7.2 Hz, 1H), 7.14 (s, 1H), 6.93 (s, 1H), 6.83 (s, 1H), 4.74 (s, 2H), 3.18 (s, 1H), 3.00 (s, 3H), 2.22 (s, 3H), 2.02 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.27, 164.29, 162.49, 160.61, 157.36, 146.74, 139.21, 137.20, 136.81, 136.23, 132.30, 130.62, 130.19, 130.07, 128.54, 124.68, 119.46, 118.55, 115.52, 108.72, 106.10, 40.61, 40.41, 40.20, 39.99, 39.78, 39.58, 39.36, 27.85, 17.96, 17.38. LC-MS (ESI, <i>m</i>/<i>z</i>): 550.2110 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>62b</b>–<b>62j</b> and <b>68a</b>–<b>68b</b> were prepared following the synthetic procedure of <b>62a</b>.</div></div><div id="sec5_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(3-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62b</b>)</h4><div class="NLM_p last">Yield 63%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H), 9.67 (s, 1H), 9.25 (s, 1H), 8.71 (s, 2H), 7.82 (s, 1H), 7.58 (s, 2H), 7.55–7.41 (m, 2H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 7.16 (s, 2H), 6.95 (d, <i>J</i> = 6.2 Hz, 1H), 6.84 (s, 1H), 3.85 (s, 3H), 3.01 (s, 3H), 2.22 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.27, 165.55, 162.51, 160.62, 159.66, 157.34, 146.73, 139.22, 137.52, 136.83, 136.73, 130.52, 130.07, 130.01, 129.71, 120.33, 119.43, 118.52, 117.72, 115.54, 113.35, 108.76, 106.13, 99.99, 55.80, 27.84, 17.95, 17.38. LC-MS (ESI, <i>m</i>/<i>z</i>): 512.2340 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(2-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62c</b>)</h4><div class="NLM_p last">Yield 63%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H), 9.67 (s, 1H), 9.25 (s, 1H), 8.71 (s, 2H), 7.82 (s, 1H), 7.58 (s, 2H), 7.55–7.41 (m, 2H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 7.16 (s, 2H), 6.95 (d, <i>J</i> = 6.2 Hz, 1H), 6.84 (s, 1H), 3.85 (s, 3H), 3.01 (s, 3H), 2.22 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.27,165.55, 162.51, 160.62, 159.66, 157.34, 146.73, 139.22, 137.52, 136.83, 136.73, 130.52, 130.07, 130.01, 129.71, 120.33, 119.43, 118.52, 117.72, 115.54, 113.35, 108.76, 106.13, 99.99, 55.80, 27.84, 17.95, 17.38. LC-MS (ESI, <i>m</i>/<i>z</i>): 512.2340 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(4-methoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62d</b>)</h4><div class="NLM_p last">Yield 83%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 9.81 (s, 1H), 9.38 (s, 1H), 8.85 (s, 2H), 8.12 (d, <i>J</i> = 8.4 Hz, 2H), 7.96 (s, 1H), 7.71 (d, <i>J</i> = 6.6 Hz, 1H), 7.35 (d, <i>J</i> = 8.2 Hz, 1H), 7.30 (s, 1H), 7.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 6.6 Hz, 1H), 6.97 (d, <i>J</i> = 7.9 Hz, 1H), 3.97 (s, 3H), 3.57 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.30, 165.26, 162.52, 162.35, 160.63, 157.33, 146.71, 139.23, 137.78, 136.69, 130.49, 130.10, 130.03, 129.44, 127.46, 119.38, 118.48, 115.59, 114.06, 108.82, 106.17, 100.20, 55.87, 27.84, 17.93, 17.36. LC-MS (ESI, <i>m</i>/<i>z</i>): 512.2340 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(3,4-dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62e</b>)</h4><div class="NLM_p last">Yield 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 9.65 (s, 1H), 9.23 (s, 1H), 8.70 (s, 2H), 7.78 (s, 1H), 7.64 (d, <i>J</i> = 8.3 Hz, 1H), 7.57 (d, <i>J</i> = 9.2 Hz, 2H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.94 (d, <i>J</i> = 7.8 Hz, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 1H), 3.86 (s, 3H), 3.40 (s, 3H), 3.00 (d, <i>J</i> = 4.3 Hz, 3H), 2.21 (s, 3H), 2.02 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.28, 165.22, 162.50, 160.61, 157.32, 152.09, 148.78, 146.72, 139.21, 137.69, 136.68, 130.48, 130.08, 129.45, 127.45, 121.51, 119.50, 118.57, 115.56, 111.49, 111.42, 108.77, 106.14, 100.17, 56.25, 27.83, 17.71, 17.07. LC-MS (ESI, <i>m</i>/<i>z</i>): 542.2445 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(benzo[<i>d</i>][1,3]dioxole-5-carboxamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62f</b>)</h4><div class="NLM_p last">Yield 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 9.66 (s, 1H), 9.24 (s, 1H), 8.71 (s, 2H), 7.81 (s, 1H), 7.61 (d, <i>J</i> = 8.1 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.16 (s, 1H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 6.95 (d, <i>J</i> = 7.6 Hz, 1H), 6.83 (d, <i>J</i> = 7.8 Hz, 1H), 6.14 (s, 2H), 4.73 (s, 2H), 3.01 (s, 3H), 2.21 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.28, 164.81, 162.51, 160.62, 157.34, 150.48, 147.85, 146.73, 139.23, 137.65, 136.70, 130.49, 130.09, 129.51, 129.21, 123.28, 119.36, 118.45, 115.56, 108.78, 108.39, 108.16, 106.14, 102.27, 27.84, 17.93, 17.36. LC-MS (ESI, <i>m</i>/<i>z</i>): 526.2130 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(3,5-dimethoxybenzamido)-2-methylphenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62g</b>)</h4><div class="NLM_p last">Yield 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 9.66 (s, 1H), 9.24 (s, 1H), 8.70 (s, 2H), 7.79 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 3H), 6.94 (d, <i>J</i> = 7.8 Hz, 1H), 6.83 (d, <i>J</i> = 7.9 Hz, 1H), 6.72 (s, 1H), 4.73 (s, 2H), 3.84 (s, 6H), 3.39 (s, 5H), 3.00 (d, <i>J</i> = 3.1 Hz, 3H), 2.21 (s, 3H), 2.02 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.28, 165.33, 162.50, 160.86, 160.62, 157.33, 146.73, 139.21, 137.43, 136.72, 130.53, 130.08, 129.75, 119.51, 118.58, 115.56, 108.76, 106.13, 106.06, 103.81, 100.15, 55.97, 27.83, 17.93, 17.36. LC-MS (ESI, <i>m</i>/<i>z</i>): 542.2440 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(5-(2,3-dihydrobenzo[<i>b</i>]-[1,4]dioxine-6-carboxamido)-2-methylphenyl)-4-(methylamino)-pyrimidine-5-carboxamide (<b>62h</b>)</h4><div class="NLM_p last">Yield 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.84 (s, 1H), 7.55 (dd, <i>J</i> = 12.6, 3.9 Hz, 3H), 7.27–7.15 (m, 2H), 7.08–6.94 (m, 2H), 6.84 (d, <i>J</i> = 8.1 Hz, 1H), 4.31 (s, 4H), 3.01 (s, 3H), 2.21 (s, 3H), 2.06 (d, <i>J</i> = 17.7 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.17, 164.78, 162.42, 160.55, 157.34, 146.83, 146.64, 143.41, 139.13, 137.61, 136.57, 130.48, 130.10, 129.42, 128.17, 121.67, 119.19, 118.33, 117.31, 117.15, 115.56, 108.74, 106.01, 100.14, 64.87, 64.49, 27.69, 17.91, 17.32. LC-MS (ESI, <i>m</i>/<i>z</i>): 540.2290 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>62i</b>)</h4><div class="NLM_p">Yield 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 9.66 (s, 1H), 9.24 (s, 1H), 8.71 (s, 2H), 7.77 (s, 1H), 7.59 (d, <i>J</i> = 7.4 Hz, 1H), 7.32 (s, 2H), 7.25 (d, <i>J</i> = 7.8 Hz, 1H), 7.16 (s, 1H), 6.95 (d, <i>J</i> = 7.1 Hz, 1H), 6.83 (d, <i>J</i> = 7.5 Hz, 1H), 4.74 (s, 2H), 3.89 (s, 6H), 3.75 (s, 3H), 3.01 (s, 3H), 2.22 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.29, 165.15, 162.49, 160.60, 157.32, 153.09, 146.70, 140.77, 139.19, 137.45, 136.72, 130.53, 130.44, 130.07, 129.68, 119.64, 118.64, 115.57, 108.77, 106.14, 105.74, 60.59, 56.56, 27.83, 17.91, 17.35. LC-MS (ESI, <i>m</i>/<i>z</i>): 572.2550 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>63</b>–<b>64</b> and <b>65a</b>–<b>65b</b> were prepared following the synthetic procedure of <b>56</b>.</div></div><div id="sec5_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Methyl 4-Methyl-3-(4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamido)benzoate (<b>63</b>)</h4><div class="NLM_p last">Yield 57%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 8.48 (s, 1H), 8.38 (s, 1H), 8.14 (s, 1H), 7.78 (d, <i>J</i> = 6.5 Hz, 1H), 7.28 (s, 1H), 3.86 (s, 3H), 3.05 (d, <i>J</i> = 4.3 Hz, 3H), 2.53 (s,3H), 2.30 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.15, 166.65, 165.76, 160.54, 152.84, 137.96,135.17, 130.80, 128.60, 127.34, 126.35, 104.00, 52.12, 27.39, 18.17, 14.07. LC-MS (ESI, <i>m</i>/<i>z</i>): 347.1158 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> 4-Methyl-3-(4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamido)benzoic Acid (<b>64</b>)</h4><div class="NLM_p last">Yield 95%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.21 (s, 1H), 8.77 (s, 1H), 8.59 (s, 1H), 7.92 (s, 1H),7.73 (s, 1H), 7.39 (s, 1H), 2.94 (s, 3H), 2.51 (s, 3H), 2.30 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.64, 167.45, 165.90, 160.48, 155.55, 139.56, 136.53, 131.01, 129.45, 128.02, 127.25, 104.86, 27.62, 18.63, 13.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 333.1046 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> <i>N</i>-(2-Methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>65a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 10.06 (s, 1H), 8.72 (s, 1H), 8.63 (s, 1H), 8.27 (s, 1H),8.10 (s, 1H), 8.01 (s, 1H), 7.86 (s, 1H), 7.60 (s, 1H), 7.46 (s, 2H), 2.97 (s, 3H), 2.53 (s, 3H), 2.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.71, 165.89, 165.66, 160.47, 155.20, 140.44, 138.82, 136.49, 132.73, 130.92, 130.29, 126.62, 125.87, 124.25,120.36, 116.85, 104.79, 27.62, 18.53, 13.97. LC-MS (ESI, <i>m</i>/<i>z</i>): 476.1877 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> <i>N</i>-(2-Methyl-5-(3,4,5-trimethoxyphenylcarbamoyl)phenyl)-4-(methylamino)-2-(methylthio)pyrimidine-5-carboxamide (<b>65b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 10.05 (s, 1H), 8.71 (s, 1H), 8.64 (s, 1H),7.99 (s, 1H), 7.82 (s, 1H), 7.45 (s, 1H), 7.26 (s, 2H), 3.79 (s, 6H), 3.66 (s, 3H), 2.97 (s,3H), 2.53 (s, 3H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.65, 165.86, 165.04, 160.46, 155.11, 153.08, 138.39, 136.37, 135.75, 134.26, 133.23, 130.84, 126.47, 125.73, 104.84, 98.63, 60.58, 56.23, 27.64, 18.40, 13.99. LC-MS (ESI, <i>m</i>/<i>z</i>): 498.1731[M + H]<sup>+</sup>.</div></div><div id="sec5_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> <i>N</i>-(2-Methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>66a</b>)</h4><div class="NLM_p last">Yield, 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 10.36 (s, 1H), 8.92 (s, 1H), 8.75 (s, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.61 (s, 1H), 7.48 (s, 2H), 3.00 (s, 3H), 2.88 (s, 3H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.14, 165.64, 165.08, 161.28, 155.65, 140.42, 138.84, 136.22, 132.78, 130.98, 130.33, 126.67, 126.08, 124.31, 120.41, 116.88, 109.51, 28.04, 18.47. LC-MS (ESI, <i>m</i>/<i>z</i>): 492.1317 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> <i>N</i>-(2-Methyl-5-(3,4,5-trimethoxyphenylcarbamoyl)phenyl)-4-(methylamino)-2-(methylsulfonyl)pyrimidine-5-carboxamide (<b>66b</b>)</h4><div class="NLM_p last">Yield, 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 10.14 (s, 1H), 8.93 (s, 1H), 8.76 (s, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.46 (s, 1H), 7.27 (s, 2H), 3.79 (s, 6H), 3.66 (s, 3H), 3.00 (s, 3H), 2.88 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.13, 165.09, 161.29, 155.62, 153.08, 138.41, 136.11, 135.74, 134.27, 133.29, 130.89, 126.54, 125.93, 109.52, 98.66, 60.60, 56.25, 28.03, 18.42. LC-MS (ESI, <i>m</i>/<i>z</i>): 514.1760 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> 2-(4-Methyl-3-nitrophenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>67a</b>)</h4><div class="NLM_p last">Yield, 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 10.03 (s, 1H), 9.89 (s, 1H), 8.97 (s, 1H), 8.80 (s, 2H), 8.26 (s, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.84 (s, 2H), 7.61 (s, 1H), 7.46 (s, 3H), 3.04 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.11, 165.71,162.35, 160.31, 157.46, 149.09, 140.46, 139.96, 138.88, 136.84, 133.19, 132.65,130.88, 130.32, 129.98, 126.65, 125.71, 124.27, 120.36, 116.89, 114.54, 101.35,27.96, 19.64, 18.54. LC-MS (ESI, <i>m</i>/<i>z</i>): 580.1815 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> 2-(4-Methyl-3-nitrophenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxyphenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>67b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 10.11 (s, 1H), 10.01 (s, 1H), 9.07 (s,1H), 8.87 (s, 1H), 8.79 (s, 1H), 7.97 (s, 1H), 7.81 (s, 2H), 7.45 (s, 2H), 7.26 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), 3.06 (s, 3H), 2.50 (s, 3H), 2.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.22, 165.05, 161.92, 153.07, 149.05, 138.78, 138.35, 136.42,135.76, 134.24, 133.37, 133.23, 130.81, 126.92, 126.49, 125.61, 124.85, 115.45,101.89, 98.62, 60.57, 56.22, 28.29, 19.66, 18.43. LC-MS (ESI, <i>m</i>/<i>z</i>): 602.2322 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_121" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>68a</b>)</h4><div class="NLM_p last">Yield, 77%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 9.85 (s, 1H), 9.29 (s, 1H), 8.74 (s,1H), 8.66 (s, 1H), 8.27 (s, 1H), 8.11 (s, 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.61 (s, 1H),7.45 (s, 2H), 7.15 (s, 1H), 6.95 (s, 1H), 6.83 (s, 1H), 2.99 (s, 3H), 2.32 (s, 3H), 2.02 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 550.2156 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_122" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 2-(3-Amino-4-methylphenylamino)-<i>N</i>-(2-methyl-5-(3,4,5-trimethoxyphenylcarbamoyl)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (<b>68b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.12 (s, 1H), 9.84 (s, 1H), 9.36 (s, 1H), 8.74 (s, 2H), 7.96 (s, 1H), 7.81 (s, 1H), 7.43(s, 1H), 7.27 (s, 2H), 7.18 (s, 1H), 6.99 (s, 1H), 6.87 (s, 1H), 3.78 (s, 6H), 3.65 (s, 3H), 3.00 (s, 3H), 2.32 (s, 3H), 2.04 (s, 3H). LC-MS (ESI, <i>m</i>/<i>z</i>): 572.2547 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> Cell Culture and Proliferation Study</h3><div class="NLM_p last">BaF3, BaF3-TEL-BMX, P210-BaF3, BaF3-TEL-cKIT, BaF3-TEL-FLT3, BaF3-FLT3-ITD, BaF3-TEL-EGFR, BaF3-TEL-JAK2, BaF3-TEL-JAK3, BaF3-TEL-BLK, BaF3-TEL-PDGFRα, BaF3-TEL-PDGFEβ, RV-1 (prostate cancer cell), DU-145 (prostate cancer cell), PC-3 (prostate cancer cell), EJ (bladder cancer cell), Hb-c (bladder cancer cell), J82 (bladder cancer cell), T24 (bladder cancer cell), 5637 (bladder cancer cell), 769-P (renal cancer cell), 769-O (renal cancer cell), A-498 (renal cancer cell), ACHN (renal cancer cell), CHL (hamster lung cell), and CHO (hamster ovary cell) were used. All the cells were grown in a humidified incubator at 37 °C under 5% CO<sub>2</sub>. A-498, ACHN, and CHO cells were maintained in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin. BaF3, BaF3-TEL-BMX, P210-BaF3, BaF3-TEL-cKIT, BaF3-TEL-FLT3, BaF3-FLT3-ITD, BaF3-TEL-EGFR, BaF3-TEL-JAK2, BaF3-TEL-JAK3, BaF3-TEL-BLK, BaF3-TEL-PDGFRα, BaF3-TEL-PDGFEβ, 769-P, 769-O, and CHL cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium supported with 10% FBS and 1% penicillin/streptomycin. Cells were grown in 6 cm Petri dishes until they were 85–95% confluent prior to use. These nonadherent cells were collected by spin down at 700 rpm/min for 4 min. A density of 1.5 to 3 × 10<sup>4</sup> cells/mL cells were mixed with various concentrations of compounds, then 100 μL was added to each well and incubated for 72 h. Cell viability was determined using the CellTiter-Glo (Promega, USA) or CCK-8 (Beboy, China). Both assays were performed according to the manufacturer instructions. For CellTiter-Glo assay, luminescence was determined in a multilabel reader (Envision, PerkinElmer, USA). For CCK-8 assay, absorbance was measured in a microplate reader (iMARK, Bio-Rad, USA) at 450 and 650 nm. Data were normalized to control group (DMSO). GI<sub>50</sub>s were calculated using Prism 6.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> TEL-Isogenic Cell Generation</h3><div class="NLM_p last">Retroviral constructs for BaF3-cKIT mutants (BaF3-TEL-BMX, P210-BaF3, BaF3-TEL-FLT3, BaF3-FLT3-ITD, BaF3-TEL-EGFR, BaF3-TEL-JAK2, BaF3-TEL-JAK3, BaF3-TEL-BLK, BaF3-TEL-PDGFRα, BaF3-TEL-PDGFEβ) were made based on the pMSCVpuro (Clontech) backbone. For TEL-cKIT vector, the first 1 kb of human TEL gene with an artificial myristoylation sequence (MGCGCSSHPEDD) was cloned into the pMSCVpuro retroviral vector, followed by a 3xFLAG tag sequence and a stop codon. Then the kinase domain coding sequence of cKIT was inserted in-frame between TEL and 3xFLAG sequences. For full-length expression vectors, the coding sequences of cKIT variants were directly cloned in pMSCVpuro vector with a 3xFLAG tag at the C-terminal end. All mutagenesis were performed using the QuikChange site-directed mutagenesis kit (Stratagene) following the manufacturer’s instructions. Retrovirus was packaged in HEK293T cells by transfecting cKIT-containing MSCV vectors together with two helper plasmids. Virus supernatants were harvested 48 h after transfection and filtered before infection. Then BaF3 cells were infected with harvested virus supernatants using spinoculation protocol, and stable cell lines were obtained by puromycin selection for 48 h. The IL-3 concentrations in the culture medium were gradually withdrawn until cells were able to grow in the absence of IL-3.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> Biochemical Assay</h3><div class="NLM_p last">The ADP-Glo kinase assay (Promega, Madison, WI) was used to screen compounds <b>41</b> and <b>42</b> for its BMX and BTK inhibition effects. The kinase reaction system contains 9 μL of BMX (4 ng/μL) or BTK (5 ng/μL), 1 μL of serially diluted compounds <b>41</b> and <b>42</b>, and 10 μL of substrate Poly(4:1 Glu, Tyr) peptide (0.4 μg/μL) (Promega, Madison, WI) with 100 μM ATP (Promega, Madison, WI). The reaction in each tube was started immediately by adding ATP and kept going for an hour under 37 °C. After the tube cooled for 5 min at room temperature, 5 μL solvent reactions were carried out in a 384-well plate. Then 5 μL of ADP-Glo reagent was added into each well to stop the reaction and consume the remaining ATP within 40 min. At the end, 10 μL of kinase detection reagent was added into the well and incubated for 30 min to produce a luminescence signal. Luminescence signal was measured with an automated plate reader (Envision, PE, USA), and the dose–response curve was fitted using Prism 5.0 (GraphPad Software Inc., San Diego, CA). The biochemical tests of CSF1R, p38α, DDR1, and DDR2 were provided by Invitrogen (Carlsbad, CA, USA).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> Microscale Thermophoresis Experiment</h3><div class="NLM_p last">The <i>K</i><sub>d</sub> values were measured using the Monolith NT.115 instrument (NanoTemper Technologies). The proteins were fluorescently labeled according to the manufacturer’s protocol. A range of concentrations of compounds <b>41</b> and <b>42</b> (from 0.05 mM to 2.5 nM) were incubated with 200 nM of purified labeled BMX protein for 10 min with or without 1 mM ATP respectively in assay buffer (50 mM HEPES, 10 mM MgCl<sub>2</sub>, 100 mM NaCl, pH 7.5, and 0.05% Tween 20). The sample was loaded into the NanoTemper glass capillaries, and microthermophoresis was carried out using 20% LED power and 20% MST. The <i>K</i><sub>d</sub> values were calculated using the mass action equation via the NanoTemper software from duplicate reads of triplicate experiments.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> In Vitro Kinase Assay for Irreversibility Confirmation</h3><div class="NLM_p last">Full length BMX with His tag was cloned into baculovirus expression vector pFASTHT-A. The recombinant bacmid was transfected into SF9 by cellfectin (Invitrogen). High titer viral stocks were obtained by two rounds of amplification of the virus. The protein was expressed by infecting SF9 cells with high titer viral stocks for 48 h. Cells were harvested and resuspended in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, and 1 mM PMSF). The cells were lysed by ultrasonication, and the cell debris was removed by ultracentrifugation. The supernatant was incubated with Ni-affinity beads (GE). The beads were then washed by lysis buffer containing 50–250 mM imidazole. The elute was loaded to Sephedex 75. The protein was concentrated to 1 mg/mL, and aliquots were frozen and stored at −80 °C. Serially diluted compounds <b>41</b> and <b>42</b> were transferred to BMX. After 30 min incubation, 40 μM ATP was added and incubated for 20 min at 37 °C. The reactions were stopped by addition of 5× sample buffer. Then the phosphorylation of BMX was detected by Western blot using antiphosphotyrosine antibody (BD Bioscience)</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Signaling Pathway Study</h3><div class="NLM_p last">DU145-BMX-WT stable cell lines were treated with serially diluted compound <b>41</b> and 10 μM BMX-IN-1 for 4 h before they were washed in PBS, harvested, and lysed in RIPA buffer supplemented with protease and phosphatase inhibitors. Cells were lysed at 4 °C for 30 min, and the insoluble fraction was removed by centrifugation at 13000 rpm for 30 min. Supernatants were incubated with FLAG-M2 monoclonal antibody agarose for 1 h and then washed twice with lysis buffer before sample buffer was added and boiled. Mouse antiphosphotyrosine (BD Bioscience) and mouse anti-FLAG (Sigma) antibodies were used in the Western blot. Quantification was done in imageJ.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> In Vivo Pharmacokinetic Study</h3><div class="NLM_p last">Compound <b>41</b> was dissolved in 55% saline containing 5% DMSO and 40% PEG400 by vortex. The final concentration of the stock solution was 1 mg/mL for administration. Six 8-week-old male Sprague–Dawley rats were fasted overnight before starting drug treatment via intravenous and oral administration. Animal blood collection time points were as follows. For groups 1, 3, and 5 (intravenous): 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h before and after administration was selected. For group 2, 4, and 6 (oral): 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h before and after dosing. Each time, about 0.2 mL of blood was collected through the jugular vein by adding heparin for anticoagulation and kept on ice. Then plasma was separated by centrifugation at 8000 rpm for 6 min at 2–8 °C. The obtained plasma was stored at −80 °C before analysis. After finishing the test, all surviving animals were transferred to the repository or euthanasia (CO<sub>2</sub> asphyxiation).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> Mass Spectrometry Experiments</h3><div class="NLM_p">Recombinant BMX protein (at a final concentration of 10 μM) was incubated with <b>41</b> (at a final concentration of 100 μM) in a buffer containing 50 mM HEPES (pH 7.4), 75 mM NaCl, and 5% glycerol at room temperature with gentle shaking for 1 h. After the reaction, the remaining inhibitors were removed by exchange into a 50 mM NH<sub>4</sub>HCO<sub>3</sub> (pH 8.5) buffer with the use of Microcon centrifugal filters (30000 NMWL, Millipore). To the protein samples were subsequently added 8 M urea for protein denaturation and dithiothreitol and iodoacetamide for cysteine reduction and alkylation, respectively. The proteins were digested with modified MS-grade trypsin (Thermo Pierce) at an enzyme/substrate ratio of 1:100 in 50 mM NH<sub>4</sub>HCO<sub>3</sub> (pH 8.5) at 37 °C for overnight. The peptide mixture was subsequently dried in a Speed-vac, desalted by employing OMIX C18 pipet tips (Agilent Technologies, Santa Clara, CA), and then subjected to LC-MS/MS analyses.</div><div class="NLM_p">The LC-MS/MS experiments were first conducted on a QE Plus Quadrupole-Orbitrap mass spectrometer. The samples were automatically loaded from a 48-well microplate autosampler using an EASY-nLC 1200 system (Thermo Fisher Scientific) at 3 μL/min onto a biphasic precolumn (150 μm i.d.) comprised of a 3.5 cm column packed with 5 μm C18 120 Å reversed-phase material (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The biphasic trapping column was connected to a 20 cm fused-silica analytical column (PicoTip Emitter, New Objective, 75 μm i.d.) with 3 μm C18 beads (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The peptides were then separated using a 180 min linear gradient of 2–45% acetonitrile in 0.1% formic acid and at a flow rate of 300 nL/min. The mass spectrometer was operated in a parallel-reaction monitoring (PRM) mode. The doubly protonated ions for the carboamidomethylated or inhibitor-conjugated Cys 496-containing tryptic peptide were collisionally activated in the HCD cell with a collision energy of 27 to yield the MS/MS.</div><div class="NLM_p last">LC-MS/MS experiments were also conducted in multiple-reaction monitoring (MRM) mode on a TSQ Vantage triple-quadrupole mass spectrometer equipped with a nanoelectrospray ionization source coupled to an EASY-nLC II system (Thermo Scientific). Samples were automatically loaded onto a 4 cm trapping column (150 μm i.d.) packed with 5 μm 120 Å reversed phase C18 material (ReproSil-Pur 120 C18-AQ, Dr. Maisch) at 3 μL/min. The trapping column was coupled to a 20 cm fused silica analytical column (PicoTip Emitter, New Objective, 75 μm i.d.) with 3 μm C18 beads (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The peptides were then separated with a 60 min linear gradient of 2–35% acetonitrile in 0.1% formic acid and at a flow rate of 230 nL/min. The spray voltage was 1.9 kV. Q1 and Q3 resolutions were 0.7 Da and the cycle time was 2 s.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> Molecular Modeling</h3><div class="NLM_p">Docking of compound <b>6</b> to BMX (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>) was performed using AutoDock 4.2.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The kinase structure contained all protein atoms in chain A in the ATP-binding pocket. The receptor coordinates were preprocessed with AmberTools15<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> to remove alternative conformations, add missing side chain atoms and hydrogen atoms, nonpolar hydrogens were removed, and Gasteiger charges were computed by AutoDockTools. The ligand was built and optimized by Bio<sup>X</sup>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the atomic Gasteiger charges were computed by AutoDockTools. A grid map was constructed with a dimension of (100 × 100 × 100) points and a spacing of 0.2 Å. A total of 200 runs were performed with the Lamarckian genetic algorithm using default parameters. The docked conformations were then sorted by binding energy, and the binding model with the lowest binding energy was used to further reveal the binding mechanism.</div><div class="NLM_p last">For compounds <b>7</b> and <b>41</b>, the flexible side chain method<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> was performed for covalent docking. The receptor was modified to remove side chain atoms of Cys 496, and the side chain of Cys 496 was tethered with the ligand and the C atom type was changed to Z. The C coordinates of Cys 496 was used for covalent grid map generation with energy barrier height of 1000 and half-width of 5 Å.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i151"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01413">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01413" class="ext-link">10.1021/acs.jmedchem.6b01413</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">DiscoverX’s KINOMEscan selectivity profiling data of compound <b>41</b>; MS/MS of the unmodified Cys 496-containing tryptic peptide derived from recombinant BMX protein without compound <b>41</b> treatment (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf">jm6b01413_si_001.pdf (411.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_002.csv">jm6b01413_si_002.csv (6.42 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01413" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision Targeted Therapy Discovery Center,
Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7100021d1804484631191c171d5f10125f121f"><span class="__cf_email__" data-cfemail="89f8fae5e0fcb0bec9e1e4efe5a7e8eaa7eae7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a5053545d56534f7a52575c56145b59145954"><span class="__cf_email__" data-cfemail="c3a9aaada4afaab683abaea5afeda2a0eda0ad">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaofei Liang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengchao Lv</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Wu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zongru Jiang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weili Miao</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, University of California—Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenquan Hu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaochuan Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Zhao</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanchuan Zhang</span> - <span class="hlFld-Affiliation affiliation">CHMFL−HCMTC Target Therapy Joint
Laboratory, 350 Shushanhu
Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei Cosource Medicine Technology Co.
Ltd., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zi Ye</span> - <span class="hlFld-Affiliation affiliation">Synthetic and Functional Biomolecules Center,
Beijing National Laboratory for Molecular Sciences, Key Laboratory
of Bioorganic Chemistry and Molecular Engineering of Ministry of Education,
College of Chemistry and Molecular Engineering, Peking-Tsinghua Center
for Life Sciences, Peking University, Beijing 100871, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chu Wang</span> - <span class="hlFld-Affiliation affiliation">Synthetic and Functional Biomolecules Center,
Beijing National Laboratory for Molecular Sciences, Key Laboratory
of Bioorganic Chemistry and Molecular Engineering of Ministry of Education,
College of Chemistry and Molecular Engineering, Peking-Tsinghua Center
for Life Sciences, Peking University, Beijing 100871, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision Targeted Therapy Discovery Center,
Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinsheng Wang</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, University of California—Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. X.L., F.L., B.W., K.Y. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Dr. Shanchun Zhang is a shareholder of Hefei Cosource Medicine Technology Co. LTD.<br /></br></div></li></ul></div><div class="ack" id="ACK-d207e9315-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i153">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (nos. U1432250, 81402797, 81603123). It was also supported by the National Key Research and Development Program of China (no. 2016YFA0400900), the Postdoctoral Innovative Talent Support Program (no. BX201600169), the Natural Science Foundation of Anhui province (no. 1608085QH180), the “Cross-Disciplinary Collaborative Teams Program for Science, Technology and Innovation” of Chinese Academy of Sciences (CAS) and the CAS/SAFEA International Partnership Program for Creative Research Teams. We are grateful for the National Program for Support of Top-Notch Young Professionals for J.L., the National “Thousand Talents Program” support for Q.L., the “Hundred Talents Program” of CAS support for J.L. and W.W., and the Youth Innovation Promotion Association of CAS support (2016385) for X.L.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i154" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i154"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i155" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i155"> Abbreviations Used</h2><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">bone marrow tyrosine kinase gene in chromosome X protein</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">TEK</td><td class="NLM_def"><p class="first last">endothelial tyrosine kinase</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">RLK</td><td class="NLM_def"><p class="first last">LysM domain receptor-like kinase 1</p></td></tr><tr><td class="NLM_term">MAP2K7</td><td class="NLM_def"><p class="first last">dual specificity mitogen-activated protein kinase kinase 7</p></td></tr><tr><td class="NLM_term">PLCγ1</td><td class="NLM_def"><p class="first last">1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">MST</td><td class="NLM_def"><p class="first last">microscale thermophoresis</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i156">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahtinen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustonen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtaneva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muscatelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3683</span><span class="NLM_x">–</span> <span class="NLM_lpage">3688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1994&pages=3683-3688&author=L.+Tamagnoneauthor=I.+Lahtinenauthor=T.+Mustonenauthor=K.+Virtanevaauthor=F.+Francisauthor=F.+Muscatelliauthor=R.+Alitaloauthor=C.+I.+Smithauthor=C.+Larssonauthor=K.+Alitalo&title=BMX%2C+a+novel+nonreceptor+tyrosine+kinase+gene+of+the+BTK%2FITK%2FTEC%2FTXK+family+located+in+chromosome+Xp22.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DLahtinen%26aufirst%3DI.%26aulast%3DMustonen%26aufirst%3DT.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DF.%26aulast%3DMuscatelli%26aufirst%3DF.%26aulast%3DAlitalo%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DLarsson%26aufirst%3DC.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DBMX%252C%2520a%2520novel%2520nonreceptor%2520tyrosine%2520kinase%2520gene%2520of%2520the%2520BTK%252FITK%252FTEC%252FTXK%2520family%2520located%2520in%2520chromosome%2520Xp22.2%26jtitle%3DOncogene%26date%3D1994%26volume%3D9%26spage%3D3683%26epage%3D3688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Smith, C. I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span> </span><span class="NLM_article-title">The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span><span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+family+of+cytoplasmic+tyrosine+kinases%3A+mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+homologs+in+other+species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0lhl1gBAKHU_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520family%2520of%2520cytoplasmic%2520tyrosine%2520kinases%253A%2520mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520homologs%2520in%2520other%2520species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span> </span><span class="NLM_article-title">Signaling network of the Btk family kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5651</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fsj.onc.1203958" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5651-5661&author=Y.+Qiuauthor=H.+J.+Kung&title=Signaling+network+of+the+Btk+family+kinases&doi=10.1038%2Fsj.onc.1203958"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203958%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26atitle%3DSignaling%2520network%2520of%2520the%2520Btk%2520family%2520kinases%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5651%26epage%3D5661%26doi%3D10.1038%2Fsj.onc.1203958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">38204</span><span class="NLM_x">–</span> <span class="NLM_lpage">38210</span><span class="refDoi"> DOI: 10.1074/jbc.274.53.38204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1074%2Fjbc.274.53.38204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=38204-38210&author=X.+Wenauthor=H.+H.+Linauthor=H.+M.+Shihauthor=H.+J.+Kungauthor=D.+K.+Ann&title=Kinase+activation+of+the+non-receptor+tyrosine+kinase+Etk%2FBMX+alone+is+sufficient+to+transactivate+STAT-mediated+gene+expression+in+salivary+and+lung+epithelial+cells&doi=10.1074%2Fjbc.274.53.38204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.53.38204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.53.38204%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DKinase%2520activation%2520of%2520the%2520non-receptor%2520tyrosine%2520kinase%2520Etk%252FBMX%2520alone%2520is%2520sufficient%2520to%2520transactivate%2520STAT-mediated%2520gene%2520expression%2520in%2520salivary%2520and%2520lung%2520epithelial%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D38204%26epage%3D38210%26doi%3D10.1074%2Fjbc.274.53.38204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Guryanova, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacSwords, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyler, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLendon, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heddleston, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambardzumyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjelmeland, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, S. D.</span><span> </span><span class="NLM_article-title">Non-receptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2Fj.ccr.2011.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=498-511&author=O.+A.+Guryanovaauthor=Q.+L.+Wuauthor=L.+Chengauthor=J.+D.+Lathiaauthor=Z.+Huangauthor=J.+B.+Yangauthor=J.+MacSwordsauthor=C.+E.+Eylerauthor=R.+E.+McLendonauthor=J.+M.+Heddlestonauthor=W.+N.+Shouauthor=D.+Hambardzumyanauthor=J.+W.+Leeauthor=A.+B.+Hjelmelandauthor=A.+E.+Sloanauthor=M.+Bredelauthor=G.+R.+Starkauthor=J.+N.+Richauthor=S.+D.+Bao&title=Non-receptor+tyrosine+kinase+BMX+maintains+self-renewal+and+tumorigenic+potential+of+glioblastoma+stem+cells+by+activating+STAT3&doi=10.1016%2Fj.ccr.2011.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGuryanova%26aufirst%3DO.%2BA.%26aulast%3DWu%26aufirst%3DQ.%2BL.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLathia%26aufirst%3DJ.%2BD.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BB.%26aulast%3DMacSwords%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DC.%2BE.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DHeddleston%26aufirst%3DJ.%2BM.%26aulast%3DShou%26aufirst%3DW.%2BN.%26aulast%3DHambardzumyan%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DSloan%26aufirst%3DA.%2BE.%26aulast%3DBredel%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DBao%26aufirst%3DS.%2BD.%26atitle%3DNon-receptor%2520tyrosine%2520kinase%2520BMX%2520maintains%2520self-renewal%2520and%2520tumorigenic%2520potential%2520of%2520glioblastoma%2520stem%2520cells%2520by%2520activating%2520STAT3%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D498%26epage%3D511%26doi%3D10.1016%2Fj.ccr.2011.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kaukonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahtinen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palotie, A.</span><span> </span><span class="NLM_article-title">BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=8790141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A280%3ADyaK28zot1aktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1996&pages=455-460&author=J.+Kaukonenauthor=I.+Lahtinenauthor=S.+Laineauthor=K.+Alitaloauthor=A.+Palotie&title=BMX+tyrosine+kinase+gene+is+expressed+in+granulocytes+and+myeloid+leukaemias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias</span></div><div class="casAuthors">Kaukonen J; Lahtinen I; Laine S; Alitalo K; Palotie A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-60</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">The growth and maturation of haemopoietic cells is regulated by signal transduction through tyrosine protein kinases.  Recently, a novel cytoplasmic tyrosine kinase gene in chromosome X, called Bmx, was identified in human bone marrow RNA.  Bmx belongs to a subfamily of tyrosine kinases which are expressed in various haemopoietic cell lineages.  We studied Bmx expression using RT-PCR of RNA from fractionated peripheral blood leucocytes, progenitor-enriched fractions of cord blood and from bone marrow or peripheral blood samples from leukaemia patients.  Bmx was strongly expressed in haemopoietic tissues and enhanced in neutrophilic granulocytes.  Bmx mRNA was also found in CD34-positive progenitor cells from cord blood.  All samples (10/10) of patients with acute myeloid leukaemia and (4/4) with chronic myeloid leukaemia showed expression of Bmx.  In contrast, none of the samples of acute lymphoid leukaemia (0/8) and only one out of six samples of chronic lymphoid leukaemia expressed Bmx.  In conclusion, Bmx expression seems to be associated with myelopoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLN5PPdgZmMVWTCLT8lX9SfW6udTcc2ebuxUqkqzsNA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zot1aktQ%253D%253D&md5=4bfb041eb01effaf70bcee1ff3609fff</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaukonen%26aufirst%3DJ.%26aulast%3DLahtinen%26aufirst%3DI.%26aulast%3DLaine%26aufirst%3DS.%26aulast%3DAlitalo%26aufirst%3DK.%26aulast%3DPalotie%26aufirst%3DA.%26atitle%3DBMX%2520tyrosine%2520kinase%2520gene%2520is%2520expressed%2520in%2520granulocytes%2520and%2520myeloid%2520leukaemias%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D1996%26volume%3D94%26spage%3D455%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Holopainen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasanen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anisimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuomainen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tvorogov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulmi, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mervaala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">13063</span><span class="NLM_x">–</span> <span class="NLM_lpage">13068</span><span class="refDoi"> DOI: 10.1073/pnas.1517810112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1073%2Fpnas.1517810112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=13063-13068&author=T.+Holopainenauthor=M.+Rasanenauthor=A.+Anisimovauthor=T.+Tuomainenauthor=W.+Zhengauthor=D.+Tvorogovauthor=J.+J.+Hulmiauthor=L.+C.+Anderssonauthor=B.+Cenniauthor=P.+Taviauthor=E.+Mervaalaauthor=R.+Kivelaauthor=K.+Alitalo&title=Endothelial+Bmx+tyrosine+kinase+activity+is+essential+for+myocardial+hypertrophy+and+remodeling&doi=10.1073%2Fpnas.1517810112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1517810112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1517810112%26sid%3Dliteratum%253Aachs%26aulast%3DHolopainen%26aufirst%3DT.%26aulast%3DRasanen%26aufirst%3DM.%26aulast%3DAnisimov%26aufirst%3DA.%26aulast%3DTuomainen%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DTvorogov%26aufirst%3DD.%26aulast%3DHulmi%26aufirst%3DJ.%2BJ.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DCenni%26aufirst%3DB.%26aulast%3DTavi%26aufirst%3DP.%26aulast%3DMervaala%26aufirst%3DE.%26aulast%3DKivela%26aufirst%3DR.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DEndothelial%2520Bmx%2520tyrosine%2520kinase%2520activity%2520is%2520essential%2520for%2520myocardial%2520hypertrophy%2520and%2520remodeling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D13063%26epage%3D13068%26doi%3D10.1073%2Fpnas.1517810112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Zhuang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S. P.</span><span> </span><span class="NLM_article-title">The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="refDoi"> DOI: 10.1186/1756-9966-33-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1186%2F1756-9966-33-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=24606948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=25&author=J.+T.+Zhuangauthor=X.+G.+Tuauthor=K.+Y.+Caoauthor=S.+J.+Guoauthor=X.+P.+Maoauthor=J.+C.+Panauthor=B.+Huangauthor=X.+Chenauthor=Y.+Gaoauthor=S.+P.+Qiu&title=The+expression+and+role+of+tyrosine+kinase+ETK%2FBMX+in+renal+cell+carcinoma&doi=10.1186%2F1756-9966-33-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma</span></div><div class="casAuthors">Zhuang, Jintao; Tu, Xiangan; Cao, Kaiyuan; Guo, Shengjie; Mao, Xiaopeng; Pan, Jincheng; Huang, Bin; Chen, Xu; Gao, Yong; Qiu, Shaopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25/1-25/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Expression of the non-receptor tyrosine kinase ETK/BMX has been reported in several solid tumors, but the underlying mol. mechanisms and its clin. significance in renal cell carcinoma (RCC) remain to be elucidated.  Methods: ETK expression in 90 human RCC and 30 human normal renal tissue samples was examd. by immunohistochem. and compared with several clinicopathol. parameters.  To further demonstrate the biol. function of ETK in RCC, Western blot was used to test the expression level of ETK protein in RCC cell lines.  Subsequent to the downregulation of ETK by small interfering RNA, the effects of ETK on RCC cell growth, apoptosis, migration and invasion were assessed by Me thiazol tetrazolium assay, flow cytometry and transwell assay.  And the varying expression of VEGF, STAT3 and phosphorylated STAT3 (p-STAT3) in RCC were evaluated by Western blot.  Results: Immunohistochem. anal. showed that ETK expression was highly increased in RCC and was pos. correlated with clin. stage, grade and metastasis.  Simultaneously, the overall survival time in patients with higher ETK expression was obviously shorter than that in patients with lower ETK expression.  ETK was also detected in RCC cell lines.  Moreover, the down-regulating ETK significantly inhibited RCC cell growth, migration, invasion and promoted apoptosis.  The expression of VEGF and p-STAT3 were also decreased.  Conclusions: Our study suggests that the overexpression of ETK is assocd. with the malignancy and disease progression of RCC.  Since ETK is also involved in RCC cell biol. function and VEGF-ETK-STAT3 loop, ETK may be used as a potential therapeutic target for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFbWdCVvmJwLVg90H21EOLACvtfcHk0lhnaDOqwOBkJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFShurY%253D&md5=c53dc37443c1ae08c9ff0c1539b85b1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-33-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-33-25%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DJ.%2BT.%26aulast%3DTu%26aufirst%3DX.%2BG.%26aulast%3DCao%26aufirst%3DK.%2BY.%26aulast%3DGuo%26aufirst%3DS.%2BJ.%26aulast%3DMao%26aufirst%3DX.%2BP.%26aulast%3DPan%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DS.%2BP.%26atitle%3DThe%2520expression%2520and%2520role%2520of%2520tyrosine%2520kinase%2520ETK%252FBMX%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D33%26spage%3D25%26doi%3D10.1186%2F1756-9966-33-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Jarboe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velu, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willey, C. D.</span><span> </span><span class="NLM_article-title">Mini-review: bmx kinase inhibitors for cancer therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.2174/15748928113089990043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.2174%2F15748928113089990043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=228-238&author=J.+S.+Jarboeauthor=S.+Duttaauthor=S.+E.+Veluauthor=C.+D.+Willey&title=Mini-review%3A+bmx+kinase+inhibitors+for+cancer+therapy&doi=10.2174%2F15748928113089990043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F15748928113089990043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748928113089990043%26sid%3Dliteratum%253Aachs%26aulast%3DJarboe%26aufirst%3DJ.%2BS.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DVelu%26aufirst%3DS.%2BE.%26aulast%3DWilley%26aufirst%3DC.%2BD.%26atitle%3DMini-review%253A%2520bmx%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D228%26epage%3D238%26doi%3D10.2174%2F15748928113089990043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Liu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a selective irreversible BMX inhibitor for prostate cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span><span class="refDoi"> DOI: 10.1021/cb4000629</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4000629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1423-1428&author=F.+Y.+Liuauthor=X.+Zhangauthor=E.+Weisbergauthor=S.+Chenauthor=W.+Hurauthor=H.+Wuauthor=Z.+Zhaoauthor=W.+C.+Wangauthor=M.+Maoauthor=C.+M.+Caiauthor=N.+I.+Simonauthor=T.+Sandaauthor=J.+H.+Wangauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=S.+P.+Balkauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+selective+irreversible+BMX+inhibitor+for+prostate+cancer&doi=10.1021%2Fcb4000629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer</span></div><div class="casAuthors">Liu, Feiyang; Zhang, Xin; Weisberg, Ellen; Chen, Sen; Hur, Wooyoung; Wu, Hong; Zhao, Zheng; Wang, Wenchao; Mao, Mao; Cai, Changmeng; Simon, Nicholas I.; Sanda, Takaomi; Wang, Jinhua; Look, A. Thomas; Griffin, James D.; Balk, Steven P.; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1428</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMX is a member of the TEC family of nonreceptor tyrosine kinases.  We have used structure-based drug design in conjunction with kinome profiling to develop a potent, selective, and irreversible BMX kinase inhibitor, BMX-IN-1, which covalently modifies Cys496.  BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concns. but requires single digit micromolar concns. to inhibit the proliferation of prostate cancer cell lines.  Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2n6bH8dNlUrVg90H21EOLACvtfcHk0lhnaDOqwOBkJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D&md5=bf861dad7c1a1f227695e8049f82a4d9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fcb4000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4000629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DC.%2BM.%26aulast%3DSimon%26aufirst%3DN.%2BI.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520irreversible%2520BMX%2520inhibitor%2520for%2520prostate%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1423%26epage%3D1428%26doi%3D10.1021%2Fcb4000629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, W. D.</span><span> </span><span class="NLM_article-title">CI-l033, a pan-erbB tyrosine kinase inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span><span class="refDoi"> DOI: 10.1016/S0093-7754(01)90285-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=W.+D.+Fry&title=CI-l033%2C+a+pan-erbB+tyrosine+kinase+inhibitor&doi=10.1016%2FS0093-7754%2801%2990285-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0ljRGwJcWHgldw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DW.%2BD.%26atitle%3DCI-l033%252C%2520a%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85%26doi%3D10.1016%2FS0093-7754%2801%2990285-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0ljRGwJcWHgldw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Chau, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8817</span><span class="NLM_x">–</span> <span class="NLM_lpage">8829</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fsj.onc.1206032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=8817-8829&author=C.+H.+Chauauthor=K.+Y.+Chenauthor=H.+T.+Dengauthor=K.+J.+Kimauthor=K.+Hosoyaauthor=T.+Terasakiauthor=H.+M.+Shihauthor=D.+K.+Ann&title=Coordinating+Etk%2FBmx+activation+and+VEGF+upregulation+to+promote+cell+survival+and+proliferation&doi=10.1038%2Fsj.onc.1206032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206032%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%2BY.%26aulast%3DDeng%26aufirst%3DH.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DHosoya%26aufirst%3DK.%26aulast%3DTerasaki%26aufirst%3DT.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DCoordinating%2520Etk%252FBmx%2520activation%2520and%2520VEGF%2520upregulation%2520to%2520promote%2520cell%2520survival%2520and%2520proliferation%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D8817%26epage%3D8829%26doi%3D10.1038%2Fsj.onc.1206032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMillin, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treon, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1091</span><span class="refDoi"> DOI: 10.1021/cb4008524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4008524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1086-1091&author=H.+Wuauthor=W.+C.+Wangauthor=F.+Y.+Liuauthor=E.+L.+Weisbergauthor=B.+Tianauthor=Y.+F.+Chenauthor=B.+H.+Liauthor=A.+L.+Wangauthor=B.+L.+Wangauthor=Z.+Zhaoauthor=D.+W.+McMillinauthor=C.+Huauthor=H.+Liauthor=J.+H.+Wangauthor=Y.+K.+Liangauthor=S.+J.+Buhrlageauthor=J.+T.+Liangauthor=J.+Liuauthor=G.+Yangauthor=J.+R.+Brownauthor=S.+P.+Treonauthor=C.+S.+Mitsiadesauthor=J.+D.+Griffinauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+potent%2C+covalent+BTK+inhibitor+for+B-cell+lymphoma&doi=10.1021%2Fcb4008524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span></div><div class="casAuthors">Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen E.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1091</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases.  The authors have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys 481.  QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr 223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr 759) with an EC50 of 318 nM.  In Ramos cells QL47 induces a G1 cell cycle arrest that is assocd. with pronounced degrdn. of BTK protein.  QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyQbTbqIpCbVg90H21EOLACvtfcHk0ljSGlx6HBJ6Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D&md5=6cee72676bcd141f79d89d708dea5db2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcb4008524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4008524%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DLi%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DY.%2BK.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520covalent%2520BTK%2520inhibitor%2520for%2520B-cell%2520lymphoma%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1086%26epage%3D1091%26doi%3D10.1021%2Fcb4008524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljSGlx6HBJ6Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljSGlx6HBJ6Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+S.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+H.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lhy6iBDvCuLNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%2BH.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Li, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z. Y.</span><span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of bruton’s tyrosine kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5112</span><span class="NLM_x">–</span> <span class="NLM_lpage">5128</span><span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+T.+Liauthor=Y.+Y.+Zuoauthor=G.+H.+Tangauthor=Y.+Wangauthor=Y.+Q.+Zhouauthor=X.+Y.+Wangauthor=T.+L.+Guoauthor=M.+Y.+Xiaauthor=N.+Dingauthor=Z.+Y.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0lhy6iBDvCuLNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BT.%26aulast%3DZuo%26aufirst%3DY.%2BY.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DT.%2BL.%26aulast%3DXia%26aufirst%3DM.%2BY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span><span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+Abelson+tyrosine+kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lhy6iBDvCuLNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520Abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lgG0iomZmlRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lgG0iomZmlRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span> </span><span class="NLM_article-title">Biochemical mechanisms of drug action: what does it take for success?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span><span class="refDoi"> DOI: 10.1038/nrd1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=15340390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=801-808&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+drug+action%3A+what+does+it+take+for+success%3F&doi=10.1038%2Fnrd1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Biochemical mechanisms of drug action: what does it take for success?</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Drug discovery is extremely difficult.  There are many unanticipated scientific, medical and business challenges to every drug discovery program.  It is important to increase our understanding of the fundamental properties of effective drugs so that we can anticipate potential problems in developing new agents.  This article addresses potential drug discovery and development risks assocd. with the biochem. mechanism of drug action, and proposes simple rules to minimize these risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXhyDgozFUdrVg90H21EOLACvtfcHk0lgG0iomZmlRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D&md5=b06bdc6ace3168dcb011679b43b72aed</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1500%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520drug%2520action%253A%2520what%2520does%2520it%2520take%2520for%2520success%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D801%26epage%3D808%26doi%3D10.1038%2Fnrd1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span><span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&issue=15&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhT2fQpChaOnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Liang, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective, and orally available BCR-ABL/SRC/p38 kinase inhibitor for chronic myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1984-2004&author=X.+F.+Liangauthor=X.+C.+Liuauthor=B.+L.+Wangauthor=F.+M.+Zouauthor=A.+L.+Wangauthor=S.+Qiauthor=C.+Chenauthor=Z.+Zhaoauthor=W.+C.+Wangauthor=Z.+P.+Qiauthor=F.+C.+Lvauthor=Z.+Q.+Huauthor=L.+Wangauthor=S.+C.+Zhangauthor=Q.+S.+Liuauthor=J.+Liu&title=Discovery+of+2-%28%283-amino-4-methylphenyl%29amino%29-N-%282-methyl-5-%283-%28trifluoromethyl%29benzamido%29phenyl%29-4-%28methylamino%29pyrimidine-5-carboxamide+%28CHMFL-ABL-053%29+as+a+potent%2C+selective%2C+and+orally+available+BCR-ABL%2FSRC%2Fp38+kinase+inhibitor+for+chronic+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01618%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BC.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DZou%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DQi%26aufirst%3DZ.%2BP.%26aulast%3DLv%26aufirst%3DF.%2BC.%26aulast%3DHu%26aufirst%3DZ.%2BQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%25202-%2528%25283-amino-4-methylphenyl%2529amino%2529-N-%25282-methyl-5-%25283-%2528trifluoromethyl%2529benzamido%2529phenyl%2529-4-%2528methylamino%2529pyrimidine-5-carboxamide%2520%2528CHMFL-ABL-053%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520BCR-ABL%252FSRC%252Fp38%2520kinase%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1984%26epage%3D2004%26doi%3D10.1021%2Facs.jmedchem.5b01618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2785</span><span class="NLM_x">–</span> <span class="NLM_lpage">2791</span><span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Autodock4+and+AutoDockTools4%3A+automated+docking+with+selective+receptor+flexiblity&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhT2fQpChaOnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutodock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520selective%2520receptor%2520flexiblity%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span>AMBER 14; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER+14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER%252014%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, A Versatile Molecular-Modeling Software; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: , <span class="NLM_publisher-loc">Basel, Switzerland</span>.<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (Updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+A+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520A%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bianco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Covalent docking using autodock: two-point attractor and flexible side chain methods</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1002/pro.2733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fpro.2733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=26103917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFehs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=295-301&author=G.+Biancoauthor=S.+Forliauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Covalent+docking+using+autodock%3A+two-point+attractor+and+flexible+side+chain+methods&doi=10.1002%2Fpro.2733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent docking using autodock: Two-point attractor and flexible side chain methods</span></div><div class="casAuthors">Bianco, Giulia; Forli, Stefano; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-301</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We describe two methods of automated covalent docking using Autodock4: the two-point attractor method and the flexible side chain method.  Both methods were applied to a training set of 20 diverse protein-ligand covalent complexes, evaluating their reliability in predicting the crystallog. pose of the ligands.  The flexible side chain method performed best, recovering the pose in 75% of cases, with failures for the largest inhibitors tested.  Both methods are freely available at the AutoDock website ().</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgwvwS_NTKrVg90H21EOLACvtfcHk0liO27BHxexPJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFehs7rI&md5=4e380f340983e78e149f48934ccc59fd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fpro.2733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2733%26sid%3Dliteratum%253Aachs%26aulast%3DBianco%26aufirst%3DG.%26aulast%3DForli%26aufirst%3DS.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DCovalent%2520docking%2520using%2520autodock%253A%2520two-point%2520attractor%2520and%2520flexible%2520side%2520chain%2520methods%26jtitle%3DProtein%2520Sci.%26date%3D2016%26volume%3D25%26spage%3D295%26epage%3D301%26doi%3D10.1002%2Fpro.2733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoding  Jiang</span>, <span class="hlFld-ContribAuthor ">Bendu  Pan</span>, <span class="hlFld-ContribAuthor ">Xu  Qian</span>, <span class="hlFld-ContribAuthor ">Hao  Liang</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Bin  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaobo  He</span>, <span class="hlFld-ContribAuthor ">Hoi Shan  Chan</span>, <span class="hlFld-ContribAuthor ">Albert S. C.  Chan</span>, <span class="hlFld-ContribAuthor ">Liqin  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Construction of Pyrimidine‐Fused Diazepinone Derivatives Bearing a Tertiary Stereogenic Center Enabled by Iridium‐Catalysed Intramolecular Allylic Substitution. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (13)
                                     , 3227-3232. <a href="https://doi.org/10.1002/adsc.202100444" title="DOI URL">https://doi.org/10.1002/adsc.202100444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100444%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DEnantioselective%252BConstruction%252Bof%252BPyrimidine%2525E2%252580%252590Fused%252BDiazepinone%252BDerivatives%252BBearing%252Ba%252BTertiary%252BStereogenic%252BCenter%252BEnabled%252Bby%252BIridium%2525E2%252580%252590Catalysed%252BIntramolecular%252BAllylic%252BSubstitution%26aulast%3DJiang%26aufirst%3DXiaoding%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D13%26spage%3D3227%26epage%3D3232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Xiaojun Julia  Liang</span>, <span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Stefan  Gerstenecker</span>, <span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9269. <a href="https://doi.org/10.3390/ijms21239269" title="DOI URL">https://doi.org/10.3390/ijms21239269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239269%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BClass%252Bof%252BCovalent%252BDual%252BInhibitors%252BTargeting%252Bthe%252BProtein%252BKinases%252BBMX%252Band%252BBTK%26aulast%3DForster%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ozildéia S.  Trefzger</span>, <span class="hlFld-ContribAuthor ">Natália V.  Barbosa</span>, <span class="hlFld-ContribAuthor ">Renata L.  Scapolatempo</span>, <span class="hlFld-ContribAuthor ">Amarith R.  Neves</span>, <span class="hlFld-ContribAuthor ">Maria L. F. S.  Ortale</span>, <span class="hlFld-ContribAuthor ">Diego B.  Carvalho</span>, <span class="hlFld-ContribAuthor ">Antônio M.  Honorato</span>, <span class="hlFld-ContribAuthor ">Mariana R.  Fragoso</span>, <span class="hlFld-ContribAuthor ">Cristiane Y. K.  Shuiguemoto</span>, <span class="hlFld-ContribAuthor ">Renata T.  Perdomo</span>, <span class="hlFld-ContribAuthor ">Maria F. C.  Matos</span>, <span class="hlFld-ContribAuthor ">Marilene R.  Chang</span>, <span class="hlFld-ContribAuthor ">Carla C. P.  Arruda</span>, <span class="hlFld-ContribAuthor ">Adriano C. M.  Baroni</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, antileishmanial, and antifungal biological evaluation of novel 3,5‐disubstituted isoxazole compounds based on 5‐nitrofuran scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (2)
                                     , 1900241. <a href="https://doi.org/10.1002/ardp.201900241" title="DOI URL">https://doi.org/10.1002/ardp.201900241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900241%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bantileishmanial%25252C%252Band%252Bantifungal%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B3%25252C5%2525E2%252580%252590disubstituted%252Bisoxazole%252Bcompounds%252Bbased%252Bon%252B5%2525E2%252580%252590nitrofuran%252Bscaffolds%26aulast%3DTrefzger%26aufirst%3DOzild%25C3%25A9ia%2BS.%26date%3D2020%26date%3D2019%26volume%3D353%26issue%3D2%26spage%3D1900241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kseniya N.  Sedenkova</span>, <span class="hlFld-ContribAuthor ">Julia V.  Kolodyazhnaya</span>, <span class="hlFld-ContribAuthor ">Dmitry A.  Vasilenko</span>, <span class="hlFld-ContribAuthor ">Yulia A.  Gracheva</span>, <span class="hlFld-ContribAuthor ">Elena V.  Kharitonoshvili</span>, <span class="hlFld-ContribAuthor ">Yuri K.  Grishin</span>, <span class="hlFld-ContribAuthor ">Alexey A.  Chistov</span>, <span class="hlFld-ContribAuthor ">Victor B.  Rybakov</span>, <span class="hlFld-ContribAuthor ">Tina  Holt</span>, <span class="hlFld-ContribAuthor ">Andrei G.  Kutateladze</span>, <span class="hlFld-ContribAuthor ">Tamara S.  Kuznetsova</span>, <span class="hlFld-ContribAuthor ">Elena R.  Milaeva</span>, <span class="hlFld-ContribAuthor ">Elena B.  Averina</span>. </span><span class="cited-content_cbyCitation_article-title">Novel π-conjugated systems based on pyrimidine N-Oxide. </span><span class="cited-content_cbyCitation_journal-name">Dyes and Pigments</span><span> <strong>2019,</strong> <em>164 </em>, 72-81. <a href="https://doi.org/10.1016/j.dyepig.2018.12.067" title="DOI URL">https://doi.org/10.1016/j.dyepig.2018.12.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dyepig.2018.12.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dyepig.2018.12.067%26sid%3Dliteratum%253Aachs%26jtitle%3DDyes%2520and%2520Pigments%26atitle%3DNovel%252B%2525CF%252580-conjugated%252Bsystems%252Bbased%252Bon%252Bpyrimidine%252BN-Oxide%26aulast%3DSedenkova%26aufirst%3DKseniya%2BN.%26date%3D2019%26volume%3D164%26spage%3D72%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Harris</span>, <span class="hlFld-ContribAuthor ">Sage E.  Foley</span>, <span class="hlFld-ContribAuthor ">Eric R.  Goedken</span>, <span class="hlFld-ContribAuthor ">Mark  Michalak</span>, <span class="hlFld-ContribAuthor ">Sara  Murdock</span>, <span class="hlFld-ContribAuthor ">Noel S.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 1040-1050. <a href="https://doi.org/10.1177/2472555218787445" title="DOI URL">https://doi.org/10.1177/2472555218787445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555218787445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555218787445%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DMerits%252Band%252BPitfalls%252Bin%252Bthe%252BCharacterization%252Bof%252BCovalent%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DHarris%26aufirst%3DChristopher%2BM.%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D1040%26epage%3D1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi-Chun  Wang</span>, <span class="hlFld-ContribAuthor ">Fu-Xian  Wan</span>, <span class="hlFld-ContribAuthor ">Si  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Antifungal Activity Evaluation of Novel Substituted Pyrimidine-5-Carboxamides Bearing the Pyridine Moiety. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2018,</strong> <em>65 </em>
                                    (4)
                                     , 445-451. <a href="https://doi.org/10.1002/jccs.201700310" title="DOI URL">https://doi.org/10.1002/jccs.201700310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.201700310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.201700310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DSynthesis%252Band%252BAntifungal%252BActivity%252BEvaluation%252Bof%252BNovel%252BSubstituted%252BPyrimidine-5-Carboxamides%252BBearing%252Bthe%252BPyridine%252BMoiety%26aulast%3DWang%26aufirst%3DShi-Chun%26date%3D2018%26date%3D2018%26volume%3D65%26issue%3D4%26spage%3D445%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative inhibitors that bear BMX kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeling of interactions of dihydropyrimidopyrimidine compounds <b>6</b> and <b>7</b> with BMX kinase (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>). (A) The Cys 496 is 5.3 Å from the N atom in the head moiety of compound <b>6</b>. (B) The covalent bond formed between the acrylamide moiety of compound <b>7</b> and Cys 496. (C) Demonstration of canonical hydrogen bonds in the type II binding mode between compound <b>6</b> and DFG-out inactive conformation of BMX kinase. (D) Demonstration of canonical hydrogen bonds in the type II binding mode between compound <b>7</b> and DFG-out inactive conformation of BMX kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of the discovery of compound <b>41</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>7</b>’s effects against the total tyrosine phosphorylation of purified BMX wt and C496S mutant proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity profiling of compound <b>41</b> with DiscoverRx KINOMEscan technology and biochemical IC<sub>50</sub> values of compounds <b>41</b> and <b>42</b> measured with Invitrogen SelectScreen Technology. (A) Treespot demonstration of <b>41</b>’s selectivity in 468 kinase targets. Measurements were performed at a concentration of 1 μM of the compound. The affinity was defined with respect to DMSO control. (B) Other targets that demonstrated strong binding to <b>41</b> with a percent control number less than 1. (C) Binding <i>K</i><sub>d</sub> values of compounds <b>41</b> and <b>42</b> with purified recombinant inactive and active BMX kinase proteins measured by MST (microscale thermophoresis) technology. (D) Biochemical IC<sub>50</sub> values of compounds <b>41</b> and <b>42</b> measured with Invitrogen SelectScreen Technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode illustration of compound <b>41</b> with BMX kinase. (A) Putative binding model of <b>41</b> with BMX inactive conformation (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR">3SXR</a>). (B) Effects of compounds <b>41</b> and <b>42</b> on BMX wt and C496S mutant’s total-tyrosine phosphorylation. Purified His-tag labeled recombinant full length of the inactive state of BMX wt and C496S mutant were first treated with the inhibitors and then incubated with 40 μM ATP before the total protein phosphorylation was detected with Western blot. (C,D) LC-MS/MS in the MRM mode revealed the compound <b>41</b>-conjugated Cys 496-containing tryptic peptide derived from recombinant BMX after reaction with <b>41</b>. Shown in (C) are the selected-ion chromatograms (SICs) for monitoring the indicated transitions arising from the fragmentations of the [M + 3H]<sup>3+</sup> ions of the unmodified (top) and compound <b>41</b>-modified (bottom) Cys 496-containing peptides. Displayed in (D) are the MS/MS for the [M + 3H]<sup>3+</sup> ions of the unmodified (top) and compound <b>41</b>-modified (bottom) cysteine-containing peptides averaged from the peak at around 69.6 min. From the peak areas found in the SICs, it can be estimated that approximately 23% of Cys 496 was modified.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>41</b> on inhibition of total tyrosine phosphorylation in DU-145 cells with overexpressed FLAG labeled full length BMX kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7</b>–<b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>Me·HCl, TEA, THF, 0 °C to rt; (b) LiAlH<sub>4</sub>, THF, 0 °C to rt; (c) MnO<sub>2</sub>, DCM, rt; (d) <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate, MeOH/AcOH, reflux, then NaBH<sub>3</sub>CN, rt; (e) triphosgene, DIPEA, dioxane, 0 °C to rt; (f) m-CPBA, DCM, 0 °C to rt; (g) <i>tert</i>-butyl 5-amino-2-methylphenylcarbamate, LHMDS, THF, −78 °C to rt; (h) 4 M HCl in MeOH, rt; (i) R-COOH, HATU, DIPEA, DMF. (j) For the synthesis of <b>7</b>–<b>22</b> and <b>27</b>–<b>31</b>: acryloyl chloride, THF, DIPEA, rt. For the synthesis of <b>23</b>–<b>26</b>: acryloyl chloride, THF, DIPEA, rt; then HCl in MeOH, rt.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>32</b>–<b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, EtOH, H<sub>2</sub>O, rt; (b) <i>tert</i>-butyl 3-amino-4-methylphenylcarbamate, HATU, DIPEA, DMF; (c) 4 M HCl in MeOH, rt; (d) R′COCl, THF, DIPEA, 0 °C; (e) m-CPBA, DCM, 0 °C; (f) 4-methyl-3-nitroaniline, dioxane, TFA, 120 °C; (g) SnCl<sub>2</sub>, MeOH, reflux. (h) For the synthesis of <b>32</b>, <b>34</b>–<b>41</b>, and <b>43</b>: acryloyl chloride, THF, DIPEA, rt. For the synthesis of <b>33</b> and <b>42</b>: propionyl chloride, THF, DIPEA, rt.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/medium/jm-2016-014135_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>44</b>–<b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01413/20170303/images/large/jm-2016-014135_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01413&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 3-amino-4-methylbenzoate, HATU, DIPEA, DMF, rt; (b) NaOH, MeOH, H<sub>2</sub>O, rt; (c) R-NH<sub>2</sub>, HATU, DIPEA, DMF, rt; (d) m-CPBA, DCM, 0 °C to rt; (e) 4-methyl-3-nitroaniline, LiHMDS, THF, −78 °C to rt; (f) SnCl<sub>2</sub>, MeOH, reflux; (g) acryloyl chloride, THF, DIPEA, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i156">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahtinen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustonen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtaneva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muscatelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3683</span><span class="NLM_x">–</span> <span class="NLM_lpage">3688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1994&pages=3683-3688&author=L.+Tamagnoneauthor=I.+Lahtinenauthor=T.+Mustonenauthor=K.+Virtanevaauthor=F.+Francisauthor=F.+Muscatelliauthor=R.+Alitaloauthor=C.+I.+Smithauthor=C.+Larssonauthor=K.+Alitalo&title=BMX%2C+a+novel+nonreceptor+tyrosine+kinase+gene+of+the+BTK%2FITK%2FTEC%2FTXK+family+located+in+chromosome+Xp22.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DLahtinen%26aufirst%3DI.%26aulast%3DMustonen%26aufirst%3DT.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DF.%26aulast%3DMuscatelli%26aufirst%3DF.%26aulast%3DAlitalo%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DLarsson%26aufirst%3DC.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DBMX%252C%2520a%2520novel%2520nonreceptor%2520tyrosine%2520kinase%2520gene%2520of%2520the%2520BTK%252FITK%252FTEC%252FTXK%2520family%2520located%2520in%2520chromosome%2520Xp22.2%26jtitle%3DOncogene%26date%3D1994%26volume%3D9%26spage%3D3683%26epage%3D3688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Smith, C. I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span> </span><span class="NLM_article-title">The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span><span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+family+of+cytoplasmic+tyrosine+kinases%3A+mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+homologs+in+other+species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0liKR1muC59Suw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520family%2520of%2520cytoplasmic%2520tyrosine%2520kinases%253A%2520mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520homologs%2520in%2520other%2520species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span> </span><span class="NLM_article-title">Signaling network of the Btk family kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5651</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fsj.onc.1203958" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5651-5661&author=Y.+Qiuauthor=H.+J.+Kung&title=Signaling+network+of+the+Btk+family+kinases&doi=10.1038%2Fsj.onc.1203958"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203958%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26atitle%3DSignaling%2520network%2520of%2520the%2520Btk%2520family%2520kinases%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5651%26epage%3D5661%26doi%3D10.1038%2Fsj.onc.1203958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">38204</span><span class="NLM_x">–</span> <span class="NLM_lpage">38210</span><span class="refDoi"> DOI: 10.1074/jbc.274.53.38204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1074%2Fjbc.274.53.38204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=38204-38210&author=X.+Wenauthor=H.+H.+Linauthor=H.+M.+Shihauthor=H.+J.+Kungauthor=D.+K.+Ann&title=Kinase+activation+of+the+non-receptor+tyrosine+kinase+Etk%2FBMX+alone+is+sufficient+to+transactivate+STAT-mediated+gene+expression+in+salivary+and+lung+epithelial+cells&doi=10.1074%2Fjbc.274.53.38204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.53.38204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.53.38204%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DKinase%2520activation%2520of%2520the%2520non-receptor%2520tyrosine%2520kinase%2520Etk%252FBMX%2520alone%2520is%2520sufficient%2520to%2520transactivate%2520STAT-mediated%2520gene%2520expression%2520in%2520salivary%2520and%2520lung%2520epithelial%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D38204%26epage%3D38210%26doi%3D10.1074%2Fjbc.274.53.38204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Guryanova, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lathia, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacSwords, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyler, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLendon, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heddleston, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambardzumyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjelmeland, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, S. D.</span><span> </span><span class="NLM_article-title">Non-receptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2Fj.ccr.2011.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=498-511&author=O.+A.+Guryanovaauthor=Q.+L.+Wuauthor=L.+Chengauthor=J.+D.+Lathiaauthor=Z.+Huangauthor=J.+B.+Yangauthor=J.+MacSwordsauthor=C.+E.+Eylerauthor=R.+E.+McLendonauthor=J.+M.+Heddlestonauthor=W.+N.+Shouauthor=D.+Hambardzumyanauthor=J.+W.+Leeauthor=A.+B.+Hjelmelandauthor=A.+E.+Sloanauthor=M.+Bredelauthor=G.+R.+Starkauthor=J.+N.+Richauthor=S.+D.+Bao&title=Non-receptor+tyrosine+kinase+BMX+maintains+self-renewal+and+tumorigenic+potential+of+glioblastoma+stem+cells+by+activating+STAT3&doi=10.1016%2Fj.ccr.2011.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGuryanova%26aufirst%3DO.%2BA.%26aulast%3DWu%26aufirst%3DQ.%2BL.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLathia%26aufirst%3DJ.%2BD.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BB.%26aulast%3DMacSwords%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DC.%2BE.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DHeddleston%26aufirst%3DJ.%2BM.%26aulast%3DShou%26aufirst%3DW.%2BN.%26aulast%3DHambardzumyan%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DSloan%26aufirst%3DA.%2BE.%26aulast%3DBredel%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DBao%26aufirst%3DS.%2BD.%26atitle%3DNon-receptor%2520tyrosine%2520kinase%2520BMX%2520maintains%2520self-renewal%2520and%2520tumorigenic%2520potential%2520of%2520glioblastoma%2520stem%2520cells%2520by%2520activating%2520STAT3%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D498%26epage%3D511%26doi%3D10.1016%2Fj.ccr.2011.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kaukonen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahtinen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palotie, A.</span><span> </span><span class="NLM_article-title">BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=8790141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A280%3ADyaK28zot1aktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1996&pages=455-460&author=J.+Kaukonenauthor=I.+Lahtinenauthor=S.+Laineauthor=K.+Alitaloauthor=A.+Palotie&title=BMX+tyrosine+kinase+gene+is+expressed+in+granulocytes+and+myeloid+leukaemias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias</span></div><div class="casAuthors">Kaukonen J; Lahtinen I; Laine S; Alitalo K; Palotie A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-60</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">The growth and maturation of haemopoietic cells is regulated by signal transduction through tyrosine protein kinases.  Recently, a novel cytoplasmic tyrosine kinase gene in chromosome X, called Bmx, was identified in human bone marrow RNA.  Bmx belongs to a subfamily of tyrosine kinases which are expressed in various haemopoietic cell lineages.  We studied Bmx expression using RT-PCR of RNA from fractionated peripheral blood leucocytes, progenitor-enriched fractions of cord blood and from bone marrow or peripheral blood samples from leukaemia patients.  Bmx was strongly expressed in haemopoietic tissues and enhanced in neutrophilic granulocytes.  Bmx mRNA was also found in CD34-positive progenitor cells from cord blood.  All samples (10/10) of patients with acute myeloid leukaemia and (4/4) with chronic myeloid leukaemia showed expression of Bmx.  In contrast, none of the samples of acute lymphoid leukaemia (0/8) and only one out of six samples of chronic lymphoid leukaemia expressed Bmx.  In conclusion, Bmx expression seems to be associated with myelopoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLN5PPdgZmMVWTCLT8lX9SfW6udTcc2ea3-aTlu27gvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zot1aktQ%253D%253D&md5=4bfb041eb01effaf70bcee1ff3609fff</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaukonen%26aufirst%3DJ.%26aulast%3DLahtinen%26aufirst%3DI.%26aulast%3DLaine%26aufirst%3DS.%26aulast%3DAlitalo%26aufirst%3DK.%26aulast%3DPalotie%26aufirst%3DA.%26atitle%3DBMX%2520tyrosine%2520kinase%2520gene%2520is%2520expressed%2520in%2520granulocytes%2520and%2520myeloid%2520leukaemias%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D1996%26volume%3D94%26spage%3D455%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Holopainen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasanen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anisimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuomainen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tvorogov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulmi, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mervaala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alitalo, K.</span><span> </span><span class="NLM_article-title">Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">13063</span><span class="NLM_x">–</span> <span class="NLM_lpage">13068</span><span class="refDoi"> DOI: 10.1073/pnas.1517810112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1073%2Fpnas.1517810112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=13063-13068&author=T.+Holopainenauthor=M.+Rasanenauthor=A.+Anisimovauthor=T.+Tuomainenauthor=W.+Zhengauthor=D.+Tvorogovauthor=J.+J.+Hulmiauthor=L.+C.+Anderssonauthor=B.+Cenniauthor=P.+Taviauthor=E.+Mervaalaauthor=R.+Kivelaauthor=K.+Alitalo&title=Endothelial+Bmx+tyrosine+kinase+activity+is+essential+for+myocardial+hypertrophy+and+remodeling&doi=10.1073%2Fpnas.1517810112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1517810112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1517810112%26sid%3Dliteratum%253Aachs%26aulast%3DHolopainen%26aufirst%3DT.%26aulast%3DRasanen%26aufirst%3DM.%26aulast%3DAnisimov%26aufirst%3DA.%26aulast%3DTuomainen%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DTvorogov%26aufirst%3DD.%26aulast%3DHulmi%26aufirst%3DJ.%2BJ.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DCenni%26aufirst%3DB.%26aulast%3DTavi%26aufirst%3DP.%26aulast%3DMervaala%26aufirst%3DE.%26aulast%3DKivela%26aufirst%3DR.%26aulast%3DAlitalo%26aufirst%3DK.%26atitle%3DEndothelial%2520Bmx%2520tyrosine%2520kinase%2520activity%2520is%2520essential%2520for%2520myocardial%2520hypertrophy%2520and%2520remodeling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D13063%26epage%3D13068%26doi%3D10.1073%2Fpnas.1517810112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Zhuang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S. P.</span><span> </span><span class="NLM_article-title">The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="refDoi"> DOI: 10.1186/1756-9966-33-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1186%2F1756-9966-33-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=24606948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=25&author=J.+T.+Zhuangauthor=X.+G.+Tuauthor=K.+Y.+Caoauthor=S.+J.+Guoauthor=X.+P.+Maoauthor=J.+C.+Panauthor=B.+Huangauthor=X.+Chenauthor=Y.+Gaoauthor=S.+P.+Qiu&title=The+expression+and+role+of+tyrosine+kinase+ETK%2FBMX+in+renal+cell+carcinoma&doi=10.1186%2F1756-9966-33-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma</span></div><div class="casAuthors">Zhuang, Jintao; Tu, Xiangan; Cao, Kaiyuan; Guo, Shengjie; Mao, Xiaopeng; Pan, Jincheng; Huang, Bin; Chen, Xu; Gao, Yong; Qiu, Shaopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25/1-25/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Expression of the non-receptor tyrosine kinase ETK/BMX has been reported in several solid tumors, but the underlying mol. mechanisms and its clin. significance in renal cell carcinoma (RCC) remain to be elucidated.  Methods: ETK expression in 90 human RCC and 30 human normal renal tissue samples was examd. by immunohistochem. and compared with several clinicopathol. parameters.  To further demonstrate the biol. function of ETK in RCC, Western blot was used to test the expression level of ETK protein in RCC cell lines.  Subsequent to the downregulation of ETK by small interfering RNA, the effects of ETK on RCC cell growth, apoptosis, migration and invasion were assessed by Me thiazol tetrazolium assay, flow cytometry and transwell assay.  And the varying expression of VEGF, STAT3 and phosphorylated STAT3 (p-STAT3) in RCC were evaluated by Western blot.  Results: Immunohistochem. anal. showed that ETK expression was highly increased in RCC and was pos. correlated with clin. stage, grade and metastasis.  Simultaneously, the overall survival time in patients with higher ETK expression was obviously shorter than that in patients with lower ETK expression.  ETK was also detected in RCC cell lines.  Moreover, the down-regulating ETK significantly inhibited RCC cell growth, migration, invasion and promoted apoptosis.  The expression of VEGF and p-STAT3 were also decreased.  Conclusions: Our study suggests that the overexpression of ETK is assocd. with the malignancy and disease progression of RCC.  Since ETK is also involved in RCC cell biol. function and VEGF-ETK-STAT3 loop, ETK may be used as a potential therapeutic target for RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFbWdCVvmJwLVg90H21EOLACvtfcHk0liy9aTh834jrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFShurY%253D&md5=c53dc37443c1ae08c9ff0c1539b85b1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-33-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-33-25%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DJ.%2BT.%26aulast%3DTu%26aufirst%3DX.%2BG.%26aulast%3DCao%26aufirst%3DK.%2BY.%26aulast%3DGuo%26aufirst%3DS.%2BJ.%26aulast%3DMao%26aufirst%3DX.%2BP.%26aulast%3DPan%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DS.%2BP.%26atitle%3DThe%2520expression%2520and%2520role%2520of%2520tyrosine%2520kinase%2520ETK%252FBMX%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D33%26spage%3D25%26doi%3D10.1186%2F1756-9966-33-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Jarboe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velu, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willey, C. D.</span><span> </span><span class="NLM_article-title">Mini-review: bmx kinase inhibitors for cancer therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.2174/15748928113089990043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.2174%2F15748928113089990043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=228-238&author=J.+S.+Jarboeauthor=S.+Duttaauthor=S.+E.+Veluauthor=C.+D.+Willey&title=Mini-review%3A+bmx+kinase+inhibitors+for+cancer+therapy&doi=10.2174%2F15748928113089990043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F15748928113089990043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748928113089990043%26sid%3Dliteratum%253Aachs%26aulast%3DJarboe%26aufirst%3DJ.%2BS.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DVelu%26aufirst%3DS.%2BE.%26aulast%3DWilley%26aufirst%3DC.%2BD.%26atitle%3DMini-review%253A%2520bmx%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D228%26epage%3D238%26doi%3D10.2174%2F15748928113089990043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Liu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a selective irreversible BMX inhibitor for prostate cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span><span class="refDoi"> DOI: 10.1021/cb4000629</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4000629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1423-1428&author=F.+Y.+Liuauthor=X.+Zhangauthor=E.+Weisbergauthor=S.+Chenauthor=W.+Hurauthor=H.+Wuauthor=Z.+Zhaoauthor=W.+C.+Wangauthor=M.+Maoauthor=C.+M.+Caiauthor=N.+I.+Simonauthor=T.+Sandaauthor=J.+H.+Wangauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=S.+P.+Balkauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+selective+irreversible+BMX+inhibitor+for+prostate+cancer&doi=10.1021%2Fcb4000629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer</span></div><div class="casAuthors">Liu, Feiyang; Zhang, Xin; Weisberg, Ellen; Chen, Sen; Hur, Wooyoung; Wu, Hong; Zhao, Zheng; Wang, Wenchao; Mao, Mao; Cai, Changmeng; Simon, Nicholas I.; Sanda, Takaomi; Wang, Jinhua; Look, A. Thomas; Griffin, James D.; Balk, Steven P.; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1428</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMX is a member of the TEC family of nonreceptor tyrosine kinases.  We have used structure-based drug design in conjunction with kinome profiling to develop a potent, selective, and irreversible BMX kinase inhibitor, BMX-IN-1, which covalently modifies Cys496.  BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concns. but requires single digit micromolar concns. to inhibit the proliferation of prostate cancer cell lines.  Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2n6bH8dNlUrVg90H21EOLACvtfcHk0lgo64jV9YY0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D&md5=bf861dad7c1a1f227695e8049f82a4d9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fcb4000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4000629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DC.%2BM.%26aulast%3DSimon%26aufirst%3DN.%2BI.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520irreversible%2520BMX%2520inhibitor%2520for%2520prostate%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1423%26epage%3D1428%26doi%3D10.1021%2Fcb4000629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, W. D.</span><span> </span><span class="NLM_article-title">CI-l033, a pan-erbB tyrosine kinase inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span><span class="refDoi"> DOI: 10.1016/S0093-7754(01)90285-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=W.+D.+Fry&title=CI-l033%2C+a+pan-erbB+tyrosine+kinase+inhibitor&doi=10.1016%2FS0093-7754%2801%2990285-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0lgo64jV9YY0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DW.%2BD.%26atitle%3DCI-l033%252C%2520a%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85%26doi%3D10.1016%2FS0093-7754%2801%2990285-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lgo64jV9YY0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Chau, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8817</span><span class="NLM_x">–</span> <span class="NLM_lpage">8829</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fsj.onc.1206032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=8817-8829&author=C.+H.+Chauauthor=K.+Y.+Chenauthor=H.+T.+Dengauthor=K.+J.+Kimauthor=K.+Hosoyaauthor=T.+Terasakiauthor=H.+M.+Shihauthor=D.+K.+Ann&title=Coordinating+Etk%2FBmx+activation+and+VEGF+upregulation+to+promote+cell+survival+and+proliferation&doi=10.1038%2Fsj.onc.1206032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206032%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%2BY.%26aulast%3DDeng%26aufirst%3DH.%2BT.%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DHosoya%26aufirst%3DK.%26aulast%3DTerasaki%26aufirst%3DT.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DCoordinating%2520Etk%252FBmx%2520activation%2520and%2520VEGF%2520upregulation%2520to%2520promote%2520cell%2520survival%2520and%2520proliferation%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D8817%26epage%3D8829%26doi%3D10.1038%2Fsj.onc.1206032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMillin, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treon, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1091</span><span class="refDoi"> DOI: 10.1021/cb4008524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4008524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1086-1091&author=H.+Wuauthor=W.+C.+Wangauthor=F.+Y.+Liuauthor=E.+L.+Weisbergauthor=B.+Tianauthor=Y.+F.+Chenauthor=B.+H.+Liauthor=A.+L.+Wangauthor=B.+L.+Wangauthor=Z.+Zhaoauthor=D.+W.+McMillinauthor=C.+Huauthor=H.+Liauthor=J.+H.+Wangauthor=Y.+K.+Liangauthor=S.+J.+Buhrlageauthor=J.+T.+Liangauthor=J.+Liuauthor=G.+Yangauthor=J.+R.+Brownauthor=S.+P.+Treonauthor=C.+S.+Mitsiadesauthor=J.+D.+Griffinauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+potent%2C+covalent+BTK+inhibitor+for+B-cell+lymphoma&doi=10.1021%2Fcb4008524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span></div><div class="casAuthors">Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen E.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1091</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases.  The authors have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys 481.  QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr 223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr 759) with an EC50 of 318 nM.  In Ramos cells QL47 induces a G1 cell cycle arrest that is assocd. with pronounced degrdn. of BTK protein.  QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyQbTbqIpCbVg90H21EOLACvtfcHk0lh7x1GQA-e5KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D&md5=6cee72676bcd141f79d89d708dea5db2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcb4008524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4008524%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DLi%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DY.%2BK.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520covalent%2520BTK%2520inhibitor%2520for%2520B-cell%2520lymphoma%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1086%26epage%3D1091%26doi%3D10.1021%2Fcb4008524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lh7x1GQA-e5KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lheZsH5x3wMEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+S.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+H.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lheZsH5x3wMEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%2BH.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Li, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z. Y.</span><span> </span><span class="NLM_article-title">Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of bruton’s tyrosine kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5112</span><span class="NLM_x">–</span> <span class="NLM_lpage">5128</span><span class="refDoi"> DOI: 10.1021/jm4017762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5112-5128&author=X.+T.+Liauthor=Y.+Y.+Zuoauthor=G.+H.+Tangauthor=Y.+Wangauthor=Y.+Q.+Zhouauthor=X.+Y.+Wangauthor=T.+L.+Guoauthor=M.+Y.+Xiaauthor=N.+Dingauthor=Z.+Y.+Pan&title=Discovery+of+a+series+of+2%2C5-diaminopyrimidine+covalent+irreversible+inhibitors+of+bruton%E2%80%99s+tyrosine+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm4017762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Li, Xitao; Zuo, Yingying; Tang, Guanghui; Wang, Yan; Zhou, Yiqing; Wang, Xueying; Guo, Tianlin; Xia, Mengying; Ding, Ning; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5112-5128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers.  Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clin. trials.  Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk.  Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a neg. regulation loop for Btk.  Two compds. from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells.  In addn., compd. 31 significantly prevented tumor growth in a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplWeWWoC0ga7Vg90H21EOLACvtfcHk0lheZsH5x3wMEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs7Y%253D&md5=9ca2c30f122addc6c46ba5a90b2e09f3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BT.%26aulast%3DZuo%26aufirst%3DY.%2BY.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DT.%2BL.%26aulast%3DXia%26aufirst%3DM.%2BY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25202%252C5-diaminopyrimidine%2520covalent%2520irreversible%2520inhibitors%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5112%26epage%3D5128%26doi%3D10.1021%2Fjm4017762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span><span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+Abelson+tyrosine+kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lgAIA_M7MAiHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520Abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+S.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lgAIA_M7MAiHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lgAIA_M7MAiHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span> </span><span class="NLM_article-title">Biochemical mechanisms of drug action: what does it take for success?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span><span class="refDoi"> DOI: 10.1038/nrd1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1038%2Fnrd1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=15340390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=801-808&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+drug+action%3A+what+does+it+take+for+success%3F&doi=10.1038%2Fnrd1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Biochemical mechanisms of drug action: what does it take for success?</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Drug discovery is extremely difficult.  There are many unanticipated scientific, medical and business challenges to every drug discovery program.  It is important to increase our understanding of the fundamental properties of effective drugs so that we can anticipate potential problems in developing new agents.  This article addresses potential drug discovery and development risks assocd. with the biochem. mechanism of drug action, and proposes simple rules to minimize these risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXhyDgozFUdrVg90H21EOLACvtfcHk0lggq4DgqBKzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D&md5=b06bdc6ace3168dcb011679b43b72aed</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1500%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520drug%2520action%253A%2520what%2520does%2520it%2520take%2520for%2520success%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D801%26epage%3D808%26doi%3D10.1038%2Fnrd1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span><span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&issue=15&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lggq4DgqBKzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Liang, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective, and orally available BCR-ABL/SRC/p38 kinase inhibitor for chronic myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1984-2004&author=X.+F.+Liangauthor=X.+C.+Liuauthor=B.+L.+Wangauthor=F.+M.+Zouauthor=A.+L.+Wangauthor=S.+Qiauthor=C.+Chenauthor=Z.+Zhaoauthor=W.+C.+Wangauthor=Z.+P.+Qiauthor=F.+C.+Lvauthor=Z.+Q.+Huauthor=L.+Wangauthor=S.+C.+Zhangauthor=Q.+S.+Liuauthor=J.+Liu&title=Discovery+of+2-%28%283-amino-4-methylphenyl%29amino%29-N-%282-methyl-5-%283-%28trifluoromethyl%29benzamido%29phenyl%29-4-%28methylamino%29pyrimidine-5-carboxamide+%28CHMFL-ABL-053%29+as+a+potent%2C+selective%2C+and+orally+available+BCR-ABL%2FSRC%2Fp38+kinase+inhibitor+for+chronic+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01618%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BC.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DZou%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DQi%26aufirst%3DZ.%2BP.%26aulast%3DLv%26aufirst%3DF.%2BC.%26aulast%3DHu%26aufirst%3DZ.%2BQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%25202-%2528%25283-amino-4-methylphenyl%2529amino%2529-N-%25282-methyl-5-%25283-%2528trifluoromethyl%2529benzamido%2529phenyl%2529-4-%2528methylamino%2529pyrimidine-5-carboxamide%2520%2528CHMFL-ABL-053%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520BCR-ABL%252FSRC%252Fp38%2520kinase%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1984%26epage%3D2004%26doi%3D10.1021%2Facs.jmedchem.5b01618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2785</span><span class="NLM_x">–</span> <span class="NLM_lpage">2791</span><span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Autodock4+and+AutoDockTools4%3A+automated+docking+with+selective+receptor+flexiblity&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lh2G1ws6ERIxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutodock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520selective%2520receptor%2520flexiblity%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span>AMBER 14; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER+14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER%252014%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, A Versatile Molecular-Modeling Software; <span class="NLM_publisher-name">Biographics Laboratory 3R</span>: , <span class="NLM_publisher-loc">Basel, Switzerland</span>.<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (Updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+A+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520A%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3DBiographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bianco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Covalent docking using autodock: two-point attractor and flexible side chain methods</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1002/pro.2733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=10.1002%2Fpro.2733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=26103917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFehs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=295-301&author=G.+Biancoauthor=S.+Forliauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Covalent+docking+using+autodock%3A+two-point+attractor+and+flexible+side+chain+methods&doi=10.1002%2Fpro.2733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent docking using autodock: Two-point attractor and flexible side chain methods</span></div><div class="casAuthors">Bianco, Giulia; Forli, Stefano; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-301</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We describe two methods of automated covalent docking using Autodock4: the two-point attractor method and the flexible side chain method.  Both methods were applied to a training set of 20 diverse protein-ligand covalent complexes, evaluating their reliability in predicting the crystallog. pose of the ligands.  The flexible side chain method performed best, recovering the pose in 75% of cases, with failures for the largest inhibitors tested.  Both methods are freely available at the AutoDock website ().</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbgwvwS_NTKrVg90H21EOLACvtfcHk0lgsZiqN93F7CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFehs7rI&md5=4e380f340983e78e149f48934ccc59fd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fpro.2733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2733%26sid%3Dliteratum%253Aachs%26aulast%3DBianco%26aufirst%3DG.%26aulast%3DForli%26aufirst%3DS.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DCovalent%2520docking%2520using%2520autodock%253A%2520two-point%2520attractor%2520and%2520flexible%2520side%2520chain%2520methods%26jtitle%3DProtein%2520Sci.%26date%3D2016%26volume%3D25%26spage%3D295%26epage%3D301%26doi%3D10.1002%2Fpro.2733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SXR','PDB','3SXR'); return false;">PDB: 3SXR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i151"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01413">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77280"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01413">10.1021/acs.jmedchem.6b01413</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">DiscoverX’s KINOMEscan selectivity profiling data of compound <b>41</b>; MS/MS of the unmodified Cys 496-containing tryptic peptide derived from recombinant BMX protein without compound <b>41</b> treatment (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_001.pdf">jm6b01413_si_001.pdf (411.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01413/suppl_file/jm6b01413_si_002.csv">jm6b01413_si_002.csv (6.42 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01413&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01413%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01413" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac98a0adc3c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
